#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Abnormal Frontostriatal Activity During Unexpected Reward Receipt in Depression and Schizophrenia: Relationship to Anhedonia
#Text=Alterations in reward processes may underlie motivational and anhedonic symptoms in depression and schizophrenia.
1-1	0-8	Abnormal	_
1-2	9-23	Frontostriatal	_
1-3	24-32	Activity	_
1-4	33-39	During	_
1-5	40-50	Unexpected	_
1-6	51-57	Reward	_
1-7	58-65	Receipt	_
1-8	66-68	in	_
1-9	69-79	Depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
1-10	80-83	and	_
1-11	84-97	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	97-98	:	_
1-13	99-111	Relationship	_
1-14	112-114	to	_
1-15	115-124	Anhedonia	_
1-16	125-136	Alterations	_
1-17	137-139	in	_
1-18	140-146	reward	_
1-19	147-156	processes	_
1-20	157-160	may	_
1-21	161-169	underlie	_
1-22	170-182	motivational	_
1-23	183-186	and	_
1-24	187-196	anhedonic	_
1-25	197-205	symptoms	_
1-26	206-208	in	_
1-27	209-219	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
1-28	220-223	and	_
1-29	224-237	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-30	237-238	.	_

#Text=However it remains unclear whether these alterations are disorder-specific or shared, and whether they clearly relate to symptom generation or not.
2-1	239-246	However	_
2-2	247-249	it	_
2-3	250-257	remains	_
2-4	258-265	unclear	_
2-5	266-273	whether	_
2-6	274-279	these	_
2-7	280-291	alterations	_
2-8	292-295	are	_
2-9	296-313	disorder-specific	_
2-10	314-316	or	_
2-11	317-323	shared	_
2-12	323-324	,	_
2-13	325-328	and	_
2-14	329-336	whether	_
2-15	337-341	they	_
2-16	342-349	clearly	_
2-17	350-356	relate	_
2-18	357-359	to	_
2-19	360-367	symptom	_
2-20	368-378	generation	_
2-21	379-381	or	_
2-22	382-385	not	_
2-23	385-386	.	_

#Text=We studied brain responses to unexpected rewards during a simulated slot-machine game in 24 patients with depression, 21 patients with schizophrenia, and 21 healthy controls using functional magnetic resonance imaging.
3-1	387-389	We	_
3-2	390-397	studied	_
3-3	398-403	brain	_
3-4	404-413	responses	_
3-5	414-416	to	_
3-6	417-427	unexpected	_
3-7	428-435	rewards	_
3-8	436-442	during	_
3-9	443-444	a	_
3-10	445-454	simulated	_
3-11	455-467	slot-machine	_
3-12	468-472	game	_
3-13	473-475	in	_
3-14	476-478	24	_
3-15	479-487	patients	http://maven.renci.org/NeuroBridge/neurobridge#Depression[1]
3-16	488-492	with	http://maven.renci.org/NeuroBridge/neurobridge#Depression[1]
3-17	493-503	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression[1]
3-18	503-504	,	_
3-19	505-507	21	_
3-20	508-516	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
3-21	517-521	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
3-22	522-535	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[2]
3-23	535-536	,	_
3-24	537-540	and	_
3-25	541-543	21	_
3-26	544-551	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
3-27	552-560	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[3]
3-28	561-566	using	_
3-29	567-577	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]
3-30	578-586	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]
3-31	587-596	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]
3-32	597-604	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[5]
3-33	604-605	.	_

#Text=We investigated relationships between brain activation, task-related motivation, and questionnaire rated anhedonia.
4-1	606-608	We	_
4-2	609-621	investigated	_
4-3	622-635	relationships	_
4-4	636-643	between	_
4-5	644-649	brain	_
4-6	650-660	activation	_
4-7	660-661	,	_
4-8	662-674	task-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]
4-9	675-685	motivation	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]
4-10	685-686	,	_
4-11	687-690	and	_
4-12	691-704	questionnaire	http://www.case.edu/ProvCaRe/provcare#Questionnaire
4-13	705-710	rated	_
4-14	711-720	anhedonia	_
4-15	720-721	.	_

#Text=There was reduced activation in the orbitofrontal cortex, ventral striatum, inferior temporal gyrus, and occipital cortex in both depression and schizophrenia in comparison with healthy participants during receipt of unexpected reward.
5-1	722-727	There	_
5-2	728-731	was	_
5-3	732-739	reduced	_
5-4	740-750	activation	_
5-5	751-753	in	_
5-6	754-757	the	_
5-7	758-771	orbitofrontal	_
5-8	772-778	cortex	_
5-9	778-779	,	_
5-10	780-787	ventral	_
5-11	788-796	striatum	_
5-12	796-797	,	_
5-13	798-806	inferior	_
5-14	807-815	temporal	_
5-15	816-821	gyrus	_
5-16	821-822	,	_
5-17	823-826	and	_
5-18	827-836	occipital	_
5-19	837-843	cortex	_
5-20	844-846	in	_
5-21	847-851	both	_
5-22	852-862	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
5-23	863-866	and	_
5-24	867-880	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
5-25	881-883	in	_
5-26	884-894	comparison	_
5-27	895-899	with	_
5-28	900-907	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]
5-29	908-920	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[7]
5-30	921-927	during	_
5-31	928-935	receipt	_
5-32	936-938	of	_
5-33	939-949	unexpected	_
5-34	950-956	reward	_
5-35	956-957	.	_

#Text=In the medial prefrontal cortex both patient groups showed reduced activation, with activation significantly more abnormal in schizophrenia than depression.
6-1	958-960	In	_
6-2	961-964	the	_
6-3	965-971	medial	_
6-4	972-982	prefrontal	_
6-5	983-989	cortex	_
6-6	990-994	both	_
6-7	995-1002	patient	_
6-8	1003-1009	groups	_
6-9	1010-1016	showed	_
6-10	1017-1024	reduced	_
6-11	1025-1035	activation	_
6-12	1035-1036	,	_
6-13	1037-1041	with	_
6-14	1042-1052	activation	_
6-15	1053-1066	significantly	_
6-16	1067-1071	more	_
6-17	1072-1080	abnormal	_
6-18	1081-1083	in	_
6-19	1084-1097	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
6-20	1098-1102	than	_
6-21	1103-1113	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
6-22	1113-1114	.	_

#Text=Anterior cingulate and medial frontal cortical activation predicted task-related motivation, which in turn predicted anhedonia severity in schizophrenia.
7-1	1115-1123	Anterior	_
7-2	1124-1133	cingulate	_
7-3	1134-1137	and	_
7-4	1138-1144	medial	_
7-5	1145-1152	frontal	_
7-6	1153-1161	cortical	_
7-7	1162-1172	activation	_
7-8	1173-1182	predicted	_
7-9	1183-1195	task-related	_
7-10	1196-1206	motivation	_
7-11	1206-1207	,	_
7-12	1208-1213	which	_
7-13	1214-1216	in	_
7-14	1217-1221	turn	_
7-15	1222-1231	predicted	_
7-16	1232-1241	anhedonia	_
7-17	1242-1250	severity	_
7-18	1251-1253	in	_
7-19	1254-1267	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
7-20	1267-1268	.	_

#Text=Our findings provide evidence for overlapping hypofunction in ventral striatal and orbitofrontal regions in depression and schizophrenia during unexpected reward receipt, and for a relationship between unexpected reward processing in the medial prefrontal cortex and the generation of motivational states.
8-1	1269-1272	Our	_
8-2	1273-1281	findings	_
8-3	1282-1289	provide	_
8-4	1290-1298	evidence	_
8-5	1299-1302	for	_
8-6	1303-1314	overlapping	_
8-7	1315-1327	hypofunction	_
8-8	1328-1330	in	_
8-9	1331-1338	ventral	_
8-10	1339-1347	striatal	_
8-11	1348-1351	and	_
8-12	1352-1365	orbitofrontal	_
8-13	1366-1373	regions	_
8-14	1374-1376	in	_
8-15	1377-1387	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
8-16	1388-1391	and	_
8-17	1392-1405	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-18	1406-1412	during	_
8-19	1413-1423	unexpected	_
8-20	1424-1430	reward	_
8-21	1431-1438	receipt	_
8-22	1438-1439	,	_
8-23	1440-1443	and	_
8-24	1444-1447	for	_
8-25	1448-1449	a	_
8-26	1450-1462	relationship	_
8-27	1463-1470	between	_
8-28	1471-1481	unexpected	_
8-29	1482-1488	reward	_
8-30	1489-1499	processing	_
8-31	1500-1502	in	_
8-32	1503-1506	the	_
8-33	1507-1513	medial	_
8-34	1514-1524	prefrontal	_
8-35	1525-1531	cortex	_
8-36	1532-1535	and	_
8-37	1536-1539	the	_
8-38	1540-1550	generation	_
8-39	1551-1553	of	_
8-40	1554-1566	motivational	_
8-41	1567-1573	states	_
8-42	1573-1574	.	_

#Text=Introduction
#Text=Depression and schizophrenia are associated with deficits in motivation and enjoyment, which have been collectively termed anhedonia by some authors.
9-1	1575-1587	Introduction	_
9-2	1588-1598	Depression	_
9-3	1599-1602	and	_
9-4	1603-1616	schizophrenia	_
9-5	1617-1620	are	_
9-6	1621-1631	associated	_
9-7	1632-1636	with	_
9-8	1637-1645	deficits	_
9-9	1646-1648	in	_
9-10	1649-1659	motivation	_
9-11	1660-1663	and	_
9-12	1664-1673	enjoyment	_
9-13	1673-1674	,	_
9-14	1675-1680	which	_
9-15	1681-1685	have	_
9-16	1686-1690	been	_
9-17	1691-1703	collectively	_
9-18	1704-1710	termed	_
9-19	1711-1720	anhedonia	_
9-20	1721-1723	by	_
9-21	1724-1728	some	_
9-22	1729-1736	authors	_
9-23	1736-1737	.	_

#Text=Clinically it is challenging to distinguish between deficits in pleasure and motivation, even though there are at least partially separable processes that underpin these functions.
10-1	1738-1748	Clinically	_
10-2	1749-1751	it	_
10-3	1752-1754	is	_
10-4	1755-1766	challenging	_
10-5	1767-1769	to	_
10-6	1770-1781	distinguish	_
10-7	1782-1789	between	_
10-8	1790-1798	deficits	_
10-9	1799-1801	in	_
10-10	1802-1810	pleasure	_
10-11	1811-1814	and	_
10-12	1815-1825	motivation	_
10-13	1825-1826	,	_
10-14	1827-1831	even	_
10-15	1832-1838	though	_
10-16	1839-1844	there	_
10-17	1845-1848	are	_
10-18	1849-1851	at	_
10-19	1852-1857	least	_
10-20	1858-1867	partially	_
10-21	1868-1877	separable	_
10-22	1878-1887	processes	_
10-23	1888-1892	that	_
10-24	1893-1901	underpin	_
10-25	1902-1907	these	_
10-26	1908-1917	functions	_
10-27	1917-1918	.	_

#Text=Some evidence suggests that striatal hypofunction during reward processing is present in schizophrenia and depression, and may contribute to the motivational and hedonic problems experienced by patients, whilst other authors have emphasized the importance of orbitofrontal cortex function in this regard.
11-1	1919-1923	Some	_
11-2	1924-1932	evidence	_
11-3	1933-1941	suggests	_
11-4	1942-1946	that	_
11-5	1947-1955	striatal	_
11-6	1956-1968	hypofunction	_
11-7	1969-1975	during	_
11-8	1976-1982	reward	_
11-9	1983-1993	processing	_
11-10	1994-1996	is	_
11-11	1997-2004	present	_
11-12	2005-2007	in	_
11-13	2008-2021	schizophrenia	_
11-14	2022-2025	and	_
11-15	2026-2036	depression	_
11-16	2036-2037	,	_
11-17	2038-2041	and	_
11-18	2042-2045	may	_
11-19	2046-2056	contribute	_
11-20	2057-2059	to	_
11-21	2060-2063	the	_
11-22	2064-2076	motivational	_
11-23	2077-2080	and	_
11-24	2081-2088	hedonic	_
11-25	2089-2097	problems	_
11-26	2098-2109	experienced	_
11-27	2110-2112	by	_
11-28	2113-2121	patients	_
11-29	2121-2122	,	_
11-30	2123-2129	whilst	_
11-31	2130-2135	other	_
11-32	2136-2143	authors	_
11-33	2144-2148	have	_
11-34	2149-2159	emphasized	_
11-35	2160-2163	the	_
11-36	2164-2174	importance	_
11-37	2175-2177	of	_
11-38	2178-2191	orbitofrontal	_
11-39	2192-2198	cortex	_
11-40	2199-2207	function	_
11-41	2208-2210	in	_
11-42	2211-2215	this	_
11-43	2216-2222	regard	_
11-44	2222-2223	.	_

#Text=It remains unknown whether the neurobiological disturbances in reward processing are different in schizophrenia and depression and it is not yet clear which aspects of reward processing are particularly problematic in these conditions, or whether any associated neural deficits are predominantly cortical or subcortical in origin.
12-1	2224-2226	It	_
12-2	2227-2234	remains	_
12-3	2235-2242	unknown	_
12-4	2243-2250	whether	_
12-5	2251-2254	the	_
12-6	2255-2270	neurobiological	_
12-7	2271-2283	disturbances	_
12-8	2284-2286	in	_
12-9	2287-2293	reward	_
12-10	2294-2304	processing	_
12-11	2305-2308	are	_
12-12	2309-2318	different	_
12-13	2319-2321	in	_
12-14	2322-2335	schizophrenia	_
12-15	2336-2339	and	_
12-16	2340-2350	depression	_
12-17	2351-2354	and	_
12-18	2355-2357	it	_
12-19	2358-2360	is	_
12-20	2361-2364	not	_
12-21	2365-2368	yet	_
12-22	2369-2374	clear	_
12-23	2375-2380	which	_
12-24	2381-2388	aspects	_
12-25	2389-2391	of	_
12-26	2392-2398	reward	_
12-27	2399-2409	processing	_
12-28	2410-2413	are	_
12-29	2414-2426	particularly	_
12-30	2427-2438	problematic	_
12-31	2439-2441	in	_
12-32	2442-2447	these	_
12-33	2448-2458	conditions	_
12-34	2458-2459	,	_
12-35	2460-2462	or	_
12-36	2463-2470	whether	_
12-37	2471-2474	any	_
12-38	2475-2485	associated	_
12-39	2486-2492	neural	_
12-40	2493-2501	deficits	_
12-41	2502-2505	are	_
12-42	2506-2519	predominantly	_
12-43	2520-2528	cortical	_
12-44	2529-2531	or	_
12-45	2532-2543	subcortical	_
12-46	2544-2546	in	_
12-47	2547-2553	origin	_
12-48	2553-2554	.	_

#Text=Insights into any shared pathophysiology underlying abnormalities in motivation and pleasure across different psychiatric diagnoses could lead to improved use of existing treatments, facilitate development of new treatments and, as is postulated by the Research Domain Criteria (RDoC) project, may contribute to improved psychiatric classification in the future.
13-1	2555-2563	Insights	_
13-2	2564-2568	into	_
13-3	2569-2572	any	_
13-4	2573-2579	shared	_
13-5	2580-2595	pathophysiology	_
13-6	2596-2606	underlying	_
13-7	2607-2620	abnormalities	_
13-8	2621-2623	in	_
13-9	2624-2634	motivation	_
13-10	2635-2638	and	_
13-11	2639-2647	pleasure	_
13-12	2648-2654	across	_
13-13	2655-2664	different	_
13-14	2665-2676	psychiatric	_
13-15	2677-2686	diagnoses	_
13-16	2687-2692	could	_
13-17	2693-2697	lead	_
13-18	2698-2700	to	_
13-19	2701-2709	improved	_
13-20	2710-2713	use	_
13-21	2714-2716	of	_
13-22	2717-2725	existing	_
13-23	2726-2736	treatments	_
13-24	2736-2737	,	_
13-25	2738-2748	facilitate	_
13-26	2749-2760	development	_
13-27	2761-2763	of	_
13-28	2764-2767	new	_
13-29	2768-2778	treatments	_
13-30	2779-2782	and	_
13-31	2782-2783	,	_
13-32	2784-2786	as	_
13-33	2787-2789	is	_
13-34	2790-2800	postulated	_
13-35	2801-2803	by	_
13-36	2804-2807	the	_
13-37	2808-2816	Research	_
13-38	2817-2823	Domain	_
13-39	2824-2832	Criteria	_
13-40	2833-2834	(	_
13-41	2834-2838	RDoC	_
13-42	2838-2839	)	_
13-43	2840-2847	project	_
13-44	2847-2848	,	_
13-45	2849-2852	may	_
13-46	2853-2863	contribute	_
13-47	2864-2866	to	_
13-48	2867-2875	improved	_
13-49	2876-2887	psychiatric	_
13-50	2888-2902	classification	_
13-51	2903-2905	in	_
13-52	2906-2909	the	_
13-53	2910-2916	future	_
13-54	2916-2917	.	_

#Text=Recently it has been suggested that in both schizophrenia and depression, the aspects of reward processing that relate to reward receipt may be relatively spared, whereas anticipatory and motivational aspects of reward processing may be more dysfunctional and may be closely linked to negative symptoms/depression.
14-1	2918-2926	Recently	_
14-2	2927-2929	it	_
14-3	2930-2933	has	_
14-4	2934-2938	been	_
14-5	2939-2948	suggested	_
14-6	2949-2953	that	_
14-7	2954-2956	in	_
14-8	2957-2961	both	_
14-9	2962-2975	schizophrenia	_
14-10	2976-2979	and	_
14-11	2980-2990	depression	_
14-12	2990-2991	,	_
14-13	2992-2995	the	_
14-14	2996-3003	aspects	_
14-15	3004-3006	of	_
14-16	3007-3013	reward	_
14-17	3014-3024	processing	_
14-18	3025-3029	that	_
14-19	3030-3036	relate	_
14-20	3037-3039	to	_
14-21	3040-3046	reward	_
14-22	3047-3054	receipt	_
14-23	3055-3058	may	_
14-24	3059-3061	be	_
14-25	3062-3072	relatively	_
14-26	3073-3079	spared	_
14-27	3079-3080	,	_
14-28	3081-3088	whereas	_
14-29	3089-3101	anticipatory	_
14-30	3102-3105	and	_
14-31	3106-3118	motivational	_
14-32	3119-3126	aspects	_
14-33	3127-3129	of	_
14-34	3130-3136	reward	_
14-35	3137-3147	processing	_
14-36	3148-3151	may	_
14-37	3152-3154	be	_
14-38	3155-3159	more	_
14-39	3160-3173	dysfunctional	_
14-40	3174-3177	and	_
14-41	3178-3181	may	_
14-42	3182-3184	be	_
14-43	3185-3192	closely	_
14-44	3193-3199	linked	_
14-45	3200-3202	to	_
14-46	3203-3211	negative	_
14-47	3212-3220	symptoms	_
14-48	3220-3221	/	_
14-49	3221-3231	depression	_
14-50	3231-3232	.	_

#Text=However, the majority of neuroimaging studies that have examined reward receipt in schizophrenia and depression have used tasks where rewards are rather predictable, and can be expected to occur more often than not; several studies using such tasks have found broadly intact neural responses to reward feedback in schizophrenia and depression (eg,).
15-1	3233-3240	However	_
15-2	3240-3241	,	_
15-3	3242-3245	the	_
15-4	3246-3254	majority	_
15-5	3255-3257	of	_
15-6	3258-3270	neuroimaging	_
15-7	3271-3278	studies	_
15-8	3279-3283	that	_
15-9	3284-3288	have	_
15-10	3289-3297	examined	_
15-11	3298-3304	reward	_
15-12	3305-3312	receipt	_
15-13	3313-3315	in	_
15-14	3316-3329	schizophrenia	_
15-15	3330-3333	and	_
15-16	3334-3344	depression	_
15-17	3345-3349	have	_
15-18	3350-3354	used	_
15-19	3355-3360	tasks	_
15-20	3361-3366	where	_
15-21	3367-3374	rewards	_
15-22	3375-3378	are	_
15-23	3379-3385	rather	_
15-24	3386-3397	predictable	_
15-25	3397-3398	,	_
15-26	3399-3402	and	_
15-27	3403-3406	can	_
15-28	3407-3409	be	_
15-29	3410-3418	expected	_
15-30	3419-3421	to	_
15-31	3422-3427	occur	_
15-32	3428-3432	more	_
15-33	3433-3438	often	_
15-34	3439-3443	than	_
15-35	3444-3447	not	_
15-36	3447-3448	;	_
15-37	3449-3456	several	_
15-38	3457-3464	studies	_
15-39	3465-3470	using	_
15-40	3471-3475	such	_
15-41	3476-3481	tasks	_
15-42	3482-3486	have	_
15-43	3487-3492	found	_
15-44	3493-3500	broadly	_
15-45	3501-3507	intact	_
15-46	3508-3514	neural	_
15-47	3515-3524	responses	_
15-48	3525-3527	to	_
15-49	3528-3534	reward	_
15-50	3535-3543	feedback	_
15-51	3544-3546	in	_
15-52	3547-3560	schizophrenia	_
15-53	3561-3564	and	_
15-54	3565-3575	depression	_
15-55	3576-3577	(	_
15-56	3577-3579	eg	_
15-57	3579-3580	,	_
15-58	3580-3581	)	_
15-59	3581-3582	.	_

#Text=Such tasks are optimized to examine brain responses during the anticipation and receipt of a highly expected reward, rather than unexpected reward responses; several studies have documented robust striatal and cortical deficits in schizophrenia and depression in the anticipation of reward.
16-1	3583-3587	Such	_
16-2	3588-3593	tasks	_
16-3	3594-3597	are	_
16-4	3598-3607	optimized	_
16-5	3608-3610	to	_
16-6	3611-3618	examine	_
16-7	3619-3624	brain	_
16-8	3625-3634	responses	_
16-9	3635-3641	during	_
16-10	3642-3645	the	_
16-11	3646-3658	anticipation	_
16-12	3659-3662	and	_
16-13	3663-3670	receipt	_
16-14	3671-3673	of	_
16-15	3674-3675	a	_
16-16	3676-3682	highly	_
16-17	3683-3691	expected	_
16-18	3692-3698	reward	_
16-19	3698-3699	,	_
16-20	3700-3706	rather	_
16-21	3707-3711	than	_
16-22	3712-3722	unexpected	_
16-23	3723-3729	reward	_
16-24	3730-3739	responses	_
16-25	3739-3740	;	_
16-26	3741-3748	several	_
16-27	3749-3756	studies	_
16-28	3757-3761	have	_
16-29	3762-3772	documented	_
16-30	3773-3779	robust	_
16-31	3780-3788	striatal	_
16-32	3789-3792	and	_
16-33	3793-3801	cortical	_
16-34	3802-3810	deficits	_
16-35	3811-3813	in	_
16-36	3814-3827	schizophrenia	_
16-37	3828-3831	and	_
16-38	3832-3842	depression	_
16-39	3843-3845	in	_
16-40	3846-3849	the	_
16-41	3850-3862	anticipation	_
16-42	3863-3865	of	_
16-43	3866-3872	reward	_
16-44	3872-3873	.	_

#Text=This still leaves open the question as to whether response to reward receipt, especially unexpected reward receipt, is normal in these disorders.
17-1	3874-3878	This	_
17-2	3879-3884	still	_
17-3	3885-3891	leaves	_
17-4	3892-3896	open	_
17-5	3897-3900	the	_
17-6	3901-3909	question	_
17-7	3910-3912	as	_
17-8	3913-3915	to	_
17-9	3916-3923	whether	_
17-10	3924-3932	response	_
17-11	3933-3935	to	_
17-12	3936-3942	reward	_
17-13	3943-3950	receipt	_
17-14	3950-3951	,	_
17-15	3952-3962	especially	_
17-16	3963-3973	unexpected	_
17-17	3974-3980	reward	_
17-18	3981-3988	receipt	_
17-19	3988-3989	,	_
17-20	3990-3992	is	_
17-21	3993-3999	normal	_
17-22	4000-4002	in	_
17-23	4003-4008	these	_
17-24	4009-4018	disorders	_
17-25	4018-4019	.	_

#Text=In this regard it is critical to examine neural responses to unpredicted rewards, which may be more pronounced than those to predicted rewards.
18-1	4020-4022	In	_
18-2	4023-4027	this	_
18-3	4028-4034	regard	_
18-4	4035-4037	it	_
18-5	4038-4040	is	_
18-6	4041-4049	critical	_
18-7	4050-4052	to	_
18-8	4053-4060	examine	_
18-9	4061-4067	neural	_
18-10	4068-4077	responses	_
18-11	4078-4080	to	_
18-12	4081-4092	unpredicted	_
18-13	4093-4100	rewards	_
18-14	4100-4101	,	_
18-15	4102-4107	which	_
18-16	4108-4111	may	_
18-17	4112-4114	be	_
18-18	4115-4119	more	_
18-19	4120-4130	pronounced	_
18-20	4131-4135	than	_
18-21	4136-4141	those	_
18-22	4142-4144	to	_
18-23	4145-4154	predicted	_
18-24	4155-4162	rewards	_
18-25	4162-4163	.	_

#Text=This is of particular interest, given that unexpected events evoke prediction errors, which are encoded within the brain at both cortical and subcortical levels.
19-1	4164-4168	This	_
19-2	4169-4171	is	_
19-3	4172-4174	of	_
19-4	4175-4185	particular	_
19-5	4186-4194	interest	_
19-6	4194-4195	,	_
19-7	4196-4201	given	_
19-8	4202-4206	that	_
19-9	4207-4217	unexpected	_
19-10	4218-4224	events	_
19-11	4225-4230	evoke	_
19-12	4231-4241	prediction	_
19-13	4242-4248	errors	_
19-14	4248-4249	,	_
19-15	4250-4255	which	_
19-16	4256-4259	are	_
19-17	4260-4267	encoded	_
19-18	4268-4274	within	_
19-19	4275-4278	the	_
19-20	4279-4284	brain	_
19-21	4285-4287	at	_
19-22	4288-4292	both	_
19-23	4293-4301	cortical	_
19-24	4302-4305	and	_
19-25	4306-4317	subcortical	_
19-26	4318-4324	levels	_
19-27	4324-4325	.	_

#Text=Prediction error signaling has been postulated to relate to many aspects of thought and behavior in health and in psychiatric illness, including learning, motivation, and attention, and abnormal brain prediction error signaling may contribute to psychotic symptoms as well as deficits in motivation and enjoyment.
20-1	4326-4336	Prediction	_
20-2	4337-4342	error	_
20-3	4343-4352	signaling	_
20-4	4353-4356	has	_
20-5	4357-4361	been	_
20-6	4362-4372	postulated	_
20-7	4373-4375	to	_
20-8	4376-4382	relate	_
20-9	4383-4385	to	_
20-10	4386-4390	many	_
20-11	4391-4398	aspects	_
20-12	4399-4401	of	_
20-13	4402-4409	thought	_
20-14	4410-4413	and	_
20-15	4414-4422	behavior	_
20-16	4423-4425	in	_
20-17	4426-4432	health	_
20-18	4433-4436	and	_
20-19	4437-4439	in	_
20-20	4440-4451	psychiatric	_
20-21	4452-4459	illness	_
20-22	4459-4460	,	_
20-23	4461-4470	including	_
20-24	4471-4479	learning	_
20-25	4479-4480	,	_
20-26	4481-4491	motivation	_
20-27	4491-4492	,	_
20-28	4493-4496	and	_
20-29	4497-4506	attention	_
20-30	4506-4507	,	_
20-31	4508-4511	and	_
20-32	4512-4520	abnormal	_
20-33	4521-4526	brain	_
20-34	4527-4537	prediction	_
20-35	4538-4543	error	_
20-36	4544-4553	signaling	_
20-37	4554-4557	may	_
20-38	4558-4568	contribute	_
20-39	4569-4571	to	_
20-40	4572-4581	psychotic	_
20-41	4582-4590	symptoms	_
20-42	4591-4593	as	_
20-43	4594-4598	well	_
20-44	4599-4601	as	_
20-45	4602-4610	deficits	_
20-46	4611-4613	in	_
20-47	4614-4624	motivation	_
20-48	4625-4628	and	_
20-49	4629-4638	enjoyment	_
20-50	4638-4639	.	_

#Text=Initial evidence suggests that the prediction error signaling during, or after, learning may be compromised in both schizophrenia and depression in cortical and subcortical regions (; although see).
21-1	4640-4647	Initial	_
21-2	4648-4656	evidence	_
21-3	4657-4665	suggests	_
21-4	4666-4670	that	_
21-5	4671-4674	the	_
21-6	4675-4685	prediction	_
21-7	4686-4691	error	_
21-8	4692-4701	signaling	_
21-9	4702-4708	during	_
21-10	4708-4709	,	_
21-11	4710-4712	or	_
21-12	4713-4718	after	_
21-13	4718-4719	,	_
21-14	4720-4728	learning	_
21-15	4729-4732	may	_
21-16	4733-4735	be	_
21-17	4736-4747	compromised	_
21-18	4748-4750	in	_
21-19	4751-4755	both	_
21-20	4756-4769	schizophrenia	_
21-21	4770-4773	and	_
21-22	4774-4784	depression	_
21-23	4785-4787	in	_
21-24	4788-4796	cortical	_
21-25	4797-4800	and	_
21-26	4801-4812	subcortical	_
21-27	4813-4820	regions	_
21-28	4821-4822	(	_
21-29	4822-4823	;	_
21-30	4824-4832	although	_
21-31	4833-4836	see	_
21-32	4836-4837	)	_
21-33	4837-4838	.	_

#Text=However, abnormal neural correlates of prediction error associated learning signals may reflect dysfunction of the learning mechanism (eg, failure to update in response to prediction error signals during learning), not necessarily to the prediction error signaling mechanism per se.
22-1	4839-4846	However	_
22-2	4846-4847	,	_
22-3	4848-4856	abnormal	_
22-4	4857-4863	neural	_
22-5	4864-4874	correlates	_
22-6	4875-4877	of	_
22-7	4878-4888	prediction	_
22-8	4889-4894	error	_
22-9	4895-4905	associated	_
22-10	4906-4914	learning	_
22-11	4915-4922	signals	_
22-12	4923-4926	may	_
22-13	4927-4934	reflect	_
22-14	4935-4946	dysfunction	_
22-15	4947-4949	of	_
22-16	4950-4953	the	_
22-17	4954-4962	learning	_
22-18	4963-4972	mechanism	_
22-19	4973-4974	(	_
22-20	4974-4976	eg	_
22-21	4976-4977	,	_
22-22	4978-4985	failure	_
22-23	4986-4988	to	_
22-24	4989-4995	update	_
22-25	4996-4998	in	_
22-26	4999-5007	response	_
22-27	5008-5010	to	_
22-28	5011-5021	prediction	_
22-29	5022-5027	error	_
22-30	5028-5035	signals	_
22-31	5036-5042	during	_
22-32	5043-5051	learning	_
22-33	5051-5052	)	_
22-34	5052-5053	,	_
22-35	5054-5057	not	_
22-36	5058-5069	necessarily	_
22-37	5070-5072	to	_
22-38	5073-5076	the	_
22-39	5077-5087	prediction	_
22-40	5088-5093	error	_
22-41	5094-5103	signaling	_
22-42	5104-5113	mechanism	_
22-43	5114-5117	per	_
22-44	5118-5120	se	_
22-45	5120-5121	.	_

#Text=To fully assess the integrity of neural systems that signal surprising/unexpected rewards, it is critical to employ an experimental scenario with little or no learning component in which reward outcome is unpredictable.
#Text=to test whether brain responses to unexpected rewards were broadly intact in schizophrenia and depression,
#Text=if brain responses to unexpected rewards are abnormal in schizophrenia and depression, to evaluate if the deficits are confined to cortical, or subcortical regions, and whether there are any shared or differential areas of deficit in the two disorders, and
#Text=to examine whether brain responses to unexpected reward receipt are related to motivation and enjoyment in these disorders.
23-1	5122-5124	To	_
23-2	5125-5130	fully	_
23-3	5131-5137	assess	_
23-4	5138-5141	the	_
23-5	5142-5151	integrity	_
23-6	5152-5154	of	_
23-7	5155-5161	neural	_
23-8	5162-5169	systems	_
23-9	5170-5174	that	_
23-10	5175-5181	signal	_
23-11	5182-5192	surprising	_
23-12	5192-5193	/	_
23-13	5193-5203	unexpected	_
23-14	5204-5211	rewards	_
23-15	5211-5212	,	_
23-16	5213-5215	it	_
23-17	5216-5218	is	_
23-18	5219-5227	critical	_
23-19	5228-5230	to	_
23-20	5231-5237	employ	_
23-21	5238-5240	an	_
23-22	5241-5253	experimental	_
23-23	5254-5262	scenario	_
23-24	5263-5267	with	_
23-25	5268-5274	little	_
23-26	5275-5277	or	_
23-27	5278-5280	no	_
23-28	5281-5289	learning	_
23-29	5290-5299	component	_
23-30	5300-5302	in	_
23-31	5303-5308	which	_
23-32	5309-5315	reward	_
23-33	5316-5323	outcome	_
23-34	5324-5326	is	_
23-35	5327-5340	unpredictable	_
23-36	5340-5341	.	_
23-37	5342-5344	to	_
23-38	5345-5349	test	_
23-39	5350-5357	whether	_
23-40	5358-5363	brain	_
23-41	5364-5373	responses	_
23-42	5374-5376	to	_
23-43	5377-5387	unexpected	_
23-44	5388-5395	rewards	_
23-45	5396-5400	were	_
23-46	5401-5408	broadly	_
23-47	5409-5415	intact	_
23-48	5416-5418	in	_
23-49	5419-5432	schizophrenia	_
23-50	5433-5436	and	_
23-51	5437-5447	depression	_
23-52	5447-5448	,	_
23-53	5449-5451	if	_
23-54	5452-5457	brain	_
23-55	5458-5467	responses	_
23-56	5468-5470	to	_
23-57	5471-5481	unexpected	_
23-58	5482-5489	rewards	_
23-59	5490-5493	are	_
23-60	5494-5502	abnormal	_
23-61	5503-5505	in	_
23-62	5506-5519	schizophrenia	_
23-63	5520-5523	and	_
23-64	5524-5534	depression	_
23-65	5534-5535	,	_
23-66	5536-5538	to	_
23-67	5539-5547	evaluate	_
23-68	5548-5550	if	_
23-69	5551-5554	the	_
23-70	5555-5563	deficits	_
23-71	5564-5567	are	_
23-72	5568-5576	confined	_
23-73	5577-5579	to	_
23-74	5580-5588	cortical	_
23-75	5588-5589	,	_
23-76	5590-5592	or	_
23-77	5593-5604	subcortical	_
23-78	5605-5612	regions	_
23-79	5612-5613	,	_
23-80	5614-5617	and	_
23-81	5618-5625	whether	_
23-82	5626-5631	there	_
23-83	5632-5635	are	_
23-84	5636-5639	any	_
23-85	5640-5646	shared	_
23-86	5647-5649	or	_
23-87	5650-5662	differential	_
23-88	5663-5668	areas	_
23-89	5669-5671	of	_
23-90	5672-5679	deficit	_
23-91	5680-5682	in	_
23-92	5683-5686	the	_
23-93	5687-5690	two	_
23-94	5691-5700	disorders	_
23-95	5700-5701	,	_
23-96	5702-5705	and	_
23-97	5706-5708	to	_
23-98	5709-5716	examine	_
23-99	5717-5724	whether	_
23-100	5725-5730	brain	_
23-101	5731-5740	responses	_
23-102	5741-5743	to	_
23-103	5744-5754	unexpected	_
23-104	5755-5761	reward	_
23-105	5762-5769	receipt	_
23-106	5770-5773	are	_
23-107	5774-5781	related	_
23-108	5782-5784	to	_
23-109	5785-5795	motivation	_
23-110	5796-5799	and	_
23-111	5800-5809	enjoyment	_
23-112	5810-5812	in	_
23-113	5813-5818	these	_
23-114	5819-5828	disorders	_
23-115	5828-5829	.	_

#Text=Our aim therefore was to explore brain responses to unexpected reward delivery in both depression and schizophrenia, and their relationship to motivation and enjoyment.
24-1	5830-5833	Our	_
24-2	5834-5837	aim	_
24-3	5838-5847	therefore	_
24-4	5848-5851	was	_
24-5	5852-5854	to	_
24-6	5855-5862	explore	_
24-7	5863-5868	brain	_
24-8	5869-5878	responses	_
24-9	5879-5881	to	_
24-10	5882-5892	unexpected	_
24-11	5893-5899	reward	_
24-12	5900-5908	delivery	_
24-13	5909-5911	in	_
24-14	5912-5916	both	_
24-15	5917-5927	depression	_
24-16	5928-5931	and	_
24-17	5932-5945	schizophrenia	_
24-18	5945-5946	,	_
24-19	5947-5950	and	_
24-20	5951-5956	their	_
24-21	5957-5969	relationship	_
24-22	5970-5972	to	_
24-23	5973-5983	motivation	_
24-24	5984-5987	and	_
24-25	5988-5997	enjoyment	_
24-26	5997-5998	.	_

#Text=We used an fMRI reward processing task involving the receipt of unexpected rewards, but minimal learning, with a sample of patients who all subjectively endorsed at least some degree of anhedonia.
25-1	5999-6001	We	_
25-2	6002-6006	used	_
25-3	6007-6009	an	_
25-4	6010-6014	fMRI	_
25-5	6015-6021	reward	_
25-6	6022-6032	processing	_
25-7	6033-6037	task	_
25-8	6038-6047	involving	_
25-9	6048-6051	the	_
25-10	6052-6059	receipt	_
25-11	6060-6062	of	_
25-12	6063-6073	unexpected	_
25-13	6074-6081	rewards	_
25-14	6081-6082	,	_
25-15	6083-6086	but	_
25-16	6087-6094	minimal	_
25-17	6095-6103	learning	_
25-18	6103-6104	,	_
25-19	6105-6109	with	_
25-20	6110-6111	a	_
25-21	6112-6118	sample	_
25-22	6119-6121	of	_
25-23	6122-6130	patients	_
25-24	6131-6134	who	_
25-25	6135-6138	all	_
25-26	6139-6151	subjectively	_
25-27	6152-6160	endorsed	_
25-28	6161-6163	at	_
25-29	6164-6169	least	_
25-30	6170-6174	some	_
25-31	6175-6181	degree	_
25-32	6182-6184	of	_
25-33	6185-6194	anhedonia	_
25-34	6194-6195	.	_

#Text=Our goals were:
#Text=Materials and methods
#Text=Participants
#Text=The study was approved by the Cambridgeshire 3 National Health Service research ethics committee.
26-1	6196-6199	Our	_
26-2	6200-6205	goals	_
26-3	6206-6210	were	_
26-4	6210-6211	:	_
26-5	6214-6223	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
26-6	6224-6227	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
26-7	6228-6235	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[8]
26-8	6236-6248	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-9	6249-6252	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-10	6253-6258	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-11	6259-6262	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-12	6263-6271	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-13	6272-6274	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-14	6275-6278	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-15	6279-6293	Cambridgeshire	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-16	6294-6295	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-17	6296-6304	National	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-18	6305-6311	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-19	6312-6319	Service	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-20	6320-6328	research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-21	6329-6335	ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-22	6336-6345	committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]
26-23	6345-6346	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]

#Text=Written informed consent was obtained from all participants.
27-1	6347-6354	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-2	6355-6363	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-3	6364-6371	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-4	6372-6375	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-5	6376-6384	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-6	6385-6389	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-7	6390-6393	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-8	6394-6406	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]
27-9	6406-6407	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[10]

#Text=Twenty-one people with DSM-IV schizophrenia, 24 people with DSM-IV major depressive disorder (MDD), and 21 healthy volunteers took part in the study (Table 1).
28-1	6408-6418	Twenty-one	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-2	6419-6425	people	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[12]
28-3	6426-6430	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[12]
28-4	6431-6437	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[12]
28-5	6438-6451	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[12]
28-6	6451-6452	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-7	6453-6455	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-8	6456-6462	people	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-9	6463-6467	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-10	6468-6474	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-11	6475-6480	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-12	6481-6491	depressive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-13	6492-6500	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-14	6501-6502	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-15	6502-6505	MDD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-16	6505-6506	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[13]
28-17	6506-6507	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-18	6508-6511	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-19	6512-6514	21	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-20	6515-6522	healthy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]
28-21	6523-6533	volunteers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[14]
28-22	6534-6538	took	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-23	6539-6543	part	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-24	6544-6546	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-25	6547-6550	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-26	6551-6556	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-27	6557-6558	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-28	6558-6563	Table	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-29	6564-6565	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-30	6565-6566	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]
28-31	6566-6567	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[11]

#Text=All schizophrenia participants were taking antipsychotic medication; eight were additionally taking antidepressant medication.
29-1	6568-6571	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-2	6572-6585	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[16]
29-3	6586-6598	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[16]
29-4	6599-6603	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-5	6604-6610	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-6	6611-6624	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[17]
29-7	6625-6635	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[17]
29-8	6635-6636	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-9	6637-6642	eight	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-10	6643-6647	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-11	6648-6660	additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-12	6661-6667	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]
29-13	6668-6682	antidepressant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[18]
29-14	6683-6693	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[18]
29-15	6693-6694	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]

#Text=Thirteen of the 24 depression participants were taking antidepressant medication, of whom four were additionally taking antipsychotic medication; medication is described in Table 1 and in further detail in Supplementary Material.
30-1	6695-6703	Thirteen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-2	6704-6706	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-3	6707-6710	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-4	6711-6713	24	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-5	6714-6724	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[20]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[21]
30-6	6725-6737	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[20]
30-7	6738-6742	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-8	6743-6749	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-9	6750-6764	antidepressant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[22]
30-10	6765-6775	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[22]
30-11	6775-6776	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-12	6777-6779	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-13	6780-6784	whom	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-14	6785-6789	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-15	6790-6794	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-16	6795-6807	additionally	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-17	6808-6814	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-18	6815-6828	antipsychotic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[23]
30-19	6829-6839	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]|http://maven.renci.org/NeuroBridge/neurobridge#MedicationStatus[23]
30-20	6839-6840	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[19]
30-21	6841-6851	medication	_
30-22	6852-6854	is	_
30-23	6855-6864	described	_
30-24	6865-6867	in	_
30-25	6868-6873	Table	_
30-26	6874-6875	1	_
30-27	6876-6879	and	_
30-28	6880-6882	in	_
30-29	6883-6890	further	_
30-30	6891-6897	detail	_
30-31	6898-6900	in	_
30-32	6901-6914	Supplementary	_
30-33	6915-6923	Material	_
30-34	6923-6924	.	_

#Text=Inclusion criteria were an age between 18 and 65 and adequate proficiency in English.
31-1	6925-6934	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-2	6935-6943	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-3	6944-6948	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-4	6949-6951	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-5	6952-6955	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-6	6956-6963	between	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-7	6964-6966	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-8	6967-6970	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-9	6971-6973	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-10	6974-6977	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-11	6978-6986	adequate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-12	6987-6998	proficiency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-13	6999-7001	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-14	7002-7009	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]
31-15	7009-7010	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]

#Text=Exclusion criteria were history of neurological disorder, physical illness, dependence on alcohol or recreational drugs, and any contraindication for MRI scanning.
32-1	7011-7020	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-2	7021-7029	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-3	7030-7034	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-4	7035-7042	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-5	7043-7045	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-6	7046-7058	neurological	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-7	7059-7067	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-8	7067-7068	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-9	7069-7077	physical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-10	7078-7085	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-11	7085-7086	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-12	7087-7097	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-13	7098-7100	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-14	7101-7108	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-15	7109-7111	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-16	7112-7124	recreational	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-17	7125-7130	drugs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-18	7130-7131	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-19	7132-7135	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-20	7136-7139	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-21	7140-7156	contraindication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-22	7157-7160	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-23	7161-7164	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-24	7165-7173	scanning	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]
32-25	7173-7174	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[25]

#Text=A first-degree family history of schizophrenia or bipolar disorder was an additional exclusion criterion in the depression and control groups.
33-1	7175-7176	A	_
33-2	7177-7189	first-degree	_
33-3	7190-7196	family	_
33-4	7197-7204	history	_
33-5	7205-7207	of	_
33-6	7208-7221	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
33-7	7222-7224	or	_
33-8	7225-7232	bipolar	_
33-9	7233-7241	disorder	_
33-10	7242-7245	was	_
33-11	7246-7248	an	_
33-12	7249-7259	additional	_
33-13	7260-7269	exclusion	_
33-14	7270-7279	criterion	_
33-15	7280-7282	in	_
33-16	7283-7286	the	_
33-17	7287-7297	depression	http://maven.renci.org/NeuroBridge/neurobridge#Depression
33-18	7298-7301	and	_
33-19	7302-7309	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
33-20	7310-7316	groups	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[26]
33-21	7316-7317	.	_

#Text=All participants with depression or schizophrenia subjectively endorsed a degree of loss of interest or pleasure.
34-1	7318-7321	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-2	7322-7334	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-3	7335-7339	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-4	7340-7350	depression	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#Depression[28]
34-5	7351-7353	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-6	7354-7367	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]|http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia[29]
34-7	7368-7380	subjectively	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-8	7381-7389	endorsed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-9	7390-7391	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-10	7392-7398	degree	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-11	7399-7401	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-12	7402-7406	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-13	7407-7409	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-14	7410-7418	interest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-15	7419-7421	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-16	7422-7430	pleasure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]
34-17	7430-7431	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[27]

#Text=Anhedonia Assessment
#Text=To assess anhedonia we used the Snaith Hamilton Pleasure Scale (SHAPS), a validated self-report measure.
#Text=fMRI Task Description
#Text=The task involved playing a computerized version of a slot-machine game; participants view two reels of a slot-machine/one arm bandit game, where the left hand reel is stationary and the right hand reel spins until it stops (Figure 1).
35-1	7432-7441	Anhedonia	_
35-2	7442-7452	Assessment	_
35-3	7453-7455	To	_
35-4	7456-7462	assess	_
35-5	7463-7472	anhedonia	_
35-6	7473-7475	we	_
35-7	7476-7480	used	_
35-8	7481-7484	the	_
35-9	7485-7491	Snaith	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-10	7492-7500	Hamilton	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-11	7501-7509	Pleasure	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-12	7510-7515	Scale	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-13	7516-7517	(	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-14	7517-7522	SHAPS	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-15	7522-7523	)	http://maven.renci.org/NeuroBridge/neurobridge#NegativeSymptomScale[30]
35-16	7523-7524	,	_
35-17	7525-7526	a	_
35-18	7527-7536	validated	_
35-19	7537-7548	self-report	_
35-20	7549-7556	measure	_
35-21	7556-7557	.	_
35-22	7558-7562	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
35-23	7563-7567	Task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]
35-24	7568-7579	Description	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[31]
35-25	7580-7583	The	_
35-26	7584-7588	task	_
35-27	7589-7597	involved	_
35-28	7598-7605	playing	_
35-29	7606-7607	a	_
35-30	7608-7620	computerized	_
35-31	7621-7628	version	_
35-32	7629-7631	of	_
35-33	7632-7633	a	_
35-34	7634-7646	slot-machine	_
35-35	7647-7651	game	_
35-36	7651-7652	;	_
35-37	7653-7665	participants	_
35-38	7666-7670	view	_
35-39	7671-7674	two	_
35-40	7675-7680	reels	_
35-41	7681-7683	of	_
35-42	7684-7685	a	_
35-43	7686-7698	slot-machine	_
35-44	7698-7699	/	_
35-45	7699-7702	one	_
35-46	7703-7706	arm	_
35-47	7707-7713	bandit	_
35-48	7714-7718	game	_
35-49	7718-7719	,	_
35-50	7720-7725	where	_
35-51	7726-7729	the	_
35-52	7730-7734	left	_
35-53	7735-7739	hand	_
35-54	7740-7744	reel	_
35-55	7745-7747	is	_
35-56	7748-7758	stationary	_
35-57	7759-7762	and	_
35-58	7763-7766	the	_
35-59	7767-7772	right	_
35-60	7773-7777	hand	_
35-61	7778-7782	reel	_
35-62	7783-7788	spins	_
35-63	7789-7794	until	_
35-64	7795-7797	it	_
35-65	7798-7803	stops	_
35-66	7804-7805	(	_
35-67	7805-7811	Figure	_
35-68	7812-7813	1	_
35-69	7813-7814	)	_
35-70	7814-7815	.	_

#Text=If the two icons in the center of view match, there is a financial reward of 50 pence.
36-1	7816-7818	If	_
36-2	7819-7822	the	_
36-3	7823-7826	two	_
36-4	7827-7832	icons	_
36-5	7833-7835	in	_
36-6	7836-7839	the	_
36-7	7840-7846	center	_
36-8	7847-7849	of	_
36-9	7850-7854	view	_
36-10	7855-7860	match	_
36-11	7860-7861	,	_
36-12	7862-7867	there	_
36-13	7868-7870	is	_
36-14	7871-7872	a	_
36-15	7873-7882	financial	_
36-16	7883-7889	reward	_
36-17	7890-7892	of	_
36-18	7893-7895	50	_
36-19	7896-7901	pence	_
36-20	7901-7902	.	_

#Text=Participants win on an average one in six trials, making rewards unexpected in this game.
37-1	7903-7915	Participants	_
37-2	7916-7919	win	_
37-3	7920-7922	on	_
37-4	7923-7925	an	_
37-5	7926-7933	average	_
37-6	7934-7937	one	_
37-7	7938-7940	in	_
37-8	7941-7944	six	_
37-9	7945-7951	trials	_
37-10	7951-7952	,	_
37-11	7953-7959	making	_
37-12	7960-7967	rewards	_
37-13	7968-7978	unexpected	_
37-14	7979-7981	in	_
37-15	7982-7986	this	_
37-16	7987-7991	game	_
37-17	7991-7992	.	_

#Text=Furthermore, the duration of the spinning of the wheel is variable in this task (delay varies between 2.8 and 6 s), so the precise timing of the outcome is also not predictable.
38-1	7993-8004	Furthermore	_
38-2	8004-8005	,	_
38-3	8006-8009	the	_
38-4	8010-8018	duration	_
38-5	8019-8021	of	_
38-6	8022-8025	the	_
38-7	8026-8034	spinning	_
38-8	8035-8037	of	_
38-9	8038-8041	the	_
38-10	8042-8047	wheel	_
38-11	8048-8050	is	_
38-12	8051-8059	variable	_
38-13	8060-8062	in	_
38-14	8063-8067	this	_
38-15	8068-8072	task	_
38-16	8073-8074	(	_
38-17	8074-8079	delay	_
38-18	8080-8086	varies	_
38-19	8087-8094	between	_
38-20	8095-8098	2.8	_
38-21	8099-8102	and	_
38-22	8103-8104	6	_
38-23	8105-8106	s	_
38-24	8106-8107	)	_
38-25	8107-8108	,	_
38-26	8109-8111	so	_
38-27	8112-8115	the	_
38-28	8116-8123	precise	_
38-29	8124-8130	timing	_
38-30	8131-8133	of	_
38-31	8134-8137	the	_
38-32	8138-8145	outcome	_
38-33	8146-8148	is	_
38-34	8149-8153	also	_
38-35	8154-8157	not	_
38-36	8158-8169	predictable	_
38-37	8169-8170	.	_

#Text=The game consisted of two runs of 60 trials, each run lasting ~20 min, and has been previously described.
39-1	8171-8174	The	_
39-2	8175-8179	game	_
39-3	8180-8189	consisted	_
39-4	8190-8192	of	_
39-5	8193-8196	two	_
39-6	8197-8201	runs	_
39-7	8202-8204	of	_
39-8	8205-8207	60	_
39-9	8208-8214	trials	_
39-10	8214-8215	,	_
39-11	8216-8220	each	_
39-12	8221-8224	run	_
39-13	8225-8232	lasting	_
39-14	8233-8234	~	_
39-15	8234-8236	20	_
39-16	8237-8240	min	_
39-17	8240-8241	,	_
39-18	8242-8245	and	_
39-19	8246-8249	has	_
39-20	8250-8254	been	_
39-21	8255-8265	previously	_
39-22	8266-8275	described	_
39-23	8275-8276	.	_

#Text=On 50% of trials, the participant selects the ‘play icon'—the image in the center of the left hand reel—by rotating the reel to the icon of their choice.
40-1	8277-8279	On	_
40-2	8280-8283	50%	_
40-3	8284-8286	of	_
40-4	8287-8293	trials	_
40-5	8293-8294	,	_
40-6	8295-8298	the	_
40-7	8299-8310	participant	_
40-8	8311-8318	selects	_
40-9	8319-8322	the	_
40-10	8323-8324	‘	_
40-11	8324-8328	play	_
40-12	8329-8333	icon	_
40-13	8333-8334	'	_
40-14	8334-8335	—	_
40-15	8335-8338	the	_
40-16	8339-8344	image	_
40-17	8345-8347	in	_
40-18	8348-8351	the	_
40-19	8352-8358	center	_
40-20	8359-8361	of	_
40-21	8362-8365	the	_
40-22	8366-8370	left	_
40-23	8371-8375	hand	_
40-24	8376-8383	reel—by	_
40-25	8384-8392	rotating	_
40-26	8393-8396	the	_
40-27	8397-8401	reel	_
40-28	8402-8404	to	_
40-29	8405-8408	the	_
40-30	8409-8413	icon	_
40-31	8414-8416	of	_
40-32	8417-8422	their	_
40-33	8423-8429	choice	_
40-34	8429-8430	.	_

#Text=In the other 50% of trials (pseudorandomised distribution), the computer selects the ‘play icon' on these trials the participant is required to confirm with a button press that he/she has noted the computer choice.
41-1	8431-8433	In	_
41-2	8434-8437	the	_
41-3	8438-8443	other	_
41-4	8444-8447	50%	_
41-5	8448-8450	of	_
41-6	8451-8457	trials	_
41-7	8458-8459	(	_
41-8	8459-8475	pseudorandomised	_
41-9	8476-8488	distribution	_
41-10	8488-8489	)	_
41-11	8489-8490	,	_
41-12	8491-8494	the	_
41-13	8495-8503	computer	_
41-14	8504-8511	selects	_
41-15	8512-8515	the	_
41-16	8516-8517	‘	_
41-17	8517-8521	play	_
41-18	8522-8526	icon	_
41-19	8526-8527	'	_
41-20	8528-8530	on	_
41-21	8531-8536	these	_
41-22	8537-8543	trials	_
41-23	8544-8547	the	_
41-24	8548-8559	participant	_
41-25	8560-8562	is	_
41-26	8563-8571	required	_
41-27	8572-8574	to	_
41-28	8575-8582	confirm	_
41-29	8583-8587	with	_
41-30	8588-8589	a	_
41-31	8590-8596	button	_
41-32	8597-8602	press	_
41-33	8603-8607	that	_
41-34	8608-8610	he	_
41-35	8610-8611	/	_
41-36	8611-8614	she	_
41-37	8615-8618	has	_
41-38	8619-8624	noted	_
41-39	8625-8628	the	_
41-40	8629-8637	computer	_
41-41	8638-8644	choice	_
41-42	8644-8645	.	_

#Text=After this selection phase the right hand reel starts to spin.
42-1	8646-8651	After	_
42-2	8652-8656	this	_
42-3	8657-8666	selection	_
42-4	8667-8672	phase	_
42-5	8673-8676	the	_
42-6	8677-8682	right	_
42-7	8683-8687	hand	_
42-8	8688-8692	reel	_
42-9	8693-8699	starts	_
42-10	8700-8702	to	_
42-11	8703-8707	spin	_
42-12	8707-8708	.	_

#Text=The selection phase lasts 5 s, followed by a variable delay stage whilst the second reel spins and comes to a stop, followed by an outcome phase of 4 s where the reward is presented: ‘£0.50 win!'
43-1	8709-8712	The	_
43-2	8713-8722	selection	_
43-3	8723-8728	phase	_
43-4	8729-8734	lasts	_
43-5	8735-8736	5	_
43-6	8737-8738	s	_
43-7	8738-8739	,	_
43-8	8740-8748	followed	_
43-9	8749-8751	by	_
43-10	8752-8753	a	_
43-11	8754-8762	variable	_
43-12	8763-8768	delay	_
43-13	8769-8774	stage	_
43-14	8775-8781	whilst	_
43-15	8782-8785	the	_
43-16	8786-8792	second	_
43-17	8793-8797	reel	_
43-18	8798-8803	spins	_
43-19	8804-8807	and	_
43-20	8808-8813	comes	_
43-21	8814-8816	to	_
43-22	8817-8818	a	_
43-23	8819-8823	stop	_
43-24	8823-8824	,	_
43-25	8825-8833	followed	_
43-26	8834-8836	by	_
43-27	8837-8839	an	_
43-28	8840-8847	outcome	_
43-29	8848-8853	phase	_
43-30	8854-8856	of	_
43-31	8857-8858	4	_
43-32	8859-8860	s	_
43-33	8861-8866	where	_
43-34	8867-8870	the	_
43-35	8871-8877	reward	_
43-36	8878-8880	is	_
43-37	8881-8890	presented	_
43-38	8890-8891	:	_
43-39	8892-8893	‘	_
43-40	8893-8898	£0.50	_
43-41	8899-8902	win	_
43-42	8902-8903	!	_
43-43	8903-8904	'	_

#Text=(if the icons on the payline of the two reels match) or ‘No win' (if they do not match).
44-1	8905-8906	(	_
44-2	8906-8908	if	_
44-3	8909-8912	the	_
44-4	8913-8918	icons	_
44-5	8919-8921	on	_
44-6	8922-8925	the	_
44-7	8926-8933	payline	_
44-8	8934-8936	of	_
44-9	8937-8940	the	_
44-10	8941-8944	two	_
44-11	8945-8950	reels	_
44-12	8951-8956	match	_
44-13	8956-8957	)	_
44-14	8958-8960	or	_
44-15	8961-8962	‘	_
44-16	8962-8964	No	_
44-17	8965-8968	win	_
44-18	8968-8969	'	_
44-19	8970-8971	(	_
44-20	8971-8973	if	_
44-21	8974-8978	they	_
44-22	8979-8981	do	_
44-23	8982-8985	not	_
44-24	8986-8991	match	_
44-25	8991-8992	)	_
44-26	8992-8993	.	_

#Text=If selection/confirmation did not occur within 5 s, ‘too late' was presented on the screen and the task moved on to the next trial.
45-1	8994-8996	If	_
45-2	8997-9006	selection	_
45-3	9006-9007	/	_
45-4	9007-9019	confirmation	_
45-5	9020-9023	did	_
45-6	9024-9027	not	_
45-7	9028-9033	occur	_
45-8	9034-9040	within	_
45-9	9041-9042	5	_
45-10	9043-9044	s	_
45-11	9044-9045	,	_
45-12	9046-9047	‘	_
45-13	9047-9050	too	_
45-14	9051-9055	late	_
45-15	9055-9056	'	_
45-16	9057-9060	was	_
45-17	9061-9070	presented	_
45-18	9071-9073	on	_
45-19	9074-9077	the	_
45-20	9078-9084	screen	_
45-21	9085-9088	and	_
45-22	9089-9092	the	_
45-23	9093-9097	task	_
45-24	9098-9103	moved	_
45-25	9104-9106	on	_
45-26	9107-9109	to	_
45-27	9110-9113	the	_
45-28	9114-9118	next	_
45-29	9119-9124	trial	_
45-30	9124-9125	.	_

#Text=At the end of each trial, there was a variable inter-trial interval of between 2 and 7 s duration.
46-1	9126-9128	At	_
46-2	9129-9132	the	_
46-3	9133-9136	end	_
46-4	9137-9139	of	_
46-5	9140-9144	each	_
46-6	9145-9150	trial	_
46-7	9150-9151	,	_
46-8	9152-9157	there	_
46-9	9158-9161	was	_
46-10	9162-9163	a	_
46-11	9164-9172	variable	_
46-12	9173-9184	inter-trial	_
46-13	9185-9193	interval	_
46-14	9194-9196	of	_
46-15	9197-9204	between	_
46-16	9205-9206	2	_
46-17	9207-9210	and	_
46-18	9211-9212	7	_
46-19	9213-9214	s	_
46-20	9215-9223	duration	_
46-21	9223-9224	.	_

#Text=Participants were told that they would be given any money they won at the end of the experiment.
47-1	9225-9237	Participants	_
47-2	9238-9242	were	_
47-3	9243-9247	told	_
47-4	9248-9252	that	_
47-5	9253-9257	they	_
47-6	9258-9263	would	_
47-7	9264-9266	be	_
47-8	9267-9272	given	_
47-9	9273-9276	any	_
47-10	9277-9282	money	_
47-11	9283-9287	they	_
47-12	9288-9291	won	_
47-13	9292-9294	at	_
47-14	9295-9298	the	_
47-15	9299-9302	end	_
47-16	9303-9305	of	_
47-17	9306-9309	the	_
47-18	9310-9320	experiment	_
47-19	9320-9321	.	_

#Text=Task-related pleasure and motivation
#Text=Immediately after the scan session the participants answered the questions, ‘When the second picture matched the chosen picture you won money.
48-1	9322-9334	Task-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
48-2	9335-9343	pleasure	_
48-3	9344-9347	and	_
48-4	9348-9358	motivation	_
48-5	9359-9370	Immediately	_
48-6	9371-9376	after	_
48-7	9377-9380	the	_
48-8	9381-9385	scan	_
48-9	9386-9393	session	_
48-10	9394-9397	the	_
48-11	9398-9410	participants	_
48-12	9411-9419	answered	_
48-13	9420-9423	the	_
48-14	9424-9433	questions	_
48-15	9433-9434	,	_
48-16	9435-9436	‘	_
48-17	9436-9440	When	_
48-18	9441-9444	the	_
48-19	9445-9451	second	_
48-20	9452-9459	picture	_
48-21	9460-9467	matched	_
48-22	9468-9471	the	_
48-23	9472-9478	chosen	_
48-24	9479-9486	picture	_
48-25	9487-9490	you	_
48-26	9491-9494	won	_
48-27	9495-9500	money	_
48-28	9500-9501	.	_

#Text=How much did you like the feeling of winning money?'
49-1	9502-9505	How	_
49-2	9506-9510	much	_
49-3	9511-9514	did	_
49-4	9515-9518	you	_
49-5	9519-9523	like	_
49-6	9524-9527	the	_
49-7	9528-9535	feeling	_
49-8	9536-9538	of	_
49-9	9539-9546	winning	_
49-10	9547-9552	money	_
49-11	9552-9553	?	_
49-12	9553-9554	'	_

#Text=and, ‘When the second picture matched the chosen picture you won money.
50-1	9555-9558	and	_
50-2	9558-9559	,	_
50-3	9560-9561	‘	_
50-4	9561-9565	When	_
50-5	9566-9569	the	_
50-6	9570-9576	second	_
50-7	9577-9584	picture	_
50-8	9585-9592	matched	_
50-9	9593-9596	the	_
50-10	9597-9603	chosen	_
50-11	9604-9611	picture	_
50-12	9612-9615	you	_
50-13	9616-9619	won	_
50-14	9620-9625	money	_
50-15	9625-9626	.	_

#Text=Did this make you want to play more?'
51-1	9627-9630	Did	_
51-2	9631-9635	this	_
51-3	9636-9640	make	_
51-4	9641-9644	you	_
51-5	9645-9649	want	_
51-6	9650-9652	to	_
51-7	9653-9657	play	_
51-8	9658-9662	more	_
51-9	9662-9663	?	_
51-10	9663-9664	'	_

#Text=The answers were marked on a visual analog scale.
#Text=fMRI Data Acquisition and Pre-Processing
#Text=A Siemens Trio Tim operating at 3T was used to collect imaging data.
52-1	9665-9668	The	_
52-2	9669-9676	answers	_
52-3	9677-9681	were	_
52-4	9682-9688	marked	_
52-5	9689-9691	on	_
52-6	9692-9693	a	_
52-7	9694-9700	visual	_
52-8	9701-9707	analog	_
52-9	9708-9713	scale	_
52-10	9713-9714	.	_
52-11	9715-9719	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]
52-12	9720-9724	Data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]
52-13	9725-9736	Acquisition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[32]
52-14	9737-9740	and	_
52-15	9741-9755	Pre-Processing	_
52-16	9756-9757	A	_
52-17	9758-9765	Siemens	_
52-18	9766-9770	Trio	_
52-19	9771-9774	Tim	_
52-20	9775-9784	operating	_
52-21	9785-9787	at	_
52-22	9788-9790	3T	_
52-23	9791-9794	was	_
52-24	9795-9799	used	_
52-25	9800-9802	to	_
52-26	9803-9810	collect	_
52-27	9811-9818	imaging	_
52-28	9819-9823	data	_
52-29	9823-9824	.	_

#Text=Gradient-echo T2*-weighted echo planar images depicting BOLD contrast were acquired from 32 noncontiguous oblique axial planes to minimize signal drop-out in ventral regions.
53-1	9825-9838	Gradient-echo	_
53-2	9839-9841	T2	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-3	9841-9842	*	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-4	9842-9843	-	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-5	9843-9851	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-6	9852-9856	echo	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-7	9857-9863	planar	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-8	9864-9870	images	http://maven.renci.org/NeuroBridge/neurobridge#T2WeightedImaging[33]
53-9	9871-9880	depicting	_
53-10	9881-9885	BOLD	_
53-11	9886-9894	contrast	_
53-12	9895-9899	were	_
53-13	9900-9908	acquired	_
53-14	9909-9913	from	_
53-15	9914-9916	32	_
53-16	9917-9930	noncontiguous	_
53-17	9931-9938	oblique	_
53-18	9939-9944	axial	_
53-19	9945-9951	planes	_
53-20	9952-9954	to	_
53-21	9955-9963	minimize	_
53-22	9964-9970	signal	_
53-23	9971-9979	drop-out	_
53-24	9980-9982	in	_
53-25	9983-9990	ventral	_
53-26	9991-9998	regions	_
53-27	9998-9999	.	_

#Text=TR=2 s; echo time=30 ms; flip angle=78; voxel size=3.14 × 3.14 × 3.75 mm3, matrix size 64 × 64; bandwidth 2232 HZ/Px.
54-1	10000-10002	TR	_
54-2	10002-10003	=	_
54-3	10003-10004	2	_
54-4	10005-10006	s	_
54-5	10006-10007	;	_
54-6	10008-10012	echo	_
54-7	10013-10017	time	_
54-8	10017-10018	=	_
54-9	10018-10020	30	_
54-10	10021-10023	ms	_
54-11	10023-10024	;	_
54-12	10025-10029	flip	_
54-13	10030-10035	angle	_
54-14	10035-10036	=	_
54-15	10036-10038	78	_
54-16	10038-10039	;	_
54-17	10040-10045	voxel	_
54-18	10046-10050	size	_
54-19	10050-10051	=	_
54-20	10051-10055	3.14	_
54-21	10056-10057	×	_
54-22	10058-10062	3.14	_
54-23	10063-10064	×	_
54-24	10065-10069	3.75	_
54-25	10070-10073	mm3	_
54-26	10073-10074	,	_
54-27	10075-10081	matrix	_
54-28	10082-10086	size	_
54-29	10087-10089	64	_
54-30	10090-10091	×	_
54-31	10092-10094	64	_
54-32	10094-10095	;	_
54-33	10096-10105	bandwidth	_
54-34	10106-10110	2232	_
54-35	10111-10113	HZ	_
54-36	10113-10114	/	_
54-37	10114-10116	Px	_
54-38	10116-10117	.	_

#Text=A high-resolution T1-weighted three-dimensional MP-RAGE structural image was also acquired for use in spatial normalization of the EPI series.
55-1	10118-10119	A	_
55-2	10120-10135	high-resolution	_
55-3	10136-10138	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-4	10138-10139	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-5	10139-10147	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-6	10148-10165	three-dimensional	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-7	10166-10173	MP-RAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-8	10174-10184	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-9	10185-10190	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[34]
55-10	10191-10194	was	_
55-11	10195-10199	also	_
55-12	10200-10208	acquired	_
55-13	10209-10212	for	_
55-14	10213-10216	use	_
55-15	10217-10219	in	_
55-16	10220-10227	spatial	_
55-17	10228-10241	normalization	_
55-18	10242-10244	of	_
55-19	10245-10248	the	_
55-20	10249-10252	EPI	_
55-21	10253-10259	series	_
55-22	10259-10260	.	_

#Text=Imaging data was analyzed using FSL software (FMRIB's Software Library, www.fmrib.ox.ac.uk/fsl).
56-1	10261-10268	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]
56-2	10269-10273	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]
56-3	10274-10277	was	_
56-4	10278-10286	analyzed	_
56-5	10287-10292	using	_
56-6	10293-10296	FSL	_
56-7	10297-10305	software	_
56-8	10306-10307	(	_
56-9	10307-10314	FMRIB's	_
56-10	10315-10323	Software	_
56-11	10324-10331	Library	_
56-12	10331-10332	,	_
56-13	10333-10351	www.fmrib.ox.ac.uk	_
56-14	10351-10352	/	_
56-15	10352-10355	fsl	_
56-16	10355-10356	)	_
56-17	10356-10357	.	_

#Text=See Supplementary Material for pre-processing details.
#Text=fMRI Data Analysis
#Text=An event-related analysis in FSL software was used to identify neural responses at the time of the unexpected win.
57-1	10358-10361	See	_
57-2	10362-10375	Supplementary	_
57-3	10376-10384	Material	_
57-4	10385-10388	for	_
57-5	10389-10403	pre-processing	_
57-6	10404-10411	details	_
57-7	10411-10412	.	_
57-8	10413-10417	fMRI	_
57-9	10418-10422	Data	_
57-10	10423-10431	Analysis	_
57-11	10432-10434	An	_
57-12	10435-10448	event-related	_
57-13	10449-10457	analysis	_
57-14	10458-10460	in	_
57-15	10461-10464	FSL	_
57-16	10465-10473	software	_
57-17	10474-10477	was	_
57-18	10478-10482	used	_
57-19	10483-10485	to	_
57-20	10486-10494	identify	_
57-21	10495-10501	neural	_
57-22	10502-10511	responses	_
57-23	10512-10514	at	_
57-24	10515-10518	the	_
57-25	10519-10523	time	_
57-26	10524-10526	of	_
57-27	10527-10530	the	_
57-28	10531-10541	unexpected	_
57-29	10542-10545	win	_
57-30	10545-10546	.	_

#Text=We used a single statistical linear regression model with four explanatory variables and their temporal derivatives: (a) anticipation phase (the duration of this event varied between 2.8 and 6 s on different trials); (b) win outcome (4 s duration, 20 events in total); (c) near-miss outcomes (4 s duration, 40 events in total); (d) full-miss outcomes (4 s duration, 60 events in total).
58-1	10547-10549	We	_
58-2	10550-10554	used	_
58-3	10555-10556	a	_
58-4	10557-10563	single	_
58-5	10564-10575	statistical	_
58-6	10576-10582	linear	_
58-7	10583-10593	regression	_
58-8	10594-10599	model	_
58-9	10600-10604	with	_
58-10	10605-10609	four	_
58-11	10610-10621	explanatory	_
58-12	10622-10631	variables	_
58-13	10632-10635	and	_
58-14	10636-10641	their	_
58-15	10642-10650	temporal	_
58-16	10651-10662	derivatives	_
58-17	10662-10663	:	_
58-18	10664-10665	(	_
58-19	10665-10666	a	_
58-20	10666-10667	)	_
58-21	10668-10680	anticipation	_
58-22	10681-10686	phase	_
58-23	10687-10688	(	_
58-24	10688-10691	the	_
58-25	10692-10700	duration	_
58-26	10701-10703	of	_
58-27	10704-10708	this	_
58-28	10709-10714	event	_
58-29	10715-10721	varied	_
58-30	10722-10729	between	_
58-31	10730-10733	2.8	_
58-32	10734-10737	and	_
58-33	10738-10739	6	_
58-34	10740-10741	s	_
58-35	10742-10744	on	_
58-36	10745-10754	different	_
58-37	10755-10761	trials	_
58-38	10761-10762	)	_
58-39	10762-10763	;	_
58-40	10764-10765	(	_
58-41	10765-10766	b	_
58-42	10766-10767	)	_
58-43	10768-10771	win	_
58-44	10772-10779	outcome	_
58-45	10780-10781	(	_
58-46	10781-10782	4	_
58-47	10783-10784	s	_
58-48	10785-10793	duration	_
58-49	10793-10794	,	_
58-50	10795-10797	20	_
58-51	10798-10804	events	_
58-52	10805-10807	in	_
58-53	10808-10813	total	_
58-54	10813-10814	)	_
58-55	10814-10815	;	_
58-56	10816-10817	(	_
58-57	10817-10818	c	_
58-58	10818-10819	)	_
58-59	10820-10829	near-miss	_
58-60	10830-10838	outcomes	_
58-61	10839-10840	(	_
58-62	10840-10841	4	_
58-63	10842-10843	s	_
58-64	10844-10852	duration	_
58-65	10852-10853	,	_
58-66	10854-10856	40	_
58-67	10857-10863	events	_
58-68	10864-10866	in	_
58-69	10867-10872	total	_
58-70	10872-10873	)	_
58-71	10873-10874	;	_
58-72	10875-10876	(	_
58-73	10876-10877	d	_
58-74	10877-10878	)	_
58-75	10879-10888	full-miss	_
58-76	10889-10897	outcomes	_
58-77	10898-10899	(	_
58-78	10899-10900	4	_
58-79	10901-10902	s	_
58-80	10903-10911	duration	_
58-81	10911-10912	,	_
58-82	10913-10915	60	_
58-83	10916-10922	events	_
58-84	10923-10925	in	_
58-85	10926-10931	total	_
58-86	10931-10932	)	_
58-87	10932-10933	.	_

#Text=A near-miss outcome is where the play icon finishes adjacent to, but not on, the payline; near-miss outcomes have been shown to evoke neural responses different to other misses.
59-1	10934-10935	A	_
59-2	10936-10945	near-miss	_
59-3	10946-10953	outcome	_
59-4	10954-10956	is	_
59-5	10957-10962	where	_
59-6	10963-10966	the	_
59-7	10967-10971	play	_
59-8	10972-10976	icon	_
59-9	10977-10985	finishes	_
59-10	10986-10994	adjacent	_
59-11	10995-10997	to	_
59-12	10997-10998	,	_
59-13	10999-11002	but	_
59-14	11003-11006	not	_
59-15	11007-11009	on	_
59-16	11009-11010	,	_
59-17	11011-11014	the	_
59-18	11015-11022	payline	_
59-19	11022-11023	;	_
59-20	11024-11033	near-miss	_
59-21	11034-11042	outcomes	_
59-22	11043-11047	have	_
59-23	11048-11052	been	_
59-24	11053-11058	shown	_
59-25	11059-11061	to	_
59-26	11062-11067	evoke	_
59-27	11068-11074	neural	_
59-28	11075-11084	responses	_
59-29	11085-11094	different	_
59-30	11095-11097	to	_
59-31	11098-11103	other	_
59-32	11104-11110	misses	_
59-33	11110-11111	.	_

#Text=Movement parameters from the realignment step were also included in the first-level model.
60-1	11112-11120	Movement	_
60-2	11121-11131	parameters	_
60-3	11132-11136	from	_
60-4	11137-11140	the	_
60-5	11141-11152	realignment	_
60-6	11153-11157	step	_
60-7	11158-11162	were	_
60-8	11163-11167	also	_
60-9	11168-11176	included	_
60-10	11177-11179	in	_
60-11	11180-11183	the	_
60-12	11184-11195	first-level	_
60-13	11196-11201	model	_
60-14	11201-11202	.	_

#Text=As our hypotheses concerned brain activation in response to unexpected reward, an ‘unexpected reward receipt' contrast was investigated, formed by the contrast of win outcomes vs full-miss outcomes.
61-1	11203-11205	As	_
61-2	11206-11209	our	_
61-3	11210-11220	hypotheses	_
61-4	11221-11230	concerned	_
61-5	11231-11236	brain	_
61-6	11237-11247	activation	_
61-7	11248-11250	in	_
61-8	11251-11259	response	_
61-9	11260-11262	to	_
61-10	11263-11273	unexpected	_
61-11	11274-11280	reward	_
61-12	11280-11281	,	_
61-13	11282-11284	an	_
61-14	11285-11286	‘	_
61-15	11286-11296	unexpected	_
61-16	11297-11303	reward	_
61-17	11304-11311	receipt	_
61-18	11311-11312	'	_
61-19	11313-11321	contrast	_
61-20	11322-11325	was	_
61-21	11326-11338	investigated	_
61-22	11338-11339	,	_
61-23	11340-11346	formed	_
61-24	11347-11349	by	_
61-25	11350-11353	the	_
61-26	11354-11362	contrast	_
61-27	11363-11365	of	_
61-28	11366-11369	win	_
61-29	11370-11378	outcomes	_
61-30	11379-11381	vs	_
61-31	11382-11391	full-miss	_
61-32	11392-11400	outcomes	_
61-33	11400-11401	.	_

#Text=This contrast was computed at the single-participant level and the β-parameters for participants from this contrast were carried forward to group analyses.
62-1	11402-11406	This	_
62-2	11407-11415	contrast	_
62-3	11416-11419	was	_
62-4	11420-11428	computed	_
62-5	11429-11431	at	_
62-6	11432-11435	the	_
62-7	11436-11454	single-participant	_
62-8	11455-11460	level	_
62-9	11461-11464	and	_
62-10	11465-11468	the	_
62-11	11469-11481	β-parameters	_
62-12	11482-11485	for	_
62-13	11486-11498	participants	_
62-14	11499-11503	from	_
62-15	11504-11508	this	_
62-16	11509-11517	contrast	_
62-17	11518-11522	were	_
62-18	11523-11530	carried	_
62-19	11531-11538	forward	_
62-20	11539-11541	to	_
62-21	11542-11547	group	_
62-22	11548-11556	analyses	_
62-23	11556-11557	.	_

#Text=One-way between participants ANOVA was conducted at the whole-brain level to compare between the three groups.
63-1	11558-11565	One-way	_
63-2	11566-11573	between	_
63-3	11574-11586	participants	_
63-4	11587-11592	ANOVA	_
63-5	11593-11596	was	_
63-6	11597-11606	conducted	_
63-7	11607-11609	at	_
63-8	11610-11613	the	_
63-9	11614-11625	whole-brain	_
63-10	11626-11631	level	_
63-11	11632-11634	to	_
63-12	11635-11642	compare	_
63-13	11643-11650	between	_
63-14	11651-11654	the	_
63-15	11655-11660	three	_
63-16	11661-11667	groups	_
63-17	11667-11668	.	_

#Text=The one-way ANOVA only identifies regions in which activation is different between groups, without indicating which groups drive the differences or the directionality of the differences.
64-1	11669-11672	The	_
64-2	11673-11680	one-way	_
64-3	11681-11686	ANOVA	_
64-4	11687-11691	only	_
64-5	11692-11702	identifies	_
64-6	11703-11710	regions	_
64-7	11711-11713	in	_
64-8	11714-11719	which	_
64-9	11720-11730	activation	_
64-10	11731-11733	is	_
64-11	11734-11743	different	_
64-12	11744-11751	between	_
64-13	11752-11758	groups	_
64-14	11758-11759	,	_
64-15	11760-11767	without	_
64-16	11768-11778	indicating	_
64-17	11779-11784	which	_
64-18	11785-11791	groups	_
64-19	11792-11797	drive	_
64-20	11798-11801	the	_
64-21	11802-11813	differences	_
64-22	11814-11816	or	_
64-23	11817-11820	the	_
64-24	11821-11835	directionality	_
64-25	11836-11838	of	_
64-26	11839-11842	the	_
64-27	11843-11854	differences	_
64-28	11854-11855	.	_

#Text=Therefore, for clusters in which the ANOVA indicated group differences we extracted the mean parameter estimates for each subject for that cluster (using the FSL tool Featquery) and conducted post hoc comparisons across groups.
65-1	11856-11865	Therefore	_
65-2	11865-11866	,	_
65-3	11867-11870	for	_
65-4	11871-11879	clusters	_
65-5	11880-11882	in	_
65-6	11883-11888	which	_
65-7	11889-11892	the	_
65-8	11893-11898	ANOVA	_
65-9	11899-11908	indicated	_
65-10	11909-11914	group	_
65-11	11915-11926	differences	_
65-12	11927-11929	we	_
65-13	11930-11939	extracted	_
65-14	11940-11943	the	_
65-15	11944-11948	mean	_
65-16	11949-11958	parameter	_
65-17	11959-11968	estimates	_
65-18	11969-11972	for	_
65-19	11973-11977	each	_
65-20	11978-11985	subject	_
65-21	11986-11989	for	_
65-22	11990-11994	that	_
65-23	11995-12002	cluster	_
65-24	12003-12004	(	_
65-25	12004-12009	using	_
65-26	12010-12013	the	_
65-27	12014-12017	FSL	_
65-28	12018-12022	tool	_
65-29	12023-12032	Featquery	_
65-30	12032-12033	)	_
65-31	12034-12037	and	_
65-32	12038-12047	conducted	_
65-33	12048-12052	post	_
65-34	12053-12056	hoc	_
65-35	12057-12068	comparisons	_
65-36	12069-12075	across	_
65-37	12076-12082	groups	_
65-38	12082-12083	.	_

#Text=Regression analyses at the whole-brain level in FSL were used to investigate relationships between brain activation and the post-scan subjective ratings of motivation and pleasure.
66-1	12084-12094	Regression	_
66-2	12095-12103	analyses	_
66-3	12104-12106	at	_
66-4	12107-12110	the	_
66-5	12111-12122	whole-brain	_
66-6	12123-12128	level	_
66-7	12129-12131	in	_
66-8	12132-12135	FSL	_
66-9	12136-12140	were	_
66-10	12141-12145	used	_
66-11	12146-12148	to	_
66-12	12149-12160	investigate	_
66-13	12161-12174	relationships	_
66-14	12175-12182	between	_
66-15	12183-12188	brain	_
66-16	12189-12199	activation	_
66-17	12200-12203	and	_
66-18	12204-12207	the	_
66-19	12208-12217	post-scan	_
66-20	12218-12228	subjective	_
66-21	12229-12236	ratings	_
66-22	12237-12239	of	_
66-23	12240-12250	motivation	_
66-24	12251-12254	and	_
66-25	12255-12263	pleasure	_
66-26	12263-12264	.	_

#Text=Imaging comparisons were cluster thresholded using the FSL tool easythresh, using a family-wise error (FWE) correction at p<0.05 (initial cluster threshold z=2).
67-1	12265-12272	Imaging	_
67-2	12273-12284	comparisons	_
67-3	12285-12289	were	_
67-4	12290-12297	cluster	_
67-5	12298-12309	thresholded	_
67-6	12310-12315	using	_
67-7	12316-12319	the	_
67-8	12320-12323	FSL	_
67-9	12324-12328	tool	_
67-10	12329-12339	easythresh	_
67-11	12339-12340	,	_
67-12	12341-12346	using	_
67-13	12347-12348	a	_
67-14	12349-12360	family-wise	_
67-15	12361-12366	error	_
67-16	12367-12368	(	_
67-17	12368-12371	FWE	_
67-18	12371-12372	)	_
67-19	12373-12383	correction	_
67-20	12384-12386	at	_
67-21	12387-12388	p	_
67-22	12388-12389	<	_
67-23	12389-12393	0.05	_
67-24	12394-12395	(	_
67-25	12395-12402	initial	_
67-26	12403-12410	cluster	_
67-27	12411-12420	threshold	_
67-28	12421-12422	z	_
67-29	12422-12423	=	_
67-30	12423-12424	2	_
67-31	12424-12425	)	_
67-32	12425-12426	.	_

#Text=Results
#Text=Demographics and Rating Scales
#Text=Groups did not differ in age, gender, handedness, years of education, IQ, or ethnicity (Table 1).
68-1	12427-12434	Results	_
68-2	12435-12447	Demographics	_
68-3	12448-12451	and	_
68-4	12452-12458	Rating	_
68-5	12459-12465	Scales	_
68-6	12466-12472	Groups	_
68-7	12473-12476	did	_
68-8	12477-12480	not	_
68-9	12481-12487	differ	_
68-10	12488-12490	in	_
68-11	12491-12494	age	_
68-12	12494-12495	,	_
68-13	12496-12502	gender	_
68-14	12502-12503	,	_
68-15	12504-12514	handedness	_
68-16	12514-12515	,	_
68-17	12516-12521	years	_
68-18	12522-12524	of	_
68-19	12525-12534	education	_
68-20	12534-12535	,	_
68-21	12536-12538	IQ	_
68-22	12538-12539	,	_
68-23	12540-12542	or	_
68-24	12543-12552	ethnicity	_
68-25	12553-12554	(	_
68-26	12554-12559	Table	_
68-27	12560-12561	1	_
68-28	12561-12562	)	_
68-29	12562-12563	.	_

#Text=Patients with depression had higher SHAPS anhedonia scores than healthy controls and patients with schizophrenia.
69-1	12564-12572	Patients	_
69-2	12573-12577	with	_
69-3	12578-12588	depression	_
69-4	12589-12592	had	_
69-5	12593-12599	higher	_
69-6	12600-12605	SHAPS	_
69-7	12606-12615	anhedonia	_
69-8	12616-12622	scores	_
69-9	12623-12627	than	_
69-10	12628-12635	healthy	_
69-11	12636-12644	controls	_
69-12	12645-12648	and	_
69-13	12649-12657	patients	_
69-14	12658-12662	with	_
69-15	12663-12676	schizophrenia	_
69-16	12676-12677	.	_

#Text=Patients with schizophrenia had higher SHAPS anhedonia scores compared with controls (Table 1).
70-1	12678-12686	Patients	_
70-2	12687-12691	with	_
70-3	12692-12705	schizophrenia	_
70-4	12706-12709	had	_
70-5	12710-12716	higher	_
70-6	12717-12722	SHAPS	_
70-7	12723-12732	anhedonia	_
70-8	12733-12739	scores	_
70-9	12740-12748	compared	_
70-10	12749-12753	with	_
70-11	12754-12762	controls	_
70-12	12763-12764	(	_
70-13	12764-12769	Table	_
70-14	12770-12771	1	_
70-15	12771-12772	)	_
70-16	12772-12773	.	_

#Text=The three groups did not differ on a visual analog measure of how much they valued 50 pence (answer to question ‘how often do you pick up a 50 pence coin when you see it in the street' p=0.843).
71-1	12774-12777	The	_
71-2	12778-12783	three	_
71-3	12784-12790	groups	_
71-4	12791-12794	did	_
71-5	12795-12798	not	_
71-6	12799-12805	differ	_
71-7	12806-12808	on	_
71-8	12809-12810	a	_
71-9	12811-12817	visual	_
71-10	12818-12824	analog	_
71-11	12825-12832	measure	_
71-12	12833-12835	of	_
71-13	12836-12839	how	_
71-14	12840-12844	much	_
71-15	12845-12849	they	_
71-16	12850-12856	valued	_
71-17	12857-12859	50	_
71-18	12860-12865	pence	_
71-19	12866-12867	(	_
71-20	12867-12873	answer	_
71-21	12874-12876	to	_
71-22	12877-12885	question	_
71-23	12886-12887	‘	_
71-24	12887-12890	how	_
71-25	12891-12896	often	_
71-26	12897-12899	do	_
71-27	12900-12903	you	_
71-28	12904-12908	pick	_
71-29	12909-12911	up	_
71-30	12912-12913	a	_
71-31	12914-12916	50	_
71-32	12917-12922	pence	_
71-33	12923-12927	coin	_
71-34	12928-12932	when	_
71-35	12933-12936	you	_
71-36	12937-12940	see	_
71-37	12941-12943	it	_
71-38	12944-12946	in	_
71-39	12947-12950	the	_
71-40	12951-12957	street	_
71-41	12957-12958	'	_
71-42	12959-12960	p	_
71-43	12960-12961	=	_
71-44	12961-12966	0.843	_
71-45	12966-12967	)	_
71-46	12967-12968	.	_

#Text=Behavioral Analysis
#Text=Reward task wins
#Text=There were no differences in the number of wins according to group, reflecting the pseudo-randomized nature of the paradigm (wins F=2.23, df=2,65, p=0.11).
72-1	12969-12979	Behavioral	_
72-2	12980-12988	Analysis	_
72-3	12989-12995	Reward	_
72-4	12996-13000	task	_
72-5	13001-13005	wins	_
72-6	13006-13011	There	_
72-7	13012-13016	were	_
72-8	13017-13019	no	_
72-9	13020-13031	differences	_
72-10	13032-13034	in	_
72-11	13035-13038	the	_
72-12	13039-13045	number	_
72-13	13046-13048	of	_
72-14	13049-13053	wins	_
72-15	13054-13063	according	_
72-16	13064-13066	to	_
72-17	13067-13072	group	_
72-18	13072-13073	,	_
72-19	13074-13084	reflecting	_
72-20	13085-13088	the	_
72-21	13089-13106	pseudo-randomized	_
72-22	13107-13113	nature	_
72-23	13114-13116	of	_
72-24	13117-13120	the	_
72-25	13121-13129	paradigm	_
72-26	13130-13131	(	_
72-27	13131-13135	wins	_
72-28	13136-13137	F	_
72-29	13137-13138	=	_
72-30	13138-13142	2.23	_
72-31	13142-13143	,	_
72-32	13144-13146	df	_
72-33	13146-13147	=	_
72-34	13147-13151	2,65	_
72-35	13151-13152	,	_
72-36	13153-13154	p	_
72-37	13154-13155	=	_
72-38	13155-13159	0.11	_
72-39	13159-13160	)	_
72-40	13160-13161	.	_

#Text=Reward task post-scan questions (reward liking and task motivation)
#Text=Participants with depression reported significantly lower liking of the feeling of winning money than controls (depression: mean=56.3, SD=23.2; controls: mean=74.3, SD=21.0; t=2.7, df=43, p=0.009).
73-1	13162-13168	Reward	_
73-2	13169-13173	task	_
73-3	13174-13183	post-scan	_
73-4	13184-13193	questions	_
73-5	13194-13195	(	_
73-6	13195-13201	reward	_
73-7	13202-13208	liking	_
73-8	13209-13212	and	_
73-9	13213-13217	task	_
73-10	13218-13228	motivation	_
73-11	13228-13229	)	_
73-12	13230-13242	Participants	_
73-13	13243-13247	with	_
73-14	13248-13258	depression	_
73-15	13259-13267	reported	_
73-16	13268-13281	significantly	_
73-17	13282-13287	lower	_
73-18	13288-13294	liking	_
73-19	13295-13297	of	_
73-20	13298-13301	the	_
73-21	13302-13309	feeling	_
73-22	13310-13312	of	_
73-23	13313-13320	winning	_
73-24	13321-13326	money	_
73-25	13327-13331	than	_
73-26	13332-13340	controls	_
73-27	13341-13342	(	_
73-28	13342-13352	depression	_
73-29	13352-13353	:	_
73-30	13354-13358	mean	_
73-31	13358-13359	=	_
73-32	13359-13363	56.3	_
73-33	13363-13364	,	_
73-34	13365-13367	SD	_
73-35	13367-13368	=	_
73-36	13368-13372	23.2	_
73-37	13372-13373	;	_
73-38	13374-13382	controls	_
73-39	13382-13383	:	_
73-40	13384-13388	mean	_
73-41	13388-13389	=	_
73-42	13389-13393	74.3	_
73-43	13393-13394	,	_
73-44	13395-13397	SD	_
73-45	13397-13398	=	_
73-46	13398-13402	21.0	_
73-47	13402-13403	;	_
73-48	13404-13405	t	_
73-49	13405-13406	=	_
73-50	13406-13409	2.7	_
73-51	13409-13410	,	_
73-52	13411-13413	df	_
73-53	13413-13414	=	_
73-54	13414-13416	43	_
73-55	13416-13417	,	_
73-56	13418-13419	p	_
73-57	13419-13420	=	_
73-58	13420-13425	0.009	_
73-59	13425-13426	)	_
73-60	13426-13427	.	_

#Text=In this measure of liking there was a marginal difference between schizophrenia participants (mean=61.1, SD=27.9) and controls (t=1.75, df=40, p=0.09), and no difference between schizophrenia and depression participants (t=0.65, df=43, p=0.52).
74-1	13428-13430	In	_
74-2	13431-13435	this	_
74-3	13436-13443	measure	_
74-4	13444-13446	of	_
74-5	13447-13453	liking	_
74-6	13454-13459	there	_
74-7	13460-13463	was	_
74-8	13464-13465	a	_
74-9	13466-13474	marginal	_
74-10	13475-13485	difference	_
74-11	13486-13493	between	_
74-12	13494-13507	schizophrenia	_
74-13	13508-13520	participants	_
74-14	13521-13522	(	_
74-15	13522-13526	mean	_
74-16	13526-13527	=	_
74-17	13527-13531	61.1	_
74-18	13531-13532	,	_
74-19	13533-13535	SD	_
74-20	13535-13536	=	_
74-21	13536-13540	27.9	_
74-22	13540-13541	)	_
74-23	13542-13545	and	_
74-24	13546-13554	controls	_
74-25	13555-13556	(	_
74-26	13556-13557	t	_
74-27	13557-13558	=	_
74-28	13558-13562	1.75	_
74-29	13562-13563	,	_
74-30	13564-13566	df	_
74-31	13566-13567	=	_
74-32	13567-13569	40	_
74-33	13569-13570	,	_
74-34	13571-13572	p	_
74-35	13572-13573	=	_
74-36	13573-13577	0.09	_
74-37	13577-13578	)	_
74-38	13578-13579	,	_
74-39	13580-13583	and	_
74-40	13584-13586	no	_
74-41	13587-13597	difference	_
74-42	13598-13605	between	_
74-43	13606-13619	schizophrenia	_
74-44	13620-13623	and	_
74-45	13624-13634	depression	_
74-46	13635-13647	participants	_
74-47	13648-13649	(	_
74-48	13649-13650	t	_
74-49	13650-13651	=	_
74-50	13651-13655	0.65	_
74-51	13655-13656	,	_
74-52	13657-13659	df	_
74-53	13659-13660	=	_
74-54	13660-13662	43	_
74-55	13662-13663	,	_
74-56	13664-13665	p	_
74-57	13665-13666	=	_
74-58	13666-13670	0.52	_
74-59	13670-13671	)	_
74-60	13671-13672	.	_

#Text=In response to the question ‘When the second picture matched the chosen picture you won money.
75-1	13673-13675	In	_
75-2	13676-13684	response	_
75-3	13685-13687	to	_
75-4	13688-13691	the	_
75-5	13692-13700	question	_
75-6	13701-13702	‘	_
75-7	13702-13706	When	_
75-8	13707-13710	the	_
75-9	13711-13717	second	_
75-10	13718-13725	picture	_
75-11	13726-13733	matched	_
75-12	13734-13737	the	_
75-13	13738-13744	chosen	_
75-14	13745-13752	picture	_
75-15	13753-13756	you	_
75-16	13757-13760	won	_
75-17	13761-13766	money	_
75-18	13766-13767	.	_

#Text=Did this make you want to play more?'
76-1	13768-13771	Did	_
76-2	13772-13776	this	_
76-3	13777-13781	make	_
76-4	13782-13785	you	_
76-5	13786-13790	want	_
76-6	13791-13793	to	_
76-7	13794-13798	play	_
76-8	13799-13803	more	_
76-9	13803-13804	?	_
76-10	13804-13805	'	_

#Text=, there was a significantly higher score in controls (mean=67.0, SD=29.2) than depression patients (mean=44.4, SD=25.7; comparison t=2.87, df=42, p=0.009).
77-1	13805-13806	,	_
77-2	13807-13812	there	_
77-3	13813-13816	was	_
77-4	13817-13818	a	_
77-5	13819-13832	significantly	_
77-6	13833-13839	higher	_
77-7	13840-13845	score	_
77-8	13846-13848	in	_
77-9	13849-13857	controls	_
77-10	13858-13859	(	_
77-11	13859-13863	mean	_
77-12	13863-13864	=	_
77-13	13864-13868	67.0	_
77-14	13868-13869	,	_
77-15	13870-13872	SD	_
77-16	13872-13873	=	_
77-17	13873-13877	29.2	_
77-18	13877-13878	)	_
77-19	13879-13883	than	_
77-20	13884-13894	depression	_
77-21	13895-13903	patients	_
77-22	13904-13905	(	_
77-23	13905-13909	mean	_
77-24	13909-13910	=	_
77-25	13910-13914	44.4	_
77-26	13914-13915	,	_
77-27	13916-13918	SD	_
77-28	13918-13919	=	_
77-29	13919-13923	25.7	_
77-30	13923-13924	;	_
77-31	13925-13935	comparison	_
77-32	13936-13937	t	_
77-33	13937-13938	=	_
77-34	13938-13942	2.87	_
77-35	13942-13943	,	_
77-36	13944-13946	df	_
77-37	13946-13947	=	_
77-38	13947-13949	42	_
77-39	13949-13950	,	_
77-40	13951-13952	p	_
77-41	13952-13953	=	_
77-42	13953-13958	0.009	_
77-43	13958-13959	)	_
77-44	13959-13960	.	_

#Text=Controls scored higher than schizophrenia patients on this measure with marginal statistical significance (schizophrenia: mean=48.3, SD=30.4; comparison controls vs schizophrenia t=2.0, df=39, p=0.05).
78-1	13961-13969	Controls	_
78-2	13970-13976	scored	_
78-3	13977-13983	higher	_
78-4	13984-13988	than	_
78-5	13989-14002	schizophrenia	_
78-6	14003-14011	patients	_
78-7	14012-14014	on	_
78-8	14015-14019	this	_
78-9	14020-14027	measure	_
78-10	14028-14032	with	_
78-11	14033-14041	marginal	_
78-12	14042-14053	statistical	_
78-13	14054-14066	significance	_
78-14	14067-14068	(	_
78-15	14068-14081	schizophrenia	_
78-16	14081-14082	:	_
78-17	14083-14087	mean	_
78-18	14087-14088	=	_
78-19	14088-14092	48.3	_
78-20	14092-14093	,	_
78-21	14094-14096	SD	_
78-22	14096-14097	=	_
78-23	14097-14101	30.4	_
78-24	14101-14102	;	_
78-25	14103-14113	comparison	_
78-26	14114-14122	controls	_
78-27	14123-14125	vs	_
78-28	14126-14139	schizophrenia	_
78-29	14140-14141	t	_
78-30	14141-14142	=	_
78-31	14142-14145	2.0	_
78-32	14145-14146	,	_
78-33	14147-14149	df	_
78-34	14149-14150	=	_
78-35	14150-14152	39	_
78-36	14152-14153	,	_
78-37	14154-14155	p	_
78-38	14155-14156	=	_
78-39	14156-14160	0.05	_
78-40	14160-14161	)	_
78-41	14161-14162	.	_

#Text=There was no significant difference between depression and schizophrenia on this motivational measure (t=0.66, df=43, p=0.64).
79-1	14163-14168	There	_
79-2	14169-14172	was	_
79-3	14173-14175	no	_
79-4	14176-14187	significant	_
79-5	14188-14198	difference	_
79-6	14199-14206	between	_
79-7	14207-14217	depression	_
79-8	14218-14221	and	_
79-9	14222-14235	schizophrenia	_
79-10	14236-14238	on	_
79-11	14239-14243	this	_
79-12	14244-14256	motivational	_
79-13	14257-14264	measure	_
79-14	14265-14266	(	_
79-15	14266-14267	t	_
79-16	14267-14268	=	_
79-17	14268-14272	0.66	_
79-18	14272-14273	,	_
79-19	14274-14276	df	_
79-20	14276-14277	=	_
79-21	14277-14279	43	_
79-22	14279-14280	,	_
79-23	14281-14282	p	_
79-24	14282-14283	=	_
79-25	14283-14287	0.64	_
79-26	14287-14288	)	_
79-27	14288-14289	.	_

#Text=One control had missing data on this measure.
80-1	14290-14293	One	_
80-2	14294-14301	control	_
80-3	14302-14305	had	_
80-4	14306-14313	missing	_
80-5	14314-14318	data	_
80-6	14319-14321	on	_
80-7	14322-14326	this	_
80-8	14327-14334	measure	_
80-9	14334-14335	.	_

#Text=Associations with anhedonia questionnaire.
81-1	14336-14348	Associations	_
81-2	14349-14353	with	_
81-3	14354-14363	anhedonia	_
81-4	14364-14377	questionnaire	_
81-5	14377-14378	.	_

#Text=Higher SHAPS anhedonia scores were associated with lower reported motivation ratings in the whole sample (β=−0.3, t=2.6, p=0.01), and in the schizophrenia group (β=−0.7, t=4.3, p<0.001).
82-1	14379-14385	Higher	_
82-2	14386-14391	SHAPS	_
82-3	14392-14401	anhedonia	_
82-4	14402-14408	scores	_
82-5	14409-14413	were	_
82-6	14414-14424	associated	_
82-7	14425-14429	with	_
82-8	14430-14435	lower	_
82-9	14436-14444	reported	_
82-10	14445-14455	motivation	_
82-11	14456-14463	ratings	_
82-12	14464-14466	in	_
82-13	14467-14470	the	_
82-14	14471-14476	whole	_
82-15	14477-14483	sample	_
82-16	14484-14485	(	_
82-17	14485-14486	β	_
82-18	14486-14487	=	_
82-19	14487-14488	−	_
82-20	14488-14491	0.3	_
82-21	14491-14492	,	_
82-22	14493-14494	t	_
82-23	14494-14495	=	_
82-24	14495-14498	2.6	_
82-25	14498-14499	,	_
82-26	14500-14501	p	_
82-27	14501-14502	=	_
82-28	14502-14506	0.01	_
82-29	14506-14507	)	_
82-30	14507-14508	,	_
82-31	14509-14512	and	_
82-32	14513-14515	in	_
82-33	14516-14519	the	_
82-34	14520-14533	schizophrenia	_
82-35	14534-14539	group	_
82-36	14540-14541	(	_
82-37	14541-14542	β	_
82-38	14542-14543	=	_
82-39	14543-14544	−	_
82-40	14544-14547	0.7	_
82-41	14547-14548	,	_
82-42	14549-14550	t	_
82-43	14550-14551	=	_
82-44	14551-14554	4.3	_
82-45	14554-14555	,	_
82-46	14556-14557	p	_
82-47	14557-14558	<	_
82-48	14558-14563	0.001	_
82-49	14563-14564	)	_
82-50	14564-14565	.	_

#Text=SHAPS anhedonia also negatively predicted the pleasure ratings after a win in the whole sample (β=−0.3, t=−2.2, p=0.03).
83-1	14566-14571	SHAPS	_
83-2	14572-14581	anhedonia	_
83-3	14582-14586	also	_
83-4	14587-14597	negatively	_
83-5	14598-14607	predicted	_
83-6	14608-14611	the	_
83-7	14612-14620	pleasure	_
83-8	14621-14628	ratings	_
83-9	14629-14634	after	_
83-10	14635-14636	a	_
83-11	14637-14640	win	_
83-12	14641-14643	in	_
83-13	14644-14647	the	_
83-14	14648-14653	whole	_
83-15	14654-14660	sample	_
83-16	14661-14662	(	_
83-17	14662-14663	β	_
83-18	14663-14664	=	_
83-19	14664-14665	−	_
83-20	14665-14668	0.3	_
83-21	14668-14669	,	_
83-22	14670-14671	t	_
83-23	14671-14672	=	_
83-24	14672-14673	−	_
83-25	14673-14676	2.2	_
83-26	14676-14677	,	_
83-27	14678-14679	p	_
83-28	14679-14680	=	_
83-29	14680-14684	0.03	_
83-30	14684-14685	)	_
83-31	14685-14686	.	_

#Text=Brain Imaging Results
#Text=We evaluated activation associated with unexpected reward receipt using the contrast of a win outcome vs full-loss outcome.
84-1	14687-14692	Brain	_
84-2	14693-14700	Imaging	_
84-3	14701-14708	Results	_
84-4	14709-14711	We	_
84-5	14712-14721	evaluated	_
84-6	14722-14732	activation	_
84-7	14733-14743	associated	_
84-8	14744-14748	with	_
84-9	14749-14759	unexpected	_
84-10	14760-14766	reward	_
84-11	14767-14774	receipt	_
84-12	14775-14780	using	_
84-13	14781-14784	the	_
84-14	14785-14793	contrast	_
84-15	14794-14796	of	_
84-16	14797-14798	a	_
84-17	14799-14802	win	_
84-18	14803-14810	outcome	_
84-19	14811-14813	vs	_
84-20	14814-14823	full-loss	_
84-21	14824-14831	outcome	_
84-22	14831-14832	.	_

#Text=Entire sample (one sample t-test)
#Text=There was a highly significant brain response in a widespread cortico-striatal network including the striatum, orbitofrontal cortex and medial prefrontal cortex.
85-1	14833-14839	Entire	_
85-2	14840-14846	sample	_
85-3	14847-14848	(	_
85-4	14848-14851	one	_
85-5	14852-14858	sample	_
85-6	14859-14865	t-test	_
85-7	14865-14866	)	_
85-8	14867-14872	There	_
85-9	14873-14876	was	_
85-10	14877-14878	a	_
85-11	14879-14885	highly	_
85-12	14886-14897	significant	_
85-13	14898-14903	brain	_
85-14	14904-14912	response	_
85-15	14913-14915	in	_
85-16	14916-14917	a	_
85-17	14918-14928	widespread	_
85-18	14929-14945	cortico-striatal	_
85-19	14946-14953	network	_
85-20	14954-14963	including	_
85-21	14964-14967	the	_
85-22	14968-14976	striatum	_
85-23	14976-14977	,	_
85-24	14978-14991	orbitofrontal	_
85-25	14992-14998	cortex	_
85-26	14999-15002	and	_
85-27	15003-15009	medial	_
85-28	15010-15020	prefrontal	_
85-29	15021-15027	cortex	_
85-30	15027-15028	.	_

#Text=The maximum significance was located in left caudate (MNI x=−8, y=10, z=2; Z-score=9.28; Figure 2, Supplementary Figures S1 and S4).
86-1	15029-15032	The	_
86-2	15033-15040	maximum	_
86-3	15041-15053	significance	_
86-4	15054-15057	was	_
86-5	15058-15065	located	_
86-6	15066-15068	in	_
86-7	15069-15073	left	_
86-8	15074-15081	caudate	_
86-9	15082-15083	(	_
86-10	15083-15086	MNI	_
86-11	15087-15088	x	_
86-12	15088-15089	=	_
86-13	15089-15090	−	_
86-14	15090-15091	8	_
86-15	15091-15092	,	_
86-16	15093-15094	y	_
86-17	15094-15095	=	_
86-18	15095-15097	10	_
86-19	15097-15098	,	_
86-20	15099-15100	z	_
86-21	15100-15101	=	_
86-22	15101-15102	2	_
86-23	15102-15103	;	_
86-24	15104-15111	Z-score	_
86-25	15111-15112	=	_
86-26	15112-15116	9.28	_
86-27	15116-15117	;	_
86-28	15118-15124	Figure	_
86-29	15125-15126	2	_
86-30	15126-15127	,	_
86-31	15128-15141	Supplementary	_
86-32	15142-15149	Figures	_
86-33	15150-15152	S1	_
86-34	15153-15156	and	_
86-35	15157-15159	S4	_
86-36	15159-15160	)	_
86-37	15160-15161	.	_

#Text=Between group analysis
#Text=One-way ANOVA analysis demonstrated 10 clusters with significant group differences (Figure 2, Table 2, Supplementary Figures S2).
87-1	15162-15169	Between	_
87-2	15170-15175	group	_
87-3	15176-15184	analysis	_
87-4	15185-15192	One-way	_
87-5	15193-15198	ANOVA	_
87-6	15199-15207	analysis	_
87-7	15208-15220	demonstrated	_
87-8	15221-15223	10	_
87-9	15224-15232	clusters	_
87-10	15233-15237	with	_
87-11	15238-15249	significant	_
87-12	15250-15255	group	_
87-13	15256-15267	differences	_
87-14	15268-15269	(	_
87-15	15269-15275	Figure	_
87-16	15276-15277	2	_
87-17	15277-15278	,	_
87-18	15279-15284	Table	_
87-19	15285-15286	2	_
87-20	15286-15287	,	_
87-21	15288-15301	Supplementary	_
87-22	15302-15309	Figures	_
87-23	15310-15312	S2	_
87-24	15312-15313	)	_
87-25	15313-15314	.	_

#Text=Post hoc pairwise tests of mean cluster parameter estimates showed that, in comparison to healthy controls, MDD and schizophrenia participants had a decreased signal (eg, Figure 3 upper panel) to unexpected rewards in clusters that encompassed bilateral orbitofrontal cortex, right caudate, right nucleus accumbens, right midbrain, right thalamus, right inferior and middle temporal gyrus, and left occipital cortex.
88-1	15315-15319	Post	_
88-2	15320-15323	hoc	_
88-3	15324-15332	pairwise	_
88-4	15333-15338	tests	_
88-5	15339-15341	of	_
88-6	15342-15346	mean	_
88-7	15347-15354	cluster	_
88-8	15355-15364	parameter	_
88-9	15365-15374	estimates	_
88-10	15375-15381	showed	_
88-11	15382-15386	that	_
88-12	15386-15387	,	_
88-13	15388-15390	in	_
88-14	15391-15401	comparison	_
88-15	15402-15404	to	_
88-16	15405-15412	healthy	_
88-17	15413-15421	controls	_
88-18	15421-15422	,	_
88-19	15423-15426	MDD	_
88-20	15427-15430	and	_
88-21	15431-15444	schizophrenia	_
88-22	15445-15457	participants	_
88-23	15458-15461	had	_
88-24	15462-15463	a	_
88-25	15464-15473	decreased	_
88-26	15474-15480	signal	_
88-27	15481-15482	(	_
88-28	15482-15484	eg	_
88-29	15484-15485	,	_
88-30	15486-15492	Figure	_
88-31	15493-15494	3	_
88-32	15495-15500	upper	_
88-33	15501-15506	panel	_
88-34	15506-15507	)	_
88-35	15508-15510	to	_
88-36	15511-15521	unexpected	_
88-37	15522-15529	rewards	_
88-38	15530-15532	in	_
88-39	15533-15541	clusters	_
88-40	15542-15546	that	_
88-41	15547-15558	encompassed	_
88-42	15559-15568	bilateral	_
88-43	15569-15582	orbitofrontal	_
88-44	15583-15589	cortex	_
88-45	15589-15590	,	_
88-46	15591-15596	right	_
88-47	15597-15604	caudate	_
88-48	15604-15605	,	_
88-49	15606-15611	right	_
88-50	15612-15619	nucleus	_
88-51	15620-15629	accumbens	_
88-52	15629-15630	,	_
88-53	15631-15636	right	_
88-54	15637-15645	midbrain	_
88-55	15645-15646	,	_
88-56	15647-15652	right	_
88-57	15653-15661	thalamus	_
88-58	15661-15662	,	_
88-59	15663-15668	right	_
88-60	15669-15677	inferior	_
88-61	15678-15681	and	_
88-62	15682-15688	middle	_
88-63	15689-15697	temporal	_
88-64	15698-15703	gyrus	_
88-65	15703-15704	,	_
88-66	15705-15708	and	_
88-67	15709-15713	left	_
88-68	15714-15723	occipital	_
88-69	15724-15730	cortex	_
88-70	15730-15731	.	_

#Text=The post hoc tests also revealed that in the medial prefrontal cortex, in a cluster including the paracingulate gyrus and superior frontal gyrus, both patient groups had reduced activity compared with controls, and the schizophrenia group also had significantly lower activation compared with depression.
89-1	15732-15735	The	_
89-2	15736-15740	post	_
89-3	15741-15744	hoc	_
89-4	15745-15750	tests	_
89-5	15751-15755	also	_
89-6	15756-15764	revealed	_
89-7	15765-15769	that	_
89-8	15770-15772	in	_
89-9	15773-15776	the	_
89-10	15777-15783	medial	_
89-11	15784-15794	prefrontal	_
89-12	15795-15801	cortex	_
89-13	15801-15802	,	_
89-14	15803-15805	in	_
89-15	15806-15807	a	_
89-16	15808-15815	cluster	_
89-17	15816-15825	including	_
89-18	15826-15829	the	_
89-19	15830-15843	paracingulate	_
89-20	15844-15849	gyrus	_
89-21	15850-15853	and	_
89-22	15854-15862	superior	_
89-23	15863-15870	frontal	_
89-24	15871-15876	gyrus	_
89-25	15876-15877	,	_
89-26	15878-15882	both	_
89-27	15883-15890	patient	_
89-28	15891-15897	groups	_
89-29	15898-15901	had	_
89-30	15902-15909	reduced	_
89-31	15910-15918	activity	_
89-32	15919-15927	compared	_
89-33	15928-15932	with	_
89-34	15933-15941	controls	_
89-35	15941-15942	,	_
89-36	15943-15946	and	_
89-37	15947-15950	the	_
89-38	15951-15964	schizophrenia	_
89-39	15965-15970	group	_
89-40	15971-15975	also	_
89-41	15976-15979	had	_
89-42	15980-15993	significantly	_
89-43	15994-15999	lower	_
89-44	16000-16010	activation	_
89-45	16011-16019	compared	_
89-46	16020-16024	with	_
89-47	16025-16035	depression	_
89-48	16035-16036	.	_

#Text=Compared with controls, the schizophrenia group had significantly lower activations in the posterior division of the cingulate gyrus, right occipital pole, and bilateral cerebellar areas.
90-1	16037-16045	Compared	_
90-2	16046-16050	with	_
90-3	16051-16059	controls	_
90-4	16059-16060	,	_
90-5	16061-16064	the	_
90-6	16065-16078	schizophrenia	_
90-7	16079-16084	group	_
90-8	16085-16088	had	_
90-9	16089-16102	significantly	_
90-10	16103-16108	lower	_
90-11	16109-16120	activations	_
90-12	16121-16123	in	_
90-13	16124-16127	the	_
90-14	16128-16137	posterior	_
90-15	16138-16146	division	_
90-16	16147-16149	of	_
90-17	16150-16153	the	_
90-18	16154-16163	cingulate	_
90-19	16164-16169	gyrus	_
90-20	16169-16170	,	_
90-21	16171-16176	right	_
90-22	16177-16186	occipital	_
90-23	16187-16191	pole	_
90-24	16191-16192	,	_
90-25	16193-16196	and	_
90-26	16197-16206	bilateral	_
90-27	16207-16217	cerebellar	_
90-28	16218-16223	areas	_
90-29	16223-16224	.	_

#Text=The posterior lateral parietal cortex bilaterally (angular and supramarginal gyri, and intraparietal sulci) showed reduced activation in schizophrenia (compared with depression and controls) but there were no differences here between depression and controls (Figure 3, lower panel).
91-1	16225-16228	The	_
91-2	16229-16238	posterior	_
91-3	16239-16246	lateral	_
91-4	16247-16255	parietal	_
91-5	16256-16262	cortex	_
91-6	16263-16274	bilaterally	_
91-7	16275-16276	(	_
91-8	16276-16283	angular	_
91-9	16284-16287	and	_
91-10	16288-16301	supramarginal	_
91-11	16302-16306	gyri	_
91-12	16306-16307	,	_
91-13	16308-16311	and	_
91-14	16312-16325	intraparietal	_
91-15	16326-16331	sulci	_
91-16	16331-16332	)	_
91-17	16333-16339	showed	_
91-18	16340-16347	reduced	_
91-19	16348-16358	activation	_
91-20	16359-16361	in	_
91-21	16362-16375	schizophrenia	_
91-22	16376-16377	(	_
91-23	16377-16385	compared	_
91-24	16386-16390	with	_
91-25	16391-16401	depression	_
91-26	16402-16405	and	_
91-27	16406-16414	controls	_
91-28	16414-16415	)	_
91-29	16416-16419	but	_
91-30	16420-16425	there	_
91-31	16426-16430	were	_
91-32	16431-16433	no	_
91-33	16434-16445	differences	_
91-34	16446-16450	here	_
91-35	16451-16458	between	_
91-36	16459-16469	depression	_
91-37	16470-16473	and	_
91-38	16474-16482	controls	_
91-39	16483-16484	(	_
91-40	16484-16490	Figure	_
91-41	16491-16492	3	_
91-42	16492-16493	,	_
91-43	16494-16499	lower	_
91-44	16500-16505	panel	_
91-45	16505-16506	)	_
91-46	16506-16507	.	_

#Text=Our results are based on the contrast of unexpected reward receipt vs full miss.
92-1	16508-16511	Our	_
92-2	16512-16519	results	_
92-3	16520-16523	are	_
92-4	16524-16529	based	_
92-5	16530-16532	on	_
92-6	16533-16536	the	_
92-7	16537-16545	contrast	_
92-8	16546-16548	of	_
92-9	16549-16559	unexpected	_
92-10	16560-16566	reward	_
92-11	16567-16574	receipt	_
92-12	16575-16577	vs	_
92-13	16578-16582	full	_
92-14	16583-16587	miss	_
92-15	16587-16588	.	_

#Text=Examination of the parameter estimates for the regressors that make up this contrast (ie, their activation compared with baseline) suggest that the group differences were secondary to reduced patient responses to unexpected reward receipt rather than differences in full-miss activation (Supplementary Figure S25).
93-1	16589-16600	Examination	_
93-2	16601-16603	of	_
93-3	16604-16607	the	_
93-4	16608-16617	parameter	_
93-5	16618-16627	estimates	_
93-6	16628-16631	for	_
93-7	16632-16635	the	_
93-8	16636-16646	regressors	_
93-9	16647-16651	that	_
93-10	16652-16656	make	_
93-11	16657-16659	up	_
93-12	16660-16664	this	_
93-13	16665-16673	contrast	_
93-14	16674-16675	(	_
93-15	16675-16677	ie	_
93-16	16677-16678	,	_
93-17	16679-16684	their	_
93-18	16685-16695	activation	_
93-19	16696-16704	compared	_
93-20	16705-16709	with	_
93-21	16710-16718	baseline	_
93-22	16718-16719	)	_
93-23	16720-16727	suggest	_
93-24	16728-16732	that	_
93-25	16733-16736	the	_
93-26	16737-16742	group	_
93-27	16743-16754	differences	_
93-28	16755-16759	were	_
93-29	16760-16769	secondary	_
93-30	16770-16772	to	_
93-31	16773-16780	reduced	_
93-32	16781-16788	patient	_
93-33	16789-16798	responses	_
93-34	16799-16801	to	_
93-35	16802-16812	unexpected	_
93-36	16813-16819	reward	_
93-37	16820-16827	receipt	_
93-38	16828-16834	rather	_
93-39	16835-16839	than	_
93-40	16840-16851	differences	_
93-41	16852-16854	in	_
93-42	16855-16864	full-miss	_
93-43	16865-16875	activation	_
93-44	16876-16877	(	_
93-45	16877-16890	Supplementary	_
93-46	16891-16897	Figure	_
93-47	16898-16901	S25	_
93-48	16901-16902	)	_
93-49	16902-16903	.	_

#Text=Associations with subjective experience
#Text=In a regression analysis in which we pooled all participants and, importantly, adjusted for group effects by modeling group means, brain activation during receipt of unexpected reward was positively associated (p<0.05 corrected) with the post-scan rating of motivation to keep playing the task after a win in a medial prefrontal cluster situated in the anterior cingulate and paracingulate gyrus and bilateral medial superior frontal gyrus (cluster size=2491, z maximum peak voxel=4.17, MNI coordinates x=−12, y=52, z=24; Figure 4; Supplementary Figure S3).
94-1	16904-16916	Associations	_
94-2	16917-16921	with	_
94-3	16922-16932	subjective	_
94-4	16933-16943	experience	_
94-5	16944-16946	In	_
94-6	16947-16948	a	_
94-7	16949-16959	regression	_
94-8	16960-16968	analysis	_
94-9	16969-16971	in	_
94-10	16972-16977	which	_
94-11	16978-16980	we	_
94-12	16981-16987	pooled	_
94-13	16988-16991	all	_
94-14	16992-17004	participants	_
94-15	17005-17008	and	_
94-16	17008-17009	,	_
94-17	17010-17021	importantly	_
94-18	17021-17022	,	_
94-19	17023-17031	adjusted	_
94-20	17032-17035	for	_
94-21	17036-17041	group	_
94-22	17042-17049	effects	_
94-23	17050-17052	by	_
94-24	17053-17061	modeling	_
94-25	17062-17067	group	_
94-26	17068-17073	means	_
94-27	17073-17074	,	_
94-28	17075-17080	brain	_
94-29	17081-17091	activation	_
94-30	17092-17098	during	_
94-31	17099-17106	receipt	_
94-32	17107-17109	of	_
94-33	17110-17120	unexpected	_
94-34	17121-17127	reward	_
94-35	17128-17131	was	_
94-36	17132-17142	positively	_
94-37	17143-17153	associated	_
94-38	17154-17155	(	_
94-39	17155-17156	p	_
94-40	17156-17157	<	_
94-41	17157-17161	0.05	_
94-42	17162-17171	corrected	_
94-43	17171-17172	)	_
94-44	17173-17177	with	_
94-45	17178-17181	the	_
94-46	17182-17191	post-scan	_
94-47	17192-17198	rating	_
94-48	17199-17201	of	_
94-49	17202-17212	motivation	_
94-50	17213-17215	to	_
94-51	17216-17220	keep	_
94-52	17221-17228	playing	_
94-53	17229-17232	the	_
94-54	17233-17237	task	_
94-55	17238-17243	after	_
94-56	17244-17245	a	_
94-57	17246-17249	win	_
94-58	17250-17252	in	_
94-59	17253-17254	a	_
94-60	17255-17261	medial	_
94-61	17262-17272	prefrontal	_
94-62	17273-17280	cluster	_
94-63	17281-17289	situated	_
94-64	17290-17292	in	_
94-65	17293-17296	the	_
94-66	17297-17305	anterior	_
94-67	17306-17315	cingulate	_
94-68	17316-17319	and	_
94-69	17320-17333	paracingulate	_
94-70	17334-17339	gyrus	_
94-71	17340-17343	and	_
94-72	17344-17353	bilateral	_
94-73	17354-17360	medial	_
94-74	17361-17369	superior	_
94-75	17370-17377	frontal	_
94-76	17378-17383	gyrus	_
94-77	17384-17385	(	_
94-78	17385-17392	cluster	_
94-79	17393-17397	size	_
94-80	17397-17398	=	_
94-81	17398-17402	2491	_
94-82	17402-17403	,	_
94-83	17404-17405	z	_
94-84	17406-17413	maximum	_
94-85	17414-17418	peak	_
94-86	17419-17424	voxel	_
94-87	17424-17425	=	_
94-88	17425-17429	4.17	_
94-89	17429-17430	,	_
94-90	17431-17434	MNI	_
94-91	17435-17446	coordinates	_
94-92	17447-17448	x	_
94-93	17448-17449	=	_
94-94	17449-17450	−	_
94-95	17450-17452	12	_
94-96	17452-17453	,	_
94-97	17454-17455	y	_
94-98	17455-17456	=	_
94-99	17456-17458	52	_
94-100	17458-17459	,	_
94-101	17460-17461	z	_
94-102	17461-17462	=	_
94-103	17462-17464	24	_
94-104	17464-17465	;	_
94-105	17466-17472	Figure	_
94-106	17473-17474	4	_
94-107	17474-17475	;	_
94-108	17476-17489	Supplementary	_
94-109	17490-17496	Figure	_
94-110	17497-17499	S3	_
94-111	17499-17500	)	_
94-112	17500-17501	.	_

#Text=The strength of this association did not differ between groups (group X motivation interaction term p=0.9).
95-1	17502-17505	The	_
95-2	17506-17514	strength	_
95-3	17515-17517	of	_
95-4	17518-17522	this	_
95-5	17523-17534	association	_
95-6	17535-17538	did	_
95-7	17539-17542	not	_
95-8	17543-17549	differ	_
95-9	17550-17557	between	_
95-10	17558-17564	groups	_
95-11	17565-17566	(	_
95-12	17566-17571	group	_
95-13	17572-17573	X	_
95-14	17574-17584	motivation	_
95-15	17585-17596	interaction	_
95-16	17597-17601	term	_
95-17	17602-17603	p	_
95-18	17603-17604	=	_
95-19	17604-17607	0.9	_
95-20	17607-17608	)	_
95-21	17608-17609	.	_

#Text=Activation in this region was not significantly associated with SHAPS total score.
96-1	17610-17620	Activation	_
96-2	17621-17623	in	_
96-3	17624-17628	this	_
96-4	17629-17635	region	_
96-5	17636-17639	was	_
96-6	17640-17643	not	_
96-7	17644-17657	significantly	_
96-8	17658-17668	associated	_
96-9	17669-17673	with	_
96-10	17674-17679	SHAPS	_
96-11	17680-17685	total	_
96-12	17686-17691	score	_
96-13	17691-17692	.	_

#Text=No associations were found between unexpected reward receipt and the hedonic feeling of winning money at p<0.05 corrected.
97-1	17693-17695	No	_
97-2	17696-17708	associations	_
97-3	17709-17713	were	_
97-4	17714-17719	found	_
97-5	17720-17727	between	_
97-6	17728-17738	unexpected	_
97-7	17739-17745	reward	_
97-8	17746-17753	receipt	_
97-9	17754-17757	and	_
97-10	17758-17761	the	_
97-11	17762-17769	hedonic	_
97-12	17770-17777	feeling	_
97-13	17778-17780	of	_
97-14	17781-17788	winning	_
97-15	17789-17794	money	_
97-16	17795-17797	at	_
97-17	17798-17799	p	_
97-18	17799-17800	<	_
97-19	17800-17804	0.05	_
97-20	17805-17814	corrected	_
97-21	17814-17815	.	_

#Text=Relationship to Medication
#Text=There were no differences in activation when comparing those depression participants with and without antidepressant treatment.
98-1	17816-17828	Relationship	_
98-2	17829-17831	to	_
98-3	17832-17842	Medication	_
98-4	17843-17848	There	_
98-5	17849-17853	were	_
98-6	17854-17856	no	_
98-7	17857-17868	differences	_
98-8	17869-17871	in	_
98-9	17872-17882	activation	_
98-10	17883-17887	when	_
98-11	17888-17897	comparing	_
98-12	17898-17903	those	_
98-13	17904-17914	depression	_
98-14	17915-17927	participants	_
98-15	17928-17932	with	_
98-16	17933-17936	and	_
98-17	17937-17944	without	_
98-18	17945-17959	antidepressant	_
98-19	17960-17969	treatment	_
98-20	17969-17970	.	_

#Text=Within the schizophrenia group, we converted treatment doses into chlorpromazine equivalents and found no associations with brain response.
99-1	17971-17977	Within	_
99-2	17978-17981	the	_
99-3	17982-17995	schizophrenia	_
99-4	17996-18001	group	_
99-5	18001-18002	,	_
99-6	18003-18005	we	_
99-7	18006-18015	converted	_
99-8	18016-18025	treatment	_
99-9	18026-18031	doses	_
99-10	18032-18036	into	_
99-11	18037-18051	chlorpromazine	_
99-12	18052-18063	equivalents	_
99-13	18064-18067	and	_
99-14	18068-18073	found	_
99-15	18074-18076	no	_
99-16	18077-18089	associations	_
99-17	18090-18094	with	_
99-18	18095-18100	brain	_
99-19	18101-18109	response	_
99-20	18109-18110	.	_

#Text=See Supplementary Material for more detail.
100-1	18111-18114	See	_
100-2	18115-18128	Supplementary	_
100-3	18129-18137	Material	_
100-4	18138-18141	for	_
100-5	18142-18146	more	_
100-6	18147-18153	detail	_
100-7	18153-18154	.	_

#Text=Discussion
#Text=We used fMRI to examine brain activation to unexpected reward (positive reward prediction error) without learning confounds.
101-1	18155-18165	Discussion	_
101-2	18166-18168	We	_
101-3	18169-18173	used	_
101-4	18174-18178	fMRI	_
101-5	18179-18181	to	_
101-6	18182-18189	examine	_
101-7	18190-18195	brain	_
101-8	18196-18206	activation	_
101-9	18207-18209	to	_
101-10	18210-18220	unexpected	_
101-11	18221-18227	reward	_
101-12	18228-18229	(	_
101-13	18229-18237	positive	_
101-14	18238-18244	reward	_
101-15	18245-18255	prediction	_
101-16	18256-18261	error	_
101-17	18261-18262	)	_
101-18	18263-18270	without	_
101-19	18271-18279	learning	_
101-20	18280-18289	confounds	_
101-21	18289-18290	.	_

#Text=The task we used, which had not been employed before in samples with mental illness, elicited activation to unexpected reward receipt in the classic reward network including striatum, orbitofrontal cortex, and medial prefrontal cortex, and yielded insights into relationships between brain activation and subjective experience during the experiment.
102-1	18291-18294	The	_
102-2	18295-18299	task	_
102-3	18300-18302	we	_
102-4	18303-18307	used	_
102-5	18307-18308	,	_
102-6	18309-18314	which	_
102-7	18315-18318	had	_
102-8	18319-18322	not	_
102-9	18323-18327	been	_
102-10	18328-18336	employed	_
102-11	18337-18343	before	_
102-12	18344-18346	in	_
102-13	18347-18354	samples	_
102-14	18355-18359	with	_
102-15	18360-18366	mental	_
102-16	18367-18374	illness	_
102-17	18374-18375	,	_
102-18	18376-18384	elicited	_
102-19	18385-18395	activation	_
102-20	18396-18398	to	_
102-21	18399-18409	unexpected	_
102-22	18410-18416	reward	_
102-23	18417-18424	receipt	_
102-24	18425-18427	in	_
102-25	18428-18431	the	_
102-26	18432-18439	classic	_
102-27	18440-18446	reward	_
102-28	18447-18454	network	_
102-29	18455-18464	including	_
102-30	18465-18473	striatum	_
102-31	18473-18474	,	_
102-32	18475-18488	orbitofrontal	_
102-33	18489-18495	cortex	_
102-34	18495-18496	,	_
102-35	18497-18500	and	_
102-36	18501-18507	medial	_
102-37	18508-18518	prefrontal	_
102-38	18519-18525	cortex	_
102-39	18525-18526	,	_
102-40	18527-18530	and	_
102-41	18531-18538	yielded	_
102-42	18539-18547	insights	_
102-43	18548-18552	into	_
102-44	18553-18566	relationships	_
102-45	18567-18574	between	_
102-46	18575-18580	brain	_
102-47	18581-18591	activation	_
102-48	18592-18595	and	_
102-49	18596-18606	subjective	_
102-50	18607-18617	experience	_
102-51	18618-18624	during	_
102-52	18625-18628	the	_
102-53	18629-18639	experiment	_
102-54	18639-18640	.	_

#Text=We demonstrated that brain responses to unexpected rewards are suppressed in a similar way in both schizophrenia and depression in several regions previously implicated in the pathology of both of these disorders, including the orbitofrontal cortex, ventral striatum, thalamus, and insular cortex.
103-1	18641-18643	We	_
103-2	18644-18656	demonstrated	_
103-3	18657-18661	that	_
103-4	18662-18667	brain	_
103-5	18668-18677	responses	_
103-6	18678-18680	to	_
103-7	18681-18691	unexpected	_
103-8	18692-18699	rewards	_
103-9	18700-18703	are	_
103-10	18704-18714	suppressed	_
103-11	18715-18717	in	_
103-12	18718-18719	a	_
103-13	18720-18727	similar	_
103-14	18728-18731	way	_
103-15	18732-18734	in	_
103-16	18735-18739	both	_
103-17	18740-18753	schizophrenia	_
103-18	18754-18757	and	_
103-19	18758-18768	depression	_
103-20	18769-18771	in	_
103-21	18772-18779	several	_
103-22	18780-18787	regions	_
103-23	18788-18798	previously	_
103-24	18799-18809	implicated	_
103-25	18810-18812	in	_
103-26	18813-18816	the	_
103-27	18817-18826	pathology	_
103-28	18827-18829	of	_
103-29	18830-18834	both	_
103-30	18835-18837	of	_
103-31	18838-18843	these	_
103-32	18844-18853	disorders	_
103-33	18853-18854	,	_
103-34	18855-18864	including	_
103-35	18865-18868	the	_
103-36	18869-18882	orbitofrontal	_
103-37	18883-18889	cortex	_
103-38	18889-18890	,	_
103-39	18891-18898	ventral	_
103-40	18899-18907	striatum	_
103-41	18907-18908	,	_
103-42	18909-18917	thalamus	_
103-43	18917-18918	,	_
103-44	18919-18922	and	_
103-45	18923-18930	insular	_
103-46	18931-18937	cortex	_
103-47	18937-18938	.	_

#Text=However, there were also areas of deficit unique to schizophrenia, such as the posterior lateral parietal cortex.
104-1	18939-18946	However	_
104-2	18946-18947	,	_
104-3	18948-18953	there	_
104-4	18954-18958	were	_
104-5	18959-18963	also	_
104-6	18964-18969	areas	_
104-7	18970-18972	of	_
104-8	18973-18980	deficit	_
104-9	18981-18987	unique	_
104-10	18988-18990	to	_
104-11	18991-19004	schizophrenia	_
104-12	19004-19005	,	_
104-13	19006-19010	such	_
104-14	19011-19013	as	_
104-15	19014-19017	the	_
104-16	19018-19027	posterior	_
104-17	19028-19035	lateral	_
104-18	19036-19044	parietal	_
104-19	19045-19051	cortex	_
104-20	19051-19052	.	_

#Text=When we examined relationships between brain activation and task-related emotional reports, we found intriguing associations between medial prefrontal unexpected reward receipt responses and motivational state that could help explain aspects of clinical anhedonia.
105-1	19053-19057	When	_
105-2	19058-19060	we	_
105-3	19061-19069	examined	_
105-4	19070-19083	relationships	_
105-5	19084-19091	between	_
105-6	19092-19097	brain	_
105-7	19098-19108	activation	_
105-8	19109-19112	and	_
105-9	19113-19125	task-related	_
105-10	19126-19135	emotional	_
105-11	19136-19143	reports	_
105-12	19143-19144	,	_
105-13	19145-19147	we	_
105-14	19148-19153	found	_
105-15	19154-19164	intriguing	_
105-16	19165-19177	associations	_
105-17	19178-19185	between	_
105-18	19186-19192	medial	_
105-19	19193-19203	prefrontal	_
105-20	19204-19214	unexpected	_
105-21	19215-19221	reward	_
105-22	19222-19229	receipt	_
105-23	19230-19239	responses	_
105-24	19240-19243	and	_
105-25	19244-19256	motivational	_
105-26	19257-19262	state	_
105-27	19263-19267	that	_
105-28	19268-19273	could	_
105-29	19274-19278	help	_
105-30	19279-19286	explain	_
105-31	19287-19294	aspects	_
105-32	19295-19297	of	_
105-33	19298-19306	clinical	_
105-34	19307-19316	anhedonia	_
105-35	19316-19317	.	_

#Text=Group Differences
#Text=Our results indicated reduced activation to the receipt of an unexpected reward in overlapping regions in schizophrenia and depression: the orbitofrontal cortex, ventral striatum, thalamus, and inferior and middle temporal gyri had reduced activation in both disorders.
106-1	19318-19323	Group	_
106-2	19324-19335	Differences	_
106-3	19336-19339	Our	_
106-4	19340-19347	results	_
106-5	19348-19357	indicated	_
106-6	19358-19365	reduced	_
106-7	19366-19376	activation	_
106-8	19377-19379	to	_
106-9	19380-19383	the	_
106-10	19384-19391	receipt	_
106-11	19392-19394	of	_
106-12	19395-19397	an	_
106-13	19398-19408	unexpected	_
106-14	19409-19415	reward	_
106-15	19416-19418	in	_
106-16	19419-19430	overlapping	_
106-17	19431-19438	regions	_
106-18	19439-19441	in	_
106-19	19442-19455	schizophrenia	_
106-20	19456-19459	and	_
106-21	19460-19470	depression	_
106-22	19470-19471	:	_
106-23	19472-19475	the	_
106-24	19476-19489	orbitofrontal	_
106-25	19490-19496	cortex	_
106-26	19496-19497	,	_
106-27	19498-19505	ventral	_
106-28	19506-19514	striatum	_
106-29	19514-19515	,	_
106-30	19516-19524	thalamus	_
106-31	19524-19525	,	_
106-32	19526-19529	and	_
106-33	19530-19538	inferior	_
106-34	19539-19542	and	_
106-35	19543-19549	middle	_
106-36	19550-19558	temporal	_
106-37	19559-19563	gyri	_
106-38	19564-19567	had	_
106-39	19568-19575	reduced	_
106-40	19576-19586	activation	_
106-41	19587-19589	in	_
106-42	19590-19594	both	_
106-43	19595-19604	disorders	_
106-44	19604-19605	.	_

#Text=There is a previous report of reduced ventral striatal reward receipt responses in unmedicated depression participants; in schizophrenia participants lower striatal activity has been described in response to an uncertain primary reward and to an unexpected monetary reward.
107-1	19606-19611	There	_
107-2	19612-19614	is	_
107-3	19615-19616	a	_
107-4	19617-19625	previous	_
107-5	19626-19632	report	_
107-6	19633-19635	of	_
107-7	19636-19643	reduced	_
107-8	19644-19651	ventral	_
107-9	19652-19660	striatal	_
107-10	19661-19667	reward	_
107-11	19668-19675	receipt	_
107-12	19676-19685	responses	_
107-13	19686-19688	in	_
107-14	19689-19700	unmedicated	_
107-15	19701-19711	depression	_
107-16	19712-19724	participants	_
107-17	19724-19725	;	_
107-18	19726-19728	in	_
107-19	19729-19742	schizophrenia	_
107-20	19743-19755	participants	_
107-21	19756-19761	lower	_
107-22	19762-19770	striatal	_
107-23	19771-19779	activity	_
107-24	19780-19783	has	_
107-25	19784-19788	been	_
107-26	19789-19798	described	_
107-27	19799-19801	in	_
107-28	19802-19810	response	_
107-29	19811-19813	to	_
107-30	19814-19816	an	_
107-31	19817-19826	uncertain	_
107-32	19827-19834	primary	_
107-33	19835-19841	reward	_
107-34	19842-19845	and	_
107-35	19846-19848	to	_
107-36	19849-19851	an	_
107-37	19852-19862	unexpected	_
107-38	19863-19871	monetary	_
107-39	19872-19878	reward	_
107-40	19878-19879	.	_

#Text=However, some previous studies have documented that processing of unexpected rewards is intact in schizophrenia, and in some circumstances it is not possible to detect case-control differences in psychological and/or brain responses to rewards.
108-1	19880-19887	However	_
108-2	19887-19888	,	_
108-3	19889-19893	some	_
108-4	19894-19902	previous	_
108-5	19903-19910	studies	_
108-6	19911-19915	have	_
108-7	19916-19926	documented	_
108-8	19927-19931	that	_
108-9	19932-19942	processing	_
108-10	19943-19945	of	_
108-11	19946-19956	unexpected	_
108-12	19957-19964	rewards	_
108-13	19965-19967	is	_
108-14	19968-19974	intact	_
108-15	19975-19977	in	_
108-16	19978-19991	schizophrenia	_
108-17	19991-19992	,	_
108-18	19993-19996	and	_
108-19	19997-19999	in	_
108-20	20000-20004	some	_
108-21	20005-20018	circumstances	_
108-22	20019-20021	it	_
108-23	20022-20024	is	_
108-24	20025-20028	not	_
108-25	20029-20037	possible	_
108-26	20038-20040	to	_
108-27	20041-20047	detect	_
108-28	20048-20060	case-control	_
108-29	20061-20072	differences	_
108-30	20073-20075	in	_
108-31	20076-20089	psychological	_
108-32	20090-20093	and	_
108-33	20093-20094	/	_
108-34	20094-20096	or	_
108-35	20097-20102	brain	_
108-36	20103-20112	responses	_
108-37	20113-20115	to	_
108-38	20116-20123	rewards	_
108-39	20123-20124	.	_

#Text=A variety of methodological factors will influence the likelihood of individual studies showing significant groups differences, including sample size, the present symptoms of the patients, the sensitivity of the particular paradigm involved, and whether a motor response is required or not.
109-1	20125-20126	A	_
109-2	20127-20134	variety	_
109-3	20135-20137	of	_
109-4	20138-20152	methodological	_
109-5	20153-20160	factors	_
109-6	20161-20165	will	_
109-7	20166-20175	influence	_
109-8	20176-20179	the	_
109-9	20180-20190	likelihood	_
109-10	20191-20193	of	_
109-11	20194-20204	individual	_
109-12	20205-20212	studies	_
109-13	20213-20220	showing	_
109-14	20221-20232	significant	_
109-15	20233-20239	groups	_
109-16	20240-20251	differences	_
109-17	20251-20252	,	_
109-18	20253-20262	including	_
109-19	20263-20269	sample	_
109-20	20270-20274	size	_
109-21	20274-20275	,	_
109-22	20276-20279	the	_
109-23	20280-20287	present	_
109-24	20288-20296	symptoms	_
109-25	20297-20299	of	_
109-26	20300-20303	the	_
109-27	20304-20312	patients	_
109-28	20312-20313	,	_
109-29	20314-20317	the	_
109-30	20318-20329	sensitivity	_
109-31	20330-20332	of	_
109-32	20333-20336	the	_
109-33	20337-20347	particular	_
109-34	20348-20356	paradigm	_
109-35	20357-20365	involved	_
109-36	20365-20366	,	_
109-37	20367-20370	and	_
109-38	20371-20378	whether	_
109-39	20379-20380	a	_
109-40	20381-20386	motor	_
109-41	20387-20395	response	_
109-42	20396-20398	is	_
109-43	20399-20407	required	_
109-44	20408-20410	or	_
109-45	20411-20414	not	_
109-46	20414-20415	.	_

#Text=In the paradigm used in the present study rewards were not predictable, as they occurred at variable times (between 2.8 and 6 s after the reel started to spin) and were uncommon (occurring in one sixth of trials in a pseudo-randomized pattern), and as such these rewards are associated with positive prediction error.
110-1	20416-20418	In	_
110-2	20419-20422	the	_
110-3	20423-20431	paradigm	_
110-4	20432-20436	used	_
110-5	20437-20439	in	_
110-6	20440-20443	the	_
110-7	20444-20451	present	_
110-8	20452-20457	study	_
110-9	20458-20465	rewards	_
110-10	20466-20470	were	_
110-11	20471-20474	not	_
110-12	20475-20486	predictable	_
110-13	20486-20487	,	_
110-14	20488-20490	as	_
110-15	20491-20495	they	_
110-16	20496-20504	occurred	_
110-17	20505-20507	at	_
110-18	20508-20516	variable	_
110-19	20517-20522	times	_
110-20	20523-20524	(	_
110-21	20524-20531	between	_
110-22	20532-20535	2.8	_
110-23	20536-20539	and	_
110-24	20540-20541	6	_
110-25	20542-20543	s	_
110-26	20544-20549	after	_
110-27	20550-20553	the	_
110-28	20554-20558	reel	_
110-29	20559-20566	started	_
110-30	20567-20569	to	_
110-31	20570-20574	spin	_
110-32	20574-20575	)	_
110-33	20576-20579	and	_
110-34	20580-20584	were	_
110-35	20585-20593	uncommon	_
110-36	20594-20595	(	_
110-37	20595-20604	occurring	_
110-38	20605-20607	in	_
110-39	20608-20611	one	_
110-40	20612-20617	sixth	_
110-41	20618-20620	of	_
110-42	20621-20627	trials	_
110-43	20628-20630	in	_
110-44	20631-20632	a	_
110-45	20633-20650	pseudo-randomized	_
110-46	20651-20658	pattern	_
110-47	20658-20659	)	_
110-48	20659-20660	,	_
110-49	20661-20664	and	_
110-50	20665-20667	as	_
110-51	20668-20672	such	_
110-52	20673-20678	these	_
110-53	20679-20686	rewards	_
110-54	20687-20690	are	_
110-55	20691-20701	associated	_
110-56	20702-20706	with	_
110-57	20707-20715	positive	_
110-58	20716-20726	prediction	_
110-59	20727-20732	error	_
110-60	20732-20733	.	_

#Text=Because not all patients with schizophrenia or depression have difficulties in motivation and enjoyment, patient heterogeneity may also contribute to variability of the results in the existing literature.
111-1	20734-20741	Because	_
111-2	20742-20745	not	_
111-3	20746-20749	all	_
111-4	20750-20758	patients	_
111-5	20759-20763	with	_
111-6	20764-20777	schizophrenia	_
111-7	20778-20780	or	_
111-8	20781-20791	depression	_
111-9	20792-20796	have	_
111-10	20797-20809	difficulties	_
111-11	20810-20812	in	_
111-12	20813-20823	motivation	_
111-13	20824-20827	and	_
111-14	20828-20837	enjoyment	_
111-15	20837-20838	,	_
111-16	20839-20846	patient	_
111-17	20847-20860	heterogeneity	_
111-18	20861-20864	may	_
111-19	20865-20869	also	_
111-20	20870-20880	contribute	_
111-21	20881-20883	to	_
111-22	20884-20895	variability	_
111-23	20896-20898	of	_
111-24	20899-20902	the	_
111-25	20903-20910	results	_
111-26	20911-20913	in	_
111-27	20914-20917	the	_
111-28	20918-20926	existing	_
111-29	20927-20937	literature	_
111-30	20937-20938	.	_

#Text=Our results, in a study where all patients had at least some degree of anhedonia, indicate that striatal, insular, thalamic, temporal cortex, and orbitofrontal cortex processing of unexpected rewards may be abnormal in both schizophrenia and depression, which may impact on hedonic experience, the ability to learn reward-cue relationships and the generation of motivational states.
112-1	20939-20942	Our	_
112-2	20943-20950	results	_
112-3	20950-20951	,	_
112-4	20952-20954	in	_
112-5	20955-20956	a	_
112-6	20957-20962	study	_
112-7	20963-20968	where	_
112-8	20969-20972	all	_
112-9	20973-20981	patients	_
112-10	20982-20985	had	_
112-11	20986-20988	at	_
112-12	20989-20994	least	_
112-13	20995-20999	some	_
112-14	21000-21006	degree	_
112-15	21007-21009	of	_
112-16	21010-21019	anhedonia	_
112-17	21019-21020	,	_
112-18	21021-21029	indicate	_
112-19	21030-21034	that	_
112-20	21035-21043	striatal	_
112-21	21043-21044	,	_
112-22	21045-21052	insular	_
112-23	21052-21053	,	_
112-24	21054-21062	thalamic	_
112-25	21062-21063	,	_
112-26	21064-21072	temporal	_
112-27	21073-21079	cortex	_
112-28	21079-21080	,	_
112-29	21081-21084	and	_
112-30	21085-21098	orbitofrontal	_
112-31	21099-21105	cortex	_
112-32	21106-21116	processing	_
112-33	21117-21119	of	_
112-34	21120-21130	unexpected	_
112-35	21131-21138	rewards	_
112-36	21139-21142	may	_
112-37	21143-21145	be	_
112-38	21146-21154	abnormal	_
112-39	21155-21157	in	_
112-40	21158-21162	both	_
112-41	21163-21176	schizophrenia	_
112-42	21177-21180	and	_
112-43	21181-21191	depression	_
112-44	21191-21192	,	_
112-45	21193-21198	which	_
112-46	21199-21202	may	_
112-47	21203-21209	impact	_
112-48	21210-21212	on	_
112-49	21213-21220	hedonic	_
112-50	21221-21231	experience	_
112-51	21231-21232	,	_
112-52	21233-21236	the	_
112-53	21237-21244	ability	_
112-54	21245-21247	to	_
112-55	21248-21253	learn	_
112-56	21254-21264	reward-cue	_
112-57	21265-21278	relationships	_
112-58	21279-21282	and	_
112-59	21283-21286	the	_
112-60	21287-21297	generation	_
112-61	21298-21300	of	_
112-62	21301-21313	motivational	_
112-63	21314-21320	states	_
112-64	21320-21321	.	_

#Text=One previous study compared reward prediction error responses in participants with depression, participants with schizophrenia and controls; that study scanned participants during learning, and the current study extends these results to demonstrate, in a task where no learning is required, areas of overlapping and differential response associated with reward prediction error in schizophrenia and depression.
113-1	21322-21325	One	_
113-2	21326-21334	previous	_
113-3	21335-21340	study	_
113-4	21341-21349	compared	_
113-5	21350-21356	reward	_
113-6	21357-21367	prediction	_
113-7	21368-21373	error	_
113-8	21374-21383	responses	_
113-9	21384-21386	in	_
113-10	21387-21399	participants	_
113-11	21400-21404	with	_
113-12	21405-21415	depression	_
113-13	21415-21416	,	_
113-14	21417-21429	participants	_
113-15	21430-21434	with	_
113-16	21435-21448	schizophrenia	_
113-17	21449-21452	and	_
113-18	21453-21461	controls	_
113-19	21461-21462	;	_
113-20	21463-21467	that	_
113-21	21468-21473	study	_
113-22	21474-21481	scanned	_
113-23	21482-21494	participants	_
113-24	21495-21501	during	_
113-25	21502-21510	learning	_
113-26	21510-21511	,	_
113-27	21512-21515	and	_
113-28	21516-21519	the	_
113-29	21520-21527	current	_
113-30	21528-21533	study	_
113-31	21534-21541	extends	_
113-32	21542-21547	these	_
113-33	21548-21555	results	_
113-34	21556-21558	to	_
113-35	21559-21570	demonstrate	_
113-36	21570-21571	,	_
113-37	21572-21574	in	_
113-38	21575-21576	a	_
113-39	21577-21581	task	_
113-40	21582-21587	where	_
113-41	21588-21590	no	_
113-42	21591-21599	learning	_
113-43	21600-21602	is	_
113-44	21603-21611	required	_
113-45	21611-21612	,	_
113-46	21613-21618	areas	_
113-47	21619-21621	of	_
113-48	21622-21633	overlapping	_
113-49	21634-21637	and	_
113-50	21638-21650	differential	_
113-51	21651-21659	response	_
113-52	21660-21670	associated	_
113-53	21671-21675	with	_
113-54	21676-21682	reward	_
113-55	21683-21693	prediction	_
113-56	21694-21699	error	_
113-57	21700-21702	in	_
113-58	21703-21716	schizophrenia	_
113-59	21717-21720	and	_
113-60	21721-21731	depression	_
113-61	21731-21732	.	_

#Text=In addition, whilst examined brain responses correlating with a composite measure of positive and negative prediction error, our study focuses on positive reward prediction error: given that rewards are infrequent in our task, there are no trials in this task where strong expectancies of a win are violated.
114-1	21733-21735	In	_
114-2	21736-21744	addition	_
114-3	21744-21745	,	_
114-4	21746-21752	whilst	_
114-5	21753-21761	examined	_
114-6	21762-21767	brain	_
114-7	21768-21777	responses	_
114-8	21778-21789	correlating	_
114-9	21790-21794	with	_
114-10	21795-21796	a	_
114-11	21797-21806	composite	_
114-12	21807-21814	measure	_
114-13	21815-21817	of	_
114-14	21818-21826	positive	_
114-15	21827-21830	and	_
114-16	21831-21839	negative	_
114-17	21840-21850	prediction	_
114-18	21851-21856	error	_
114-19	21856-21857	,	_
114-20	21858-21861	our	_
114-21	21862-21867	study	_
114-22	21868-21875	focuses	_
114-23	21876-21878	on	_
114-24	21879-21887	positive	_
114-25	21888-21894	reward	_
114-26	21895-21905	prediction	_
114-27	21906-21911	error	_
114-28	21911-21912	:	_
114-29	21913-21918	given	_
114-30	21919-21923	that	_
114-31	21924-21931	rewards	_
114-32	21932-21935	are	_
114-33	21936-21946	infrequent	_
114-34	21947-21949	in	_
114-35	21950-21953	our	_
114-36	21954-21958	task	_
114-37	21958-21959	,	_
114-38	21960-21965	there	_
114-39	21966-21969	are	_
114-40	21970-21972	no	_
114-41	21973-21979	trials	_
114-42	21980-21982	in	_
114-43	21983-21987	this	_
114-44	21988-21992	task	_
114-45	21993-21998	where	_
114-46	21999-22005	strong	_
114-47	22006-22018	expectancies	_
114-48	22019-22021	of	_
114-49	22022-22023	a	_
114-50	22024-22027	win	_
114-51	22028-22031	are	_
114-52	22032-22040	violated	_
114-53	22040-22041	.	_

#Text=Although our results indicate many shared areas of reward processing deficit in schizophrenia and depression, there are also areas of difference.
115-1	22042-22050	Although	_
115-2	22051-22054	our	_
115-3	22055-22062	results	_
115-4	22063-22071	indicate	_
115-5	22072-22076	many	_
115-6	22077-22083	shared	_
115-7	22084-22089	areas	_
115-8	22090-22092	of	_
115-9	22093-22099	reward	_
115-10	22100-22110	processing	_
115-11	22111-22118	deficit	_
115-12	22119-22121	in	_
115-13	22122-22135	schizophrenia	_
115-14	22136-22139	and	_
115-15	22140-22150	depression	_
115-16	22150-22151	,	_
115-17	22152-22157	there	_
115-18	22158-22161	are	_
115-19	22162-22166	also	_
115-20	22167-22172	areas	_
115-21	22173-22175	of	_
115-22	22176-22186	difference	_
115-23	22186-22187	.	_

#Text=There were schizophrenia specific deficits in unexpected reward receipt activation in the posterior cingulate gyrus, occipital pole, and cerebellum: these areas were not significantly abnormal in depression, although post hoc analysis did not demonstrate significant differences in activation between patient groups.
116-1	22188-22193	There	_
116-2	22194-22198	were	_
116-3	22199-22212	schizophrenia	_
116-4	22213-22221	specific	_
116-5	22222-22230	deficits	_
116-6	22231-22233	in	_
116-7	22234-22244	unexpected	_
116-8	22245-22251	reward	_
116-9	22252-22259	receipt	_
116-10	22260-22270	activation	_
116-11	22271-22273	in	_
116-12	22274-22277	the	_
116-13	22278-22287	posterior	_
116-14	22288-22297	cingulate	_
116-15	22298-22303	gyrus	_
116-16	22303-22304	,	_
116-17	22305-22314	occipital	_
116-18	22315-22319	pole	_
116-19	22319-22320	,	_
116-20	22321-22324	and	_
116-21	22325-22335	cerebellum	_
116-22	22335-22336	:	_
116-23	22337-22342	these	_
116-24	22343-22348	areas	_
116-25	22349-22353	were	_
116-26	22354-22357	not	_
116-27	22358-22371	significantly	_
116-28	22372-22380	abnormal	_
116-29	22381-22383	in	_
116-30	22384-22394	depression	_
116-31	22394-22395	,	_
116-32	22396-22404	although	_
116-33	22405-22409	post	_
116-34	22410-22413	hoc	_
116-35	22414-22422	analysis	_
116-36	22423-22426	did	_
116-37	22427-22430	not	_
116-38	22431-22442	demonstrate	_
116-39	22443-22454	significant	_
116-40	22455-22466	differences	_
116-41	22467-22469	in	_
116-42	22470-22480	activation	_
116-43	22481-22488	between	_
116-44	22489-22496	patient	_
116-45	22497-22503	groups	_
116-46	22503-22504	.	_

#Text=We note there were however significant differences between the patient groups in the lateral parietal cortex, in the supramarginal and angular gyri, and intraparietal sulci, which had abnormal activation in schizophrenia but not depression, confirmed in an additional analysis using exclusive masking (see Supplementary Text and Supplementary Figures S11 and S12).
117-1	22505-22507	We	_
117-2	22508-22512	note	_
117-3	22513-22518	there	_
117-4	22519-22523	were	_
117-5	22524-22531	however	_
117-6	22532-22543	significant	_
117-7	22544-22555	differences	_
117-8	22556-22563	between	_
117-9	22564-22567	the	_
117-10	22568-22575	patient	_
117-11	22576-22582	groups	_
117-12	22583-22585	in	_
117-13	22586-22589	the	_
117-14	22590-22597	lateral	_
117-15	22598-22606	parietal	_
117-16	22607-22613	cortex	_
117-17	22613-22614	,	_
117-18	22615-22617	in	_
117-19	22618-22621	the	_
117-20	22622-22635	supramarginal	_
117-21	22636-22639	and	_
117-22	22640-22647	angular	_
117-23	22648-22652	gyri	_
117-24	22652-22653	,	_
117-25	22654-22657	and	_
117-26	22658-22671	intraparietal	_
117-27	22672-22677	sulci	_
117-28	22677-22678	,	_
117-29	22679-22684	which	_
117-30	22685-22688	had	_
117-31	22689-22697	abnormal	_
117-32	22698-22708	activation	_
117-33	22709-22711	in	_
117-34	22712-22725	schizophrenia	_
117-35	22726-22729	but	_
117-36	22730-22733	not	_
117-37	22734-22744	depression	_
117-38	22744-22745	,	_
117-39	22746-22755	confirmed	_
117-40	22756-22758	in	_
117-41	22759-22761	an	_
117-42	22762-22772	additional	_
117-43	22773-22781	analysis	_
117-44	22782-22787	using	_
117-45	22788-22797	exclusive	_
117-46	22798-22805	masking	_
117-47	22806-22807	(	_
117-48	22807-22810	see	_
117-49	22811-22824	Supplementary	_
117-50	22825-22829	Text	_
117-51	22830-22833	and	_
117-52	22834-22847	Supplementary	_
117-53	22848-22855	Figures	_
117-54	22856-22859	S11	_
117-55	22860-22863	and	_
117-56	22864-22867	S12	_
117-57	22867-22868	)	_
117-58	22868-22869	.	_

#Text=There is previous evidence for the role of this part of the parietal cortex in signaling surprising outcomes, with some evidence that reward processing in this region is dopaminergically mediated; in this regard it is of interest that dysfunction of this region was specific to schizophrenia.
118-1	22870-22875	There	_
118-2	22876-22878	is	_
118-3	22879-22887	previous	_
118-4	22888-22896	evidence	_
118-5	22897-22900	for	_
118-6	22901-22904	the	_
118-7	22905-22909	role	_
118-8	22910-22912	of	_
118-9	22913-22917	this	_
118-10	22918-22922	part	_
118-11	22923-22925	of	_
118-12	22926-22929	the	_
118-13	22930-22938	parietal	_
118-14	22939-22945	cortex	_
118-15	22946-22948	in	_
118-16	22949-22958	signaling	_
118-17	22959-22969	surprising	_
118-18	22970-22978	outcomes	_
118-19	22978-22979	,	_
118-20	22980-22984	with	_
118-21	22985-22989	some	_
118-22	22990-22998	evidence	_
118-23	22999-23003	that	_
118-24	23004-23010	reward	_
118-25	23011-23021	processing	_
118-26	23022-23024	in	_
118-27	23025-23029	this	_
118-28	23030-23036	region	_
118-29	23037-23039	is	_
118-30	23040-23056	dopaminergically	_
118-31	23057-23065	mediated	_
118-32	23065-23066	;	_
118-33	23067-23069	in	_
118-34	23070-23074	this	_
118-35	23075-23081	regard	_
118-36	23082-23084	it	_
118-37	23085-23087	is	_
118-38	23088-23090	of	_
118-39	23091-23099	interest	_
118-40	23100-23104	that	_
118-41	23105-23116	dysfunction	_
118-42	23117-23119	of	_
118-43	23120-23124	this	_
118-44	23125-23131	region	_
118-45	23132-23135	was	_
118-46	23136-23144	specific	_
118-47	23145-23147	to	_
118-48	23148-23161	schizophrenia	_
118-49	23161-23162	.	_

#Text=Parietal activation associated with the uncertainty of outcomes has previously been shown to be abnormal in schizophrenia.
119-1	23163-23171	Parietal	_
119-2	23172-23182	activation	_
119-3	23183-23193	associated	_
119-4	23194-23198	with	_
119-5	23199-23202	the	_
119-6	23203-23214	uncertainty	_
119-7	23215-23217	of	_
119-8	23218-23226	outcomes	_
119-9	23227-23230	has	_
119-10	23231-23241	previously	_
119-11	23242-23246	been	_
119-12	23247-23252	shown	_
119-13	23253-23255	to	_
119-14	23256-23258	be	_
119-15	23259-23267	abnormal	_
119-16	23268-23270	in	_
119-17	23271-23284	schizophrenia	_
119-18	23284-23285	.	_

#Text=In the medial prefrontal cortex, including the superior frontal gyrus and anterior paracingulate, activation in both patient groups was significantly abnormal (showing hypoactivation to unexpected reward receipt) with the schizophrenia group showing significantly greater abnormality than the depression group.
120-1	23286-23288	In	_
120-2	23289-23292	the	_
120-3	23293-23299	medial	_
120-4	23300-23310	prefrontal	_
120-5	23311-23317	cortex	_
120-6	23317-23318	,	_
120-7	23319-23328	including	_
120-8	23329-23332	the	_
120-9	23333-23341	superior	_
120-10	23342-23349	frontal	_
120-11	23350-23355	gyrus	_
120-12	23356-23359	and	_
120-13	23360-23368	anterior	_
120-14	23369-23382	paracingulate	_
120-15	23382-23383	,	_
120-16	23384-23394	activation	_
120-17	23395-23397	in	_
120-18	23398-23402	both	_
120-19	23403-23410	patient	_
120-20	23411-23417	groups	_
120-21	23418-23421	was	_
120-22	23422-23435	significantly	_
120-23	23436-23444	abnormal	_
120-24	23445-23446	(	_
120-25	23446-23453	showing	_
120-26	23454-23468	hypoactivation	_
120-27	23469-23471	to	_
120-28	23472-23482	unexpected	_
120-29	23483-23489	reward	_
120-30	23490-23497	receipt	_
120-31	23497-23498	)	_
120-32	23499-23503	with	_
120-33	23504-23507	the	_
120-34	23508-23521	schizophrenia	_
120-35	23522-23527	group	_
120-36	23528-23535	showing	_
120-37	23536-23549	significantly	_
120-38	23550-23557	greater	_
120-39	23558-23569	abnormality	_
120-40	23570-23574	than	_
120-41	23575-23578	the	_
120-42	23579-23589	depression	_
120-43	23590-23595	group	_
120-44	23595-23596	.	_

#Text=Medial frontal and anterior cingulate hypoactivation has been reported during the receipt of an expected reward in schizophrenia, and preclinical studies indicate that these cortical regions are critical for motivated behavior.
121-1	23597-23603	Medial	_
121-2	23604-23611	frontal	_
121-3	23612-23615	and	_
121-4	23616-23624	anterior	_
121-5	23625-23634	cingulate	_
121-6	23635-23649	hypoactivation	_
121-7	23650-23653	has	_
121-8	23654-23658	been	_
121-9	23659-23667	reported	_
121-10	23668-23674	during	_
121-11	23675-23678	the	_
121-12	23679-23686	receipt	_
121-13	23687-23689	of	_
121-14	23690-23692	an	_
121-15	23693-23701	expected	_
121-16	23702-23708	reward	_
121-17	23709-23711	in	_
121-18	23712-23725	schizophrenia	_
121-19	23725-23726	,	_
121-20	23727-23730	and	_
121-21	23731-23742	preclinical	_
121-22	23743-23750	studies	_
121-23	23751-23759	indicate	_
121-24	23760-23764	that	_
121-25	23765-23770	these	_
121-26	23771-23779	cortical	_
121-27	23780-23787	regions	_
121-28	23788-23791	are	_
121-29	23792-23800	critical	_
121-30	23801-23804	for	_
121-31	23805-23814	motivated	_
121-32	23815-23823	behavior	_
121-33	23823-23824	.	_

#Text=Relationship Between Brain Responses to an Unexpected Reward And Motivational Scores
#Text=Motivation to play the game was positively associated with activation to unexpected reward in a cluster situated in medial prefrontal areas, including the anterior cingulate and paracingulate gyrus, in the whole sample (adjusting for diagnosis); this cluster overlapped with the medial prefrontal cluster in which schizophrenia participants showed lower activation than controls and depression, and depression participants showed lower activation than controls, when receiving an unexpected reward.
122-1	23825-23837	Relationship	_
122-2	23838-23845	Between	_
122-3	23846-23851	Brain	_
122-4	23852-23861	Responses	_
122-5	23862-23864	to	_
122-6	23865-23867	an	_
122-7	23868-23878	Unexpected	_
122-8	23879-23885	Reward	_
122-9	23886-23889	And	_
122-10	23890-23902	Motivational	_
122-11	23903-23909	Scores	_
122-12	23910-23920	Motivation	_
122-13	23921-23923	to	_
122-14	23924-23928	play	_
122-15	23929-23932	the	_
122-16	23933-23937	game	_
122-17	23938-23941	was	_
122-18	23942-23952	positively	_
122-19	23953-23963	associated	_
122-20	23964-23968	with	_
122-21	23969-23979	activation	_
122-22	23980-23982	to	_
122-23	23983-23993	unexpected	_
122-24	23994-24000	reward	_
122-25	24001-24003	in	_
122-26	24004-24005	a	_
122-27	24006-24013	cluster	_
122-28	24014-24022	situated	_
122-29	24023-24025	in	_
122-30	24026-24032	medial	_
122-31	24033-24043	prefrontal	_
122-32	24044-24049	areas	_
122-33	24049-24050	,	_
122-34	24051-24060	including	_
122-35	24061-24064	the	_
122-36	24065-24073	anterior	_
122-37	24074-24083	cingulate	_
122-38	24084-24087	and	_
122-39	24088-24101	paracingulate	_
122-40	24102-24107	gyrus	_
122-41	24107-24108	,	_
122-42	24109-24111	in	_
122-43	24112-24115	the	_
122-44	24116-24121	whole	_
122-45	24122-24128	sample	_
122-46	24129-24130	(	_
122-47	24130-24139	adjusting	_
122-48	24140-24143	for	_
122-49	24144-24153	diagnosis	_
122-50	24153-24154	)	_
122-51	24154-24155	;	_
122-52	24156-24160	this	_
122-53	24161-24168	cluster	_
122-54	24169-24179	overlapped	_
122-55	24180-24184	with	_
122-56	24185-24188	the	_
122-57	24189-24195	medial	_
122-58	24196-24206	prefrontal	_
122-59	24207-24214	cluster	_
122-60	24215-24217	in	_
122-61	24218-24223	which	_
122-62	24224-24237	schizophrenia	_
122-63	24238-24250	participants	_
122-64	24251-24257	showed	_
122-65	24258-24263	lower	_
122-66	24264-24274	activation	_
122-67	24275-24279	than	_
122-68	24280-24288	controls	_
122-69	24289-24292	and	_
122-70	24293-24303	depression	_
122-71	24303-24304	,	_
122-72	24305-24308	and	_
122-73	24309-24319	depression	_
122-74	24320-24332	participants	_
122-75	24333-24339	showed	_
122-76	24340-24345	lower	_
122-77	24346-24356	activation	_
122-78	24357-24361	than	_
122-79	24362-24370	controls	_
122-80	24370-24371	,	_
122-81	24372-24376	when	_
122-82	24377-24386	receiving	_
122-83	24387-24389	an	_
122-84	24390-24400	unexpected	_
122-85	24401-24407	reward	_
122-86	24407-24408	.	_

#Text=This evidence of an association between brain response to unexpected reward receipt and motivation, rather than pleasure, adds complexity and nuance to models of reward processing that parse pleasure and motivation into separable psychological processes with distinct neural components.
123-1	24409-24413	This	_
123-2	24414-24422	evidence	_
123-3	24423-24425	of	_
123-4	24426-24428	an	_
123-5	24429-24440	association	_
123-6	24441-24448	between	_
123-7	24449-24454	brain	_
123-8	24455-24463	response	_
123-9	24464-24466	to	_
123-10	24467-24477	unexpected	_
123-11	24478-24484	reward	_
123-12	24485-24492	receipt	_
123-13	24493-24496	and	_
123-14	24497-24507	motivation	_
123-15	24507-24508	,	_
123-16	24509-24515	rather	_
123-17	24516-24520	than	_
123-18	24521-24529	pleasure	_
123-19	24529-24530	,	_
123-20	24531-24535	adds	_
123-21	24536-24546	complexity	_
123-22	24547-24550	and	_
123-23	24551-24557	nuance	_
123-24	24558-24560	to	_
123-25	24561-24567	models	_
123-26	24568-24570	of	_
123-27	24571-24577	reward	_
123-28	24578-24588	processing	_
123-29	24589-24593	that	_
123-30	24594-24599	parse	_
123-31	24600-24608	pleasure	_
123-32	24609-24612	and	_
123-33	24613-24623	motivation	_
123-34	24624-24628	into	_
123-35	24629-24638	separable	_
123-36	24639-24652	psychological	_
123-37	24653-24662	processes	_
123-38	24663-24667	with	_
123-39	24668-24676	distinct	_
123-40	24677-24683	neural	_
123-41	24684-24694	components	_
123-42	24694-24695	.	_

#Text=However, a full-model should take account of how unexpected reward-related responses influences future behavior through motivation.
124-1	24696-24703	However	_
124-2	24703-24704	,	_
124-3	24705-24706	a	_
124-4	24707-24717	full-model	_
124-5	24718-24724	should	_
124-6	24725-24729	take	_
124-7	24730-24737	account	_
124-8	24738-24740	of	_
124-9	24741-24744	how	_
124-10	24745-24755	unexpected	_
124-11	24756-24770	reward-related	_
124-12	24771-24780	responses	_
124-13	24781-24791	influences	_
124-14	24792-24798	future	_
124-15	24799-24807	behavior	_
124-16	24808-24815	through	_
124-17	24816-24826	motivation	_
124-18	24826-24827	.	_

#Text=Although SHAPS scores were associated with task-related measures of motivation, and brain activation in the medial prefrontal cortex was associated with task-related motivation, there was no direct association between brain activation and SHAPS scores, suggesting that medial prefrontal activation may be indirectly associated with anhedonic symptoms via its association with task-related motivation.
125-1	24828-24836	Although	_
125-2	24837-24842	SHAPS	_
125-3	24843-24849	scores	_
125-4	24850-24854	were	_
125-5	24855-24865	associated	_
125-6	24866-24870	with	_
125-7	24871-24883	task-related	_
125-8	24884-24892	measures	_
125-9	24893-24895	of	_
125-10	24896-24906	motivation	_
125-11	24906-24907	,	_
125-12	24908-24911	and	_
125-13	24912-24917	brain	_
125-14	24918-24928	activation	_
125-15	24929-24931	in	_
125-16	24932-24935	the	_
125-17	24936-24942	medial	_
125-18	24943-24953	prefrontal	_
125-19	24954-24960	cortex	_
125-20	24961-24964	was	_
125-21	24965-24975	associated	_
125-22	24976-24980	with	_
125-23	24981-24993	task-related	_
125-24	24994-25004	motivation	_
125-25	25004-25005	,	_
125-26	25006-25011	there	_
125-27	25012-25015	was	_
125-28	25016-25018	no	_
125-29	25019-25025	direct	_
125-30	25026-25037	association	_
125-31	25038-25045	between	_
125-32	25046-25051	brain	_
125-33	25052-25062	activation	_
125-34	25063-25066	and	_
125-35	25067-25072	SHAPS	_
125-36	25073-25079	scores	_
125-37	25079-25080	,	_
125-38	25081-25091	suggesting	_
125-39	25092-25096	that	_
125-40	25097-25103	medial	_
125-41	25104-25114	prefrontal	_
125-42	25115-25125	activation	_
125-43	25126-25129	may	_
125-44	25130-25132	be	_
125-45	25133-25143	indirectly	_
125-46	25144-25154	associated	_
125-47	25155-25159	with	_
125-48	25160-25169	anhedonic	_
125-49	25170-25178	symptoms	_
125-50	25179-25182	via	_
125-51	25183-25186	its	_
125-52	25187-25198	association	_
125-53	25199-25203	with	_
125-54	25204-25216	task-related	_
125-55	25217-25227	motivation	_
125-56	25227-25228	.	_

#Text=Our results suggest that medial prefrontal and anterior cingulate activation to unexpected reward receipt may be a mechanism that enables the brain to update the motivational state to reinforce actions that maximize future reward.
126-1	25229-25232	Our	_
126-2	25233-25240	results	_
126-3	25241-25248	suggest	_
126-4	25249-25253	that	_
126-5	25254-25260	medial	_
126-6	25261-25271	prefrontal	_
126-7	25272-25275	and	_
126-8	25276-25284	anterior	_
126-9	25285-25294	cingulate	_
126-10	25295-25305	activation	_
126-11	25306-25308	to	_
126-12	25309-25319	unexpected	_
126-13	25320-25326	reward	_
126-14	25327-25334	receipt	_
126-15	25335-25338	may	_
126-16	25339-25341	be	_
126-17	25342-25343	a	_
126-18	25344-25353	mechanism	_
126-19	25354-25358	that	_
126-20	25359-25366	enables	_
126-21	25367-25370	the	_
126-22	25371-25376	brain	_
126-23	25377-25379	to	_
126-24	25380-25386	update	_
126-25	25387-25390	the	_
126-26	25391-25403	motivational	_
126-27	25404-25409	state	_
126-28	25410-25412	to	_
126-29	25413-25422	reinforce	_
126-30	25423-25430	actions	_
126-31	25431-25435	that	_
126-32	25436-25444	maximize	_
126-33	25445-25451	future	_
126-34	25452-25458	reward	_
126-35	25458-25459	.	_

#Text=Our finding, linking neural response to a reward receipt with an index of motivation, is reminiscent of the results of Waltz et al (2009) who found that putamen and gustatory cortex responses to sweet liquid rewards predicted clinical avolition as measured by the SANS.
127-1	25460-25463	Our	_
127-2	25464-25471	finding	_
127-3	25471-25472	,	_
127-4	25473-25480	linking	_
127-5	25481-25487	neural	_
127-6	25488-25496	response	_
127-7	25497-25499	to	_
127-8	25500-25501	a	_
127-9	25502-25508	reward	_
127-10	25509-25516	receipt	_
127-11	25517-25521	with	_
127-12	25522-25524	an	_
127-13	25525-25530	index	_
127-14	25531-25533	of	_
127-15	25534-25544	motivation	_
127-16	25544-25545	,	_
127-17	25546-25548	is	_
127-18	25549-25560	reminiscent	_
127-19	25561-25563	of	_
127-20	25564-25567	the	_
127-21	25568-25575	results	_
127-22	25576-25578	of	_
127-23	25579-25584	Waltz	_
127-24	25585-25587	et	_
127-25	25588-25590	al	_
127-26	25591-25592	(	_
127-27	25592-25596	2009	_
127-28	25596-25597	)	_
127-29	25598-25601	who	_
127-30	25602-25607	found	_
127-31	25608-25612	that	_
127-32	25613-25620	putamen	_
127-33	25621-25624	and	_
127-34	25625-25634	gustatory	_
127-35	25635-25641	cortex	_
127-36	25642-25651	responses	_
127-37	25652-25654	to	_
127-38	25655-25660	sweet	_
127-39	25661-25667	liquid	_
127-40	25668-25675	rewards	_
127-41	25676-25685	predicted	_
127-42	25686-25694	clinical	_
127-43	25695-25704	avolition	_
127-44	25705-25707	as	_
127-45	25708-25716	measured	_
127-46	25717-25719	by	_
127-47	25720-25723	the	_
127-48	25724-25728	SANS	_
127-49	25728-25729	.	_

#Text=Our findings extend those of Waltz et al (2009) to relationships between reward receipt and motivation to the medial prefrontal and anterior cingulate cortices, key regions in processing reward information and in goal-directed behavior, which are implicated in the pathophysiology of both depression and schizophrenia.
128-1	25730-25733	Our	_
128-2	25734-25742	findings	_
128-3	25743-25749	extend	_
128-4	25750-25755	those	_
128-5	25756-25758	of	_
128-6	25759-25764	Waltz	_
128-7	25765-25767	et	_
128-8	25768-25770	al	_
128-9	25771-25772	(	_
128-10	25772-25776	2009	_
128-11	25776-25777	)	_
128-12	25778-25780	to	_
128-13	25781-25794	relationships	_
128-14	25795-25802	between	_
128-15	25803-25809	reward	_
128-16	25810-25817	receipt	_
128-17	25818-25821	and	_
128-18	25822-25832	motivation	_
128-19	25833-25835	to	_
128-20	25836-25839	the	_
128-21	25840-25846	medial	_
128-22	25847-25857	prefrontal	_
128-23	25858-25861	and	_
128-24	25862-25870	anterior	_
128-25	25871-25880	cingulate	_
128-26	25881-25889	cortices	_
128-27	25889-25890	,	_
128-28	25891-25894	key	_
128-29	25895-25902	regions	_
128-30	25903-25905	in	_
128-31	25906-25916	processing	_
128-32	25917-25923	reward	_
128-33	25924-25935	information	_
128-34	25936-25939	and	_
128-35	25940-25942	in	_
128-36	25943-25956	goal-directed	_
128-37	25957-25965	behavior	_
128-38	25965-25966	,	_
128-39	25967-25972	which	_
128-40	25973-25976	are	_
128-41	25977-25987	implicated	_
128-42	25988-25990	in	_
128-43	25991-25994	the	_
128-44	25995-26010	pathophysiology	_
128-45	26011-26013	of	_
128-46	26014-26018	both	_
128-47	26019-26029	depression	_
128-48	26030-26033	and	_
128-49	26034-26047	schizophrenia	_
128-50	26047-26048	.	_

#Text=Taken together our results indicate an important role for the medial prefrontal cortex and anterior cingulate in the genesis of anhedonic symptoms (especially in schizophrenia).
129-1	26049-26054	Taken	_
129-2	26055-26063	together	_
129-3	26064-26067	our	_
129-4	26068-26075	results	_
129-5	26076-26084	indicate	_
129-6	26085-26087	an	_
129-7	26088-26097	important	_
129-8	26098-26102	role	_
129-9	26103-26106	for	_
129-10	26107-26110	the	_
129-11	26111-26117	medial	_
129-12	26118-26128	prefrontal	_
129-13	26129-26135	cortex	_
129-14	26136-26139	and	_
129-15	26140-26148	anterior	_
129-16	26149-26158	cingulate	_
129-17	26159-26161	in	_
129-18	26162-26165	the	_
129-19	26166-26173	genesis	_
129-20	26174-26176	of	_
129-21	26177-26186	anhedonic	_
129-22	26187-26195	symptoms	_
129-23	26196-26197	(	_
129-24	26197-26207	especially	_
129-25	26208-26210	in	_
129-26	26211-26224	schizophrenia	_
129-27	26224-26225	)	_
129-28	26225-26226	.	_

#Text=We show that the activity in these regions is reduced in schizophrenia compared with controls during unexpected reward receipt, that the degree of reward receipt related activation in this area is associated with the degree of motivation to continue playing a game, and that the degree of motivation to continue playing in our experiment relates to severity of anhedonia in schizophrenia.
130-1	26227-26229	We	_
130-2	26230-26234	show	_
130-3	26235-26239	that	_
130-4	26240-26243	the	_
130-5	26244-26252	activity	_
130-6	26253-26255	in	_
130-7	26256-26261	these	_
130-8	26262-26269	regions	_
130-9	26270-26272	is	_
130-10	26273-26280	reduced	_
130-11	26281-26283	in	_
130-12	26284-26297	schizophrenia	_
130-13	26298-26306	compared	_
130-14	26307-26311	with	_
130-15	26312-26320	controls	_
130-16	26321-26327	during	_
130-17	26328-26338	unexpected	_
130-18	26339-26345	reward	_
130-19	26346-26353	receipt	_
130-20	26353-26354	,	_
130-21	26355-26359	that	_
130-22	26360-26363	the	_
130-23	26364-26370	degree	_
130-24	26371-26373	of	_
130-25	26374-26380	reward	_
130-26	26381-26388	receipt	_
130-27	26389-26396	related	_
130-28	26397-26407	activation	_
130-29	26408-26410	in	_
130-30	26411-26415	this	_
130-31	26416-26420	area	_
130-32	26421-26423	is	_
130-33	26424-26434	associated	_
130-34	26435-26439	with	_
130-35	26440-26443	the	_
130-36	26444-26450	degree	_
130-37	26451-26453	of	_
130-38	26454-26464	motivation	_
130-39	26465-26467	to	_
130-40	26468-26476	continue	_
130-41	26477-26484	playing	_
130-42	26485-26486	a	_
130-43	26487-26491	game	_
130-44	26491-26492	,	_
130-45	26493-26496	and	_
130-46	26497-26501	that	_
130-47	26502-26505	the	_
130-48	26506-26512	degree	_
130-49	26513-26515	of	_
130-50	26516-26526	motivation	_
130-51	26527-26529	to	_
130-52	26530-26538	continue	_
130-53	26539-26546	playing	_
130-54	26547-26549	in	_
130-55	26550-26553	our	_
130-56	26554-26564	experiment	_
130-57	26565-26572	relates	_
130-58	26573-26575	to	_
130-59	26576-26584	severity	_
130-60	26585-26587	of	_
130-61	26588-26597	anhedonia	_
130-62	26598-26600	in	_
130-63	26601-26614	schizophrenia	_
130-64	26614-26615	.	_

#Text=Limitations
#Text=One significant limitation of the current study is that all the schizophrenia patients and about half the depression patients were taking psychotropic medication, given that both of these classes of medication have been shown to affect brain activity during reward processing experiments.
131-1	26616-26627	Limitations	_
131-2	26628-26631	One	_
131-3	26632-26643	significant	_
131-4	26644-26654	limitation	_
131-5	26655-26657	of	_
131-6	26658-26661	the	_
131-7	26662-26669	current	_
131-8	26670-26675	study	_
131-9	26676-26678	is	_
131-10	26679-26683	that	_
131-11	26684-26687	all	_
131-12	26688-26691	the	_
131-13	26692-26705	schizophrenia	_
131-14	26706-26714	patients	_
131-15	26715-26718	and	_
131-16	26719-26724	about	_
131-17	26725-26729	half	_
131-18	26730-26733	the	_
131-19	26734-26744	depression	_
131-20	26745-26753	patients	_
131-21	26754-26758	were	_
131-22	26759-26765	taking	_
131-23	26766-26778	psychotropic	_
131-24	26779-26789	medication	_
131-25	26789-26790	,	_
131-26	26791-26796	given	_
131-27	26797-26801	that	_
131-28	26802-26806	both	_
131-29	26807-26809	of	_
131-30	26810-26815	these	_
131-31	26816-26823	classes	_
131-32	26824-26826	of	_
131-33	26827-26837	medication	_
131-34	26838-26842	have	_
131-35	26843-26847	been	_
131-36	26848-26853	shown	_
131-37	26854-26856	to	_
131-38	26857-26863	affect	_
131-39	26864-26869	brain	_
131-40	26870-26878	activity	_
131-41	26879-26885	during	_
131-42	26886-26892	reward	_
131-43	26893-26903	processing	_
131-44	26904-26915	experiments	_
131-45	26915-26916	.	_

#Text=In experiments in healthy volunteers, certain antipsychotics and antidepressants have been shown to result in reduced reward-related brain activation; other experiments in healthy controls and in patients with schizophrenia have suggested that atypical antipsychotic medications may improve reward-related brain activation relative to placebo or to typical antipsychotic medication.
132-1	26917-26919	In	_
132-2	26920-26931	experiments	_
132-3	26932-26934	in	_
132-4	26935-26942	healthy	_
132-5	26943-26953	volunteers	_
132-6	26953-26954	,	_
132-7	26955-26962	certain	_
132-8	26963-26977	antipsychotics	_
132-9	26978-26981	and	_
132-10	26982-26997	antidepressants	_
132-11	26998-27002	have	_
132-12	27003-27007	been	_
132-13	27008-27013	shown	_
132-14	27014-27016	to	_
132-15	27017-27023	result	_
132-16	27024-27026	in	_
132-17	27027-27034	reduced	_
132-18	27035-27049	reward-related	_
132-19	27050-27055	brain	_
132-20	27056-27066	activation	_
132-21	27066-27067	;	_
132-22	27068-27073	other	_
132-23	27074-27085	experiments	_
132-24	27086-27088	in	_
132-25	27089-27096	healthy	_
132-26	27097-27105	controls	_
132-27	27106-27109	and	_
132-28	27110-27112	in	_
132-29	27113-27121	patients	_
132-30	27122-27126	with	_
132-31	27127-27140	schizophrenia	_
132-32	27141-27145	have	_
132-33	27146-27155	suggested	_
132-34	27156-27160	that	_
132-35	27161-27169	atypical	_
132-36	27170-27183	antipsychotic	_
132-37	27184-27195	medications	_
132-38	27196-27199	may	_
132-39	27200-27207	improve	_
132-40	27208-27222	reward-related	_
132-41	27223-27228	brain	_
132-42	27229-27239	activation	_
132-43	27240-27248	relative	_
132-44	27249-27251	to	_
132-45	27252-27259	placebo	_
132-46	27260-27262	or	_
132-47	27263-27265	to	_
132-48	27266-27273	typical	_
132-49	27274-27287	antipsychotic	_
132-50	27288-27298	medication	_
132-51	27298-27299	.	_

#Text=The balance of the (limited) evidence suggests that antidepressant and (atypical) antipsychotic treatment help normalize brain responses to reward-related stimuli in patients with depression and schizophrenia, respectively.
133-1	27300-27303	The	_
133-2	27304-27311	balance	_
133-3	27312-27314	of	_
133-4	27315-27318	the	_
133-5	27319-27320	(	_
133-6	27320-27327	limited	_
133-7	27327-27328	)	_
133-8	27329-27337	evidence	_
133-9	27338-27346	suggests	_
133-10	27347-27351	that	_
133-11	27352-27366	antidepressant	_
133-12	27367-27370	and	_
133-13	27371-27372	(	_
133-14	27372-27380	atypical	_
133-15	27380-27381	)	_
133-16	27382-27395	antipsychotic	_
133-17	27396-27405	treatment	_
133-18	27406-27410	help	_
133-19	27411-27420	normalize	_
133-20	27421-27426	brain	_
133-21	27427-27436	responses	_
133-22	27437-27439	to	_
133-23	27440-27454	reward-related	_
133-24	27455-27462	stimuli	_
133-25	27463-27465	in	_
133-26	27466-27474	patients	_
133-27	27475-27479	with	_
133-28	27480-27490	depression	_
133-29	27491-27494	and	_
133-30	27495-27508	schizophrenia	_
133-31	27508-27509	,	_
133-32	27510-27522	respectively	_
133-33	27522-27523	.	_

#Text=All of our schizophrenia participants were taking atypical antipsychotic medication.
134-1	27524-27527	All	_
134-2	27528-27530	of	_
134-3	27531-27534	our	_
134-4	27535-27548	schizophrenia	_
134-5	27549-27561	participants	_
134-6	27562-27566	were	_
134-7	27567-27573	taking	_
134-8	27574-27582	atypical	_
134-9	27583-27596	antipsychotic	_
134-10	27597-27607	medication	_
134-11	27607-27608	.	_

#Text=Given that we did not find significant differences between medicated vs unmedicated depressed participants and no associations between brain activity and dose of medication, it is not likely that medication completely explains the reward processing group differences observed in our study, though we recognize that studies in patients not taking medication are required to confirm our results.
135-1	27609-27614	Given	_
135-2	27615-27619	that	_
135-3	27620-27622	we	_
135-4	27623-27626	did	_
135-5	27627-27630	not	_
135-6	27631-27635	find	_
135-7	27636-27647	significant	_
135-8	27648-27659	differences	_
135-9	27660-27667	between	_
135-10	27668-27677	medicated	_
135-11	27678-27680	vs	_
135-12	27681-27692	unmedicated	_
135-13	27693-27702	depressed	_
135-14	27703-27715	participants	_
135-15	27716-27719	and	_
135-16	27720-27722	no	_
135-17	27723-27735	associations	_
135-18	27736-27743	between	_
135-19	27744-27749	brain	_
135-20	27750-27758	activity	_
135-21	27759-27762	and	_
135-22	27763-27767	dose	_
135-23	27768-27770	of	_
135-24	27771-27781	medication	_
135-25	27781-27782	,	_
135-26	27783-27785	it	_
135-27	27786-27788	is	_
135-28	27789-27792	not	_
135-29	27793-27799	likely	_
135-30	27800-27804	that	_
135-31	27805-27815	medication	_
135-32	27816-27826	completely	_
135-33	27827-27835	explains	_
135-34	27836-27839	the	_
135-35	27840-27846	reward	_
135-36	27847-27857	processing	_
135-37	27858-27863	group	_
135-38	27864-27875	differences	_
135-39	27876-27884	observed	_
135-40	27885-27887	in	_
135-41	27888-27891	our	_
135-42	27892-27897	study	_
135-43	27897-27898	,	_
135-44	27899-27905	though	_
135-45	27906-27908	we	_
135-46	27909-27918	recognize	_
135-47	27919-27923	that	_
135-48	27924-27931	studies	_
135-49	27932-27934	in	_
135-50	27935-27943	patients	_
135-51	27944-27947	not	_
135-52	27948-27954	taking	_
135-53	27955-27965	medication	_
135-54	27966-27969	are	_
135-55	27970-27978	required	_
135-56	27979-27981	to	_
135-57	27982-27989	confirm	_
135-58	27990-27993	our	_
135-59	27994-28001	results	_
135-60	28001-28002	.	_

#Text=We note that there have been some previous studies documenting altered striatal reward prediction error signaling in unmedicated schizophrenia patients (eg,).
136-1	28003-28005	We	_
136-2	28006-28010	note	_
136-3	28011-28015	that	_
136-4	28016-28021	there	_
136-5	28022-28026	have	_
136-6	28027-28031	been	_
136-7	28032-28036	some	_
136-8	28037-28045	previous	_
136-9	28046-28053	studies	_
136-10	28054-28065	documenting	_
136-11	28066-28073	altered	_
136-12	28074-28082	striatal	_
136-13	28083-28089	reward	_
136-14	28090-28100	prediction	_
136-15	28101-28106	error	_
136-16	28107-28116	signaling	_
136-17	28117-28119	in	_
136-18	28120-28131	unmedicated	_
136-19	28132-28145	schizophrenia	_
136-20	28146-28154	patients	_
136-21	28155-28156	(	_
136-22	28156-28158	eg	_
136-23	28158-28159	,	_
136-24	28159-28160	)	_
136-25	28160-28161	.	_

#Text=All of our patient participants subjectively endorsed at least some degree of anhedonia, so our results may not be representative of patients with schizophrenia and depression who are not anhedonic.
137-1	28162-28165	All	_
137-2	28166-28168	of	_
137-3	28169-28172	our	_
137-4	28173-28180	patient	_
137-5	28181-28193	participants	_
137-6	28194-28206	subjectively	_
137-7	28207-28215	endorsed	_
137-8	28216-28218	at	_
137-9	28219-28224	least	_
137-10	28225-28229	some	_
137-11	28230-28236	degree	_
137-12	28237-28239	of	_
137-13	28240-28249	anhedonia	_
137-14	28249-28250	,	_
137-15	28251-28253	so	_
137-16	28254-28257	our	_
137-17	28258-28265	results	_
137-18	28266-28269	may	_
137-19	28270-28273	not	_
137-20	28274-28276	be	_
137-21	28277-28291	representative	_
137-22	28292-28294	of	_
137-23	28295-28303	patients	_
137-24	28304-28308	with	_
137-25	28309-28322	schizophrenia	_
137-26	28323-28326	and	_
137-27	28327-28337	depression	_
137-28	28338-28341	who	_
137-29	28342-28345	are	_
137-30	28346-28349	not	_
137-31	28350-28359	anhedonic	_
137-32	28359-28360	.	_

#Text=The measure of anhedonia that we used, the SHAPS, provides a summary measure of anhedonia and does not distinguish between different components.
138-1	28361-28364	The	_
138-2	28365-28372	measure	_
138-3	28373-28375	of	_
138-4	28376-28385	anhedonia	_
138-5	28386-28390	that	_
138-6	28391-28393	we	_
138-7	28394-28398	used	_
138-8	28398-28399	,	_
138-9	28400-28403	the	_
138-10	28404-28409	SHAPS	_
138-11	28409-28410	,	_
138-12	28411-28419	provides	_
138-13	28420-28421	a	_
138-14	28422-28429	summary	_
138-15	28430-28437	measure	_
138-16	28438-28440	of	_
138-17	28441-28450	anhedonia	_
138-18	28451-28454	and	_
138-19	28455-28459	does	_
138-20	28460-28463	not	_
138-21	28464-28475	distinguish	_
138-22	28476-28483	between	_
138-23	28484-28493	different	_
138-24	28494-28504	components	_
138-25	28504-28505	.	_

#Text=The task we used delivered unpredictable rewards, and as such rewards were surprising (and hence associated with positive reward prediction error).
139-1	28506-28509	The	_
139-2	28510-28514	task	_
139-3	28515-28517	we	_
139-4	28518-28522	used	_
139-5	28523-28532	delivered	_
139-6	28533-28546	unpredictable	_
139-7	28547-28554	rewards	_
139-8	28554-28555	,	_
139-9	28556-28559	and	_
139-10	28560-28562	as	_
139-11	28563-28567	such	_
139-12	28568-28575	rewards	_
139-13	28576-28580	were	_
139-14	28581-28591	surprising	_
139-15	28592-28593	(	_
139-16	28593-28596	and	_
139-17	28597-28602	hence	_
139-18	28603-28613	associated	_
139-19	28614-28618	with	_
139-20	28619-28627	positive	_
139-21	28628-28634	reward	_
139-22	28635-28645	prediction	_
139-23	28646-28651	error	_
139-24	28651-28652	)	_
139-25	28652-28653	.	_

#Text=The activity formed by our contrast of interest (unexpected reward receipt vs full miss), could reflect either activity due to reward value or reward prediction error, hence inferences should be drawn accordingly.
140-1	28654-28657	The	_
140-2	28658-28666	activity	_
140-3	28667-28673	formed	_
140-4	28674-28676	by	_
140-5	28677-28680	our	_
140-6	28681-28689	contrast	_
140-7	28690-28692	of	_
140-8	28693-28701	interest	_
140-9	28702-28703	(	_
140-10	28703-28713	unexpected	_
140-11	28714-28720	reward	_
140-12	28721-28728	receipt	_
140-13	28729-28731	vs	_
140-14	28732-28736	full	_
140-15	28737-28741	miss	_
140-16	28741-28742	)	_
140-17	28742-28743	,	_
140-18	28744-28749	could	_
140-19	28750-28757	reflect	_
140-20	28758-28764	either	_
140-21	28765-28773	activity	_
140-22	28774-28777	due	_
140-23	28778-28780	to	_
140-24	28781-28787	reward	_
140-25	28788-28793	value	_
140-26	28794-28796	or	_
140-27	28797-28803	reward	_
140-28	28804-28814	prediction	_
140-29	28815-28820	error	_
140-30	28820-28821	,	_
140-31	28822-28827	hence	_
140-32	28828-28838	inferences	_
140-33	28839-28845	should	_
140-34	28846-28848	be	_
140-35	28849-28854	drawn	_
140-36	28855-28866	accordingly	_
140-37	28866-28867	.	_

#Text=Our findings of some similarities in dysfunction of the brain representations of unexpected reward receipt in depression and schizophrenia is broadly consistent with recent reports that examined a related area of reward processing—reward anticipation—in patients with a variety of psychiatric disorders.
141-1	28868-28871	Our	_
141-2	28872-28880	findings	_
141-3	28881-28883	of	_
141-4	28884-28888	some	_
141-5	28889-28901	similarities	_
141-6	28902-28904	in	_
141-7	28905-28916	dysfunction	_
141-8	28917-28919	of	_
141-9	28920-28923	the	_
141-10	28924-28929	brain	_
141-11	28930-28945	representations	_
141-12	28946-28948	of	_
141-13	28949-28959	unexpected	_
141-14	28960-28966	reward	_
141-15	28967-28974	receipt	_
141-16	28975-28977	in	_
141-17	28978-28988	depression	_
141-18	28989-28992	and	_
141-19	28993-29006	schizophrenia	_
141-20	29007-29009	is	_
141-21	29010-29017	broadly	_
141-22	29018-29028	consistent	_
141-23	29029-29033	with	_
141-24	29034-29040	recent	_
141-25	29041-29048	reports	_
141-26	29049-29053	that	_
141-27	29054-29062	examined	_
141-28	29063-29064	a	_
141-29	29065-29072	related	_
141-30	29073-29077	area	_
141-31	29078-29080	of	_
141-32	29081-29087	reward	_
141-33	29088-29105	processing—reward	_
141-34	29106-29121	anticipation—in	_
141-35	29122-29130	patients	_
141-36	29131-29135	with	_
141-37	29136-29137	a	_
141-38	29138-29145	variety	_
141-39	29146-29148	of	_
141-40	29149-29160	psychiatric	_
141-41	29161-29170	disorders	_
141-42	29170-29171	.	_

#Text=In a fascinating analysis, Hägele et al (2014) pooled a large number of patients with depression, schizophrenia, ADHD, mania, and alcohol dependence, who had all previously taken part in separate case-control studies using a reward anticipation task, and found evidence of right ventral striatal dysfunction linked to depressive symptom severity across diagnostic categories.
142-1	29172-29174	In	_
142-2	29175-29176	a	_
142-3	29177-29188	fascinating	_
142-4	29189-29197	analysis	_
142-5	29197-29198	,	_
142-6	29199-29205	Hägele	_
142-7	29206-29208	et	_
142-8	29209-29211	al	_
142-9	29212-29213	(	_
142-10	29213-29217	2014	_
142-11	29217-29218	)	_
142-12	29219-29225	pooled	_
142-13	29226-29227	a	_
142-14	29228-29233	large	_
142-15	29234-29240	number	_
142-16	29241-29243	of	_
142-17	29244-29252	patients	_
142-18	29253-29257	with	_
142-19	29258-29268	depression	_
142-20	29268-29269	,	_
142-21	29270-29283	schizophrenia	_
142-22	29283-29284	,	_
142-23	29285-29289	ADHD	_
142-24	29289-29290	,	_
142-25	29291-29296	mania	_
142-26	29296-29297	,	_
142-27	29298-29301	and	_
142-28	29302-29309	alcohol	_
142-29	29310-29320	dependence	_
142-30	29320-29321	,	_
142-31	29322-29325	who	_
142-32	29326-29329	had	_
142-33	29330-29333	all	_
142-34	29334-29344	previously	_
142-35	29345-29350	taken	_
142-36	29351-29355	part	_
142-37	29356-29358	in	_
142-38	29359-29367	separate	_
142-39	29368-29380	case-control	_
142-40	29381-29388	studies	_
142-41	29389-29394	using	_
142-42	29395-29396	a	_
142-43	29397-29403	reward	_
142-44	29404-29416	anticipation	_
142-45	29417-29421	task	_
142-46	29421-29422	,	_
142-47	29423-29426	and	_
142-48	29427-29432	found	_
142-49	29433-29441	evidence	_
142-50	29442-29444	of	_
142-51	29445-29450	right	_
142-52	29451-29458	ventral	_
142-53	29459-29467	striatal	_
142-54	29468-29479	dysfunction	_
142-55	29480-29486	linked	_
142-56	29487-29489	to	_
142-57	29490-29500	depressive	_
142-58	29501-29508	symptom	_
142-59	29509-29517	severity	_
142-60	29518-29524	across	_
142-61	29525-29535	diagnostic	_
142-62	29536-29546	categories	_
142-63	29546-29547	.	_

#Text=This finding, and our results indicating shared areas of reward-related pathophysiology across disorders, are highly relevant to the RDoC initiative, and are supportive of its dimensional approach to psychopathology.
143-1	29548-29552	This	_
143-2	29553-29560	finding	_
143-3	29560-29561	,	_
143-4	29562-29565	and	_
143-5	29566-29569	our	_
143-6	29570-29577	results	_
143-7	29578-29588	indicating	_
143-8	29589-29595	shared	_
143-9	29596-29601	areas	_
143-10	29602-29604	of	_
143-11	29605-29619	reward-related	_
143-12	29620-29635	pathophysiology	_
143-13	29636-29642	across	_
143-14	29643-29652	disorders	_
143-15	29652-29653	,	_
143-16	29654-29657	are	_
143-17	29658-29664	highly	_
143-18	29665-29673	relevant	_
143-19	29674-29676	to	_
143-20	29677-29680	the	_
143-21	29681-29685	RDoC	_
143-22	29686-29696	initiative	_
143-23	29696-29697	,	_
143-24	29698-29701	and	_
143-25	29702-29705	are	_
143-26	29706-29716	supportive	_
143-27	29717-29719	of	_
143-28	29720-29723	its	_
143-29	29724-29735	dimensional	_
143-30	29736-29744	approach	_
143-31	29745-29747	to	_
143-32	29748-29763	psychopathology	_
143-33	29763-29764	.	_

#Text=RDoC aims to increase research that validates new cross-diagnostic dimensions that will ultimately inform future diagnostic systems.
144-1	29765-29769	RDoC	_
144-2	29770-29774	aims	_
144-3	29775-29777	to	_
144-4	29778-29786	increase	_
144-5	29787-29795	research	_
144-6	29796-29800	that	_
144-7	29801-29810	validates	_
144-8	29811-29814	new	_
144-9	29815-29831	cross-diagnostic	_
144-10	29832-29842	dimensions	_
144-11	29843-29847	that	_
144-12	29848-29852	will	_
144-13	29853-29863	ultimately	_
144-14	29864-29870	inform	_
144-15	29871-29877	future	_
144-16	29878-29888	diagnostic	_
144-17	29889-29896	systems	_
144-18	29896-29897	.	_

#Text=One proposed RDoc domain is ‘positive valence systems', and proposed dimensions within that domain include responsiveness to reward, approach motivation, reward prediction error, and reward learning.
145-1	29898-29901	One	_
145-2	29902-29910	proposed	_
145-3	29911-29915	RDoc	_
145-4	29916-29922	domain	_
145-5	29923-29925	is	_
145-6	29926-29927	‘	_
145-7	29927-29935	positive	_
145-8	29936-29943	valence	_
145-9	29944-29951	systems	_
145-10	29951-29952	'	_
145-11	29952-29953	,	_
145-12	29954-29957	and	_
145-13	29958-29966	proposed	_
145-14	29967-29977	dimensions	_
145-15	29978-29984	within	_
145-16	29985-29989	that	_
145-17	29990-29996	domain	_
145-18	29997-30004	include	_
145-19	30005-30019	responsiveness	_
145-20	30020-30022	to	_
145-21	30023-30029	reward	_
145-22	30029-30030	,	_
145-23	30031-30039	approach	_
145-24	30040-30050	motivation	_
145-25	30050-30051	,	_
145-26	30052-30058	reward	_
145-27	30059-30069	prediction	_
145-28	30070-30075	error	_
145-29	30075-30076	,	_
145-30	30077-30080	and	_
145-31	30081-30087	reward	_
145-32	30088-30096	learning	_
145-33	30096-30097	.	_

#Text=Our approach is in keeping with the RDoc framework, and our results may encourage further research examining areas of commonality (and difference) across various dimensions of reward processing in a cross-diagnostic fashion.
146-1	30098-30101	Our	_
146-2	30102-30110	approach	_
146-3	30111-30113	is	_
146-4	30114-30116	in	_
146-5	30117-30124	keeping	_
146-6	30125-30129	with	_
146-7	30130-30133	the	_
146-8	30134-30138	RDoc	_
146-9	30139-30148	framework	_
146-10	30148-30149	,	_
146-11	30150-30153	and	_
146-12	30154-30157	our	_
146-13	30158-30165	results	_
146-14	30166-30169	may	_
146-15	30170-30179	encourage	_
146-16	30180-30187	further	_
146-17	30188-30196	research	_
146-18	30197-30206	examining	_
146-19	30207-30212	areas	_
146-20	30213-30215	of	_
146-21	30216-30227	commonality	_
146-22	30228-30229	(	_
146-23	30229-30232	and	_
146-24	30233-30243	difference	_
146-25	30243-30244	)	_
146-26	30245-30251	across	_
146-27	30252-30259	various	_
146-28	30260-30270	dimensions	_
146-29	30271-30273	of	_
146-30	30274-30280	reward	_
146-31	30281-30291	processing	_
146-32	30292-30294	in	_
146-33	30295-30296	a	_
146-34	30297-30313	cross-diagnostic	_
146-35	30314-30321	fashion	_
146-36	30321-30322	.	_

#Text=Conclusion
#Text=In this study we provide evidence of similar hypofunction of the striatum and orbitofrontal cortex in both schizophrenia and depression during receipt of an unexpected reward.
147-1	30323-30333	Conclusion	_
147-2	30334-30336	In	_
147-3	30337-30341	this	_
147-4	30342-30347	study	_
147-5	30348-30350	we	_
147-6	30351-30358	provide	_
147-7	30359-30367	evidence	_
147-8	30368-30370	of	_
147-9	30371-30378	similar	_
147-10	30379-30391	hypofunction	_
147-11	30392-30394	of	_
147-12	30395-30398	the	_
147-13	30399-30407	striatum	_
147-14	30408-30411	and	_
147-15	30412-30425	orbitofrontal	_
147-16	30426-30432	cortex	_
147-17	30433-30435	in	_
147-18	30436-30440	both	_
147-19	30441-30454	schizophrenia	_
147-20	30455-30458	and	_
147-21	30459-30469	depression	_
147-22	30470-30476	during	_
147-23	30477-30484	receipt	_
147-24	30485-30487	of	_
147-25	30488-30490	an	_
147-26	30491-30501	unexpected	_
147-27	30502-30508	reward	_
147-28	30508-30509	.	_

#Text=Similarities in the way that reward processing was disturbed in both disorders suggests that there may be at least some shared pathophysiology common to both disorders, which may indicate that similar treatments could be effective in both conditions in some circumstances.
148-1	30510-30522	Similarities	_
148-2	30523-30525	in	_
148-3	30526-30529	the	_
148-4	30530-30533	way	_
148-5	30534-30538	that	_
148-6	30539-30545	reward	_
148-7	30546-30556	processing	_
148-8	30557-30560	was	_
148-9	30561-30570	disturbed	_
148-10	30571-30573	in	_
148-11	30574-30578	both	_
148-12	30579-30588	disorders	_
148-13	30589-30597	suggests	_
148-14	30598-30602	that	_
148-15	30603-30608	there	_
148-16	30609-30612	may	_
148-17	30613-30615	be	_
148-18	30616-30618	at	_
148-19	30619-30624	least	_
148-20	30625-30629	some	_
148-21	30630-30636	shared	_
148-22	30637-30652	pathophysiology	_
148-23	30653-30659	common	_
148-24	30660-30662	to	_
148-25	30663-30667	both	_
148-26	30668-30677	disorders	_
148-27	30677-30678	,	_
148-28	30679-30684	which	_
148-29	30685-30688	may	_
148-30	30689-30697	indicate	_
148-31	30698-30702	that	_
148-32	30703-30710	similar	_
148-33	30711-30721	treatments	_
148-34	30722-30727	could	_
148-35	30728-30730	be	_
148-36	30731-30740	effective	_
148-37	30741-30743	in	_
148-38	30744-30748	both	_
148-39	30749-30759	conditions	_
148-40	30760-30762	in	_
148-41	30763-30767	some	_
148-42	30768-30781	circumstances	_
148-43	30781-30782	.	_

#Text=We also show that the degree of frontal activation whilst playing a computer reward game is linked to subjective experience of motivation and that measure in turn is associated with severity of anhedonia (in schizophrenia), suggesting a possible causal pathway between brain activity, immediate measures of motivation, and longer-term levels of anhedonia.
149-1	30783-30785	We	_
149-2	30786-30790	also	_
149-3	30791-30795	show	_
149-4	30796-30800	that	_
149-5	30801-30804	the	_
149-6	30805-30811	degree	_
149-7	30812-30814	of	_
149-8	30815-30822	frontal	_
149-9	30823-30833	activation	_
149-10	30834-30840	whilst	_
149-11	30841-30848	playing	_
149-12	30849-30850	a	_
149-13	30851-30859	computer	_
149-14	30860-30866	reward	_
149-15	30867-30871	game	_
149-16	30872-30874	is	_
149-17	30875-30881	linked	_
149-18	30882-30884	to	_
149-19	30885-30895	subjective	_
149-20	30896-30906	experience	_
149-21	30907-30909	of	_
149-22	30910-30920	motivation	_
149-23	30921-30924	and	_
149-24	30925-30929	that	_
149-25	30930-30937	measure	_
149-26	30938-30940	in	_
149-27	30941-30945	turn	_
149-28	30946-30948	is	_
149-29	30949-30959	associated	_
149-30	30960-30964	with	_
149-31	30965-30973	severity	_
149-32	30974-30976	of	_
149-33	30977-30986	anhedonia	_
149-34	30987-30988	(	_
149-35	30988-30990	in	_
149-36	30991-31004	schizophrenia	_
149-37	31004-31005	)	_
149-38	31005-31006	,	_
149-39	31007-31017	suggesting	_
149-40	31018-31019	a	_
149-41	31020-31028	possible	_
149-42	31029-31035	causal	_
149-43	31036-31043	pathway	_
149-44	31044-31051	between	_
149-45	31052-31057	brain	_
149-46	31058-31066	activity	_
149-47	31066-31067	,	_
149-48	31068-31077	immediate	_
149-49	31078-31086	measures	_
149-50	31087-31089	of	_
149-51	31090-31100	motivation	_
149-52	31100-31101	,	_
149-53	31102-31105	and	_
149-54	31106-31117	longer-term	_
149-55	31118-31124	levels	_
149-56	31125-31127	of	_
149-57	31128-31137	anhedonia	_
149-58	31137-31138	.	_

#Text=Funding and disclosure
#Text=Dr Robbins has received research support from or served as a consultant to Cambridge Cognition, Eli Lilly, GlaxoSmithKline, and Lundbeck.
150-1	31139-31146	Funding	_
150-2	31147-31150	and	_
150-3	31151-31161	disclosure	_
150-4	31162-31164	Dr	_
150-5	31165-31172	Robbins	_
150-6	31173-31176	has	_
150-7	31177-31185	received	_
150-8	31186-31194	research	_
150-9	31195-31202	support	_
150-10	31203-31207	from	_
150-11	31208-31210	or	_
150-12	31211-31217	served	_
150-13	31218-31220	as	_
150-14	31221-31222	a	_
150-15	31223-31233	consultant	_
150-16	31234-31236	to	_
150-17	31237-31246	Cambridge	_
150-18	31247-31256	Cognition	_
150-19	31256-31257	,	_
150-20	31258-31261	Eli	_
150-21	31262-31267	Lilly	_
150-22	31267-31268	,	_
150-23	31269-31284	GlaxoSmithKline	_
150-24	31284-31285	,	_
150-25	31286-31289	and	_
150-26	31290-31298	Lundbeck	_
150-27	31298-31299	.	_

#Text=Dr Clark has served as a consultant to Cambridge Cognition; the Centre for Gambling Research at UBC was funded by the Province of BC government and the British Columbia Lottery Corporation.
151-1	31300-31302	Dr	_
151-2	31303-31308	Clark	_
151-3	31309-31312	has	_
151-4	31313-31319	served	_
151-5	31320-31322	as	_
151-6	31323-31324	a	_
151-7	31325-31335	consultant	_
151-8	31336-31338	to	_
151-9	31339-31348	Cambridge	_
151-10	31349-31358	Cognition	_
151-11	31358-31359	;	_
151-12	31360-31363	the	_
151-13	31364-31370	Centre	_
151-14	31371-31374	for	_
151-15	31375-31383	Gambling	_
151-16	31384-31392	Research	_
151-17	31393-31395	at	_
151-18	31396-31399	UBC	_
151-19	31400-31403	was	_
151-20	31404-31410	funded	_
151-21	31411-31413	by	_
151-22	31414-31417	the	_
151-23	31418-31426	Province	_
151-24	31427-31429	of	_
151-25	31430-31432	BC	_
151-26	31433-31443	government	_
151-27	31444-31447	and	_
151-28	31448-31451	the	_
151-29	31452-31459	British	_
151-30	31460-31468	Columbia	_
151-31	31469-31476	Lottery	_
151-32	31477-31488	Corporation	_
151-33	31488-31489	.	_

#Text=Dr Ziauddeen has been jointly funded by the Wellcome Trust and GlaxoSmithKline on the Translational Medicine and Therapeutics programme.
152-1	31490-31492	Dr	_
152-2	31493-31502	Ziauddeen	_
152-3	31503-31506	has	_
152-4	31507-31511	been	_
152-5	31512-31519	jointly	_
152-6	31520-31526	funded	_
152-7	31527-31529	by	_
152-8	31530-31533	the	_
152-9	31534-31542	Wellcome	_
152-10	31543-31548	Trust	_
152-11	31549-31552	and	_
152-12	31553-31568	GlaxoSmithKline	_
152-13	31569-31571	on	_
152-14	31572-31575	the	_
152-15	31576-31589	Translational	_
152-16	31590-31598	Medicine	_
152-17	31599-31602	and	_
152-18	31603-31615	Therapeutics	_
152-19	31616-31625	programme	_
152-20	31625-31626	.	_

#Text=Professor Fletcher has received funds from GlaxoSmithKline for consultation services and from Astra Zeneca for a lecture.
153-1	31627-31636	Professor	_
153-2	31637-31645	Fletcher	_
153-3	31646-31649	has	_
153-4	31650-31658	received	_
153-5	31659-31664	funds	_
153-6	31665-31669	from	_
153-7	31670-31685	GlaxoSmithKline	_
153-8	31686-31689	for	_
153-9	31690-31702	consultation	_
153-10	31703-31711	services	_
153-11	31712-31715	and	_
153-12	31716-31720	from	_
153-13	31721-31726	Astra	_
153-14	31727-31733	Zeneca	_
153-15	31734-31737	for	_
153-16	31738-31739	a	_
153-17	31740-31747	lecture	_
153-18	31747-31748	.	_

#Text=Drs Segarra, Metastasio, Spencer, Dudas, Arrondo, and Murray and Mr Reinders have no financial interests to disclose.
154-1	31749-31752	Drs	_
154-2	31753-31760	Segarra	_
154-3	31760-31761	,	_
154-4	31762-31772	Metastasio	_
154-5	31772-31773	,	_
154-6	31774-31781	Spencer	_
154-7	31781-31782	,	_
154-8	31783-31788	Dudas	_
154-9	31788-31789	,	_
154-10	31790-31797	Arrondo	_
154-11	31797-31798	,	_
154-12	31799-31802	and	_
154-13	31803-31809	Murray	_
154-14	31810-31813	and	_
154-15	31814-31816	Mr	_
154-16	31817-31825	Reinders	_
154-17	31826-31830	have	_
154-18	31831-31833	no	_
154-19	31834-31843	financial	_
154-20	31844-31853	interests	_
154-21	31854-31856	to	_
154-22	31857-31865	disclose	_
154-23	31865-31866	.	_

#Text=Supplementary Information accompanies the paper on the Neuropsychopharmacology website (http://www.nature.com/npp)
#Text=Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study
#Text=Abnormal reward system activation in mania
#Text=Anhedonia revisited: is there a role for dopamine-targeting drugs for depression
#Text=Reduction in ventral striatal activity when anticipating a reward in depression and schizophrenia: a replicated cross-diagnostic finding
#Text=Goal representations and motivational drive in schizophrenia: the role of prefrontal-striatal interactions
#Text=Parsing reward
#Text=Gambling near-misses enhance motivation to gamble and recruit win-related brain circuitry
#Text=The RDoC framework: facilitating transition from ICD/DSM to dimensional approaches that integrate neuroscience and psychopathology
#Text=Peril and pleasure: an RDoC-inspired examination of threat responses and reward processing in anxiety and depression
#Text=Pavlovian reward prediction and receipt in schizophrenia: relationship to anhedonia
#Text=Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders
#Text=Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia
#Text=Anatomic abnormalities of the anterior cingulate cortex before psychosis onset: an MRI study of ultra-high-risk individuals
#Text=The assessment of anhedonia in clinical and non-clinical populations: further validation of the Snaith-Hamilton Pleasure Scale (SHAPS)
#Text=Anhedonia in schizophrenia: distinctions between anticipatory and consummatory pleasure
#Text=Prediction error in reinforcement learning: a meta-analysis of neuroimaging studies
#Text=Impaired subjective well-being in schizophrenia is associated with reduced anterior cingulate activity during reward processing
#Text=States versus rewards: dissociable neural prediction error signals underlying model-based and model-free reinforcement learning
#Text=Negative symptoms and the failure to represent the expected reward value of actions: behavioural and computational modeling evidence
#Text=Expected value and prediction error abnormalities in depression and schizophrenia
#Text=Erotic stimulus processing under amisulpride and reboxetine: a placebo-controlled fMRI study in healthy subjects
#Text=The reward circuit: linking primate anatomy and human imaging
#Text=Anhedonia in schizophrenic, depressed or alcohol-dependent patients—neurobiological correlates
#Text=Dimensional psychiatry: reward dysfunction and depressive mood across psychiatric disorders
#Text=Research domain criteria (RDoC): toward a new classification framework for research on mental disorders
#Text=
#Text=Dopamine-mediated reinforcement learning signals in the striatum and ventromedial prefrontal cortex underlie value-based choices
#Text=Dysfunction of ventral striatal reward prediction in schizophrenia
#Text=The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients
#Text=Anticipation of increasing monetary reward selectively recruits nucleus accumbens
#Text=A region of mesial prefrontal cortex tracks monetarily rewarding outcomes: characterization with rapid event-related fMRI
#Text=Emotion in schizophrenia: where feeling meets thinking
#Text=Towards a functional neuroanatomy of pleasure and happiness
#Text=Abnormal temporal difference reward-learning signals in major depression
#Text=Serotonergic modulation of reward and punishment: evidence from pharmacological fMRI studies
#Text=Dopamine modulates the neural representation of subjective value of food in hungry subjects
#Text=Disambiguating ventral striatum fMRI-related BOLD signal during reward prediction in schizophrenia
#Text=Dissociation of response and feedback negativity in schizophrenia: electrophysiological and computational evidence for a deficit in the representation of value
#Text=Dopamine dysfunction and delusions, hallucinations and anhedonia
#Text=Substantia nigra/ventral tegmental reward prediction error disruption in psychosis
#Text=Improvement of brain reward abnormalities by antipsychotic monotherapy in schizophrenia
#Text=Activity in human reward-sensitive brain areas is strongly context dependent
#Text=Schizophrenia subjects show intact success-related neural activation but impaired uncertainty processing during decision-making
#Text=Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans
#Text=Ventral striatum response during reward and punishment reversal learning in unmedicated major depressive disorder
#Text=A role for the macaque anterior cingulate gyrus in social valuation
#Text=Striatal dysfunction during reversal learning in unmedicated schizophrenia patients
#Text=Reward feedback alterations in unmedicated schizophrenia patients: relevance for delusions
#Text=A neural substrate of prediction and reward
#Text=Neuronal coding of prediction errors
#Text=Neural correlates of reward processing in schizophrenia–relationship to apathy and depression
#Text=fMRI of alterations in reward selection, anticipation, and feedback in major depressive disorder
#Text=Major depressive disorder is characterized by greater reward network activation to monetary than pleasant image rewards
#Text=A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale
#Text=Hyporeactivity of ventral striatum towards incentive stimuli in unmedicated depressed patients normalizes after treatment with escitalopram
#Text=A review of reward processing and motivational impairment in schizophrenia
#Text=Variants of uncertainty in decision-making and their neural correlates
#Text=Functional specialization within medial frontal cortex of the anterior cingulate for evaluating effort-related decisions
#Text=The role of rat medial frontal cortex in effort-based decision making
#Text=Patients with schizophrenia have a reduced neural response to both unpredictable and predictable primary reinforcers
#Text=Abnormal responses to monetary outcomes in cortex, but not in the basal ganglia, in schizophrenia
#Text=The relevance of reward pathways for schizrophrenia
#Text=Supplementary Material
#Text=Example of a ‘win trial' in the fMRI simulated slot-machine game.
#Text=fMRI results: receipt of unexpected reward.
155-1	31867-31880	Supplementary	_
155-2	31881-31892	Information	_
155-3	31893-31904	accompanies	_
155-4	31905-31908	the	_
155-5	31909-31914	paper	_
155-6	31915-31917	on	_
155-7	31918-31921	the	_
155-8	31922-31945	Neuropsychopharmacology	_
155-9	31946-31953	website	_
155-10	31954-31955	(	_
155-11	31955-31959	http	_
155-12	31959-31960	:	_
155-13	31960-31961	/	_
155-14	31961-31962	/	_
155-15	31962-31976	www.nature.com	_
155-16	31976-31977	/	_
155-17	31977-31980	npp	_
155-18	31980-31981	)	_
155-19	31982-31987	Human	_
155-20	31988-31994	reward	_
155-21	31995-32001	system	_
155-22	32002-32012	activation	_
155-23	32013-32015	is	_
155-24	32016-32025	modulated	_
155-25	32026-32028	by	_
155-26	32029-32030	a	_
155-27	32031-32037	single	_
155-28	32038-32042	dose	_
155-29	32043-32045	of	_
155-30	32046-32056	olanzapine	_
155-31	32057-32059	in	_
155-32	32060-32067	healthy	_
155-33	32068-32076	subjects	_
155-34	32077-32079	in	_
155-35	32080-32082	an	_
155-36	32083-32096	event-related	_
155-37	32096-32097	,	_
155-38	32098-32110	double-blind	_
155-39	32110-32111	,	_
155-40	32112-32130	placebo-controlled	_
155-41	32131-32135	fMRI	_
155-42	32136-32141	study	_
155-43	32142-32150	Abnormal	_
155-44	32151-32157	reward	_
155-45	32158-32164	system	_
155-46	32165-32175	activation	_
155-47	32176-32178	in	_
155-48	32179-32184	mania	_
155-49	32185-32194	Anhedonia	_
155-50	32195-32204	revisited	_
155-51	32204-32205	:	_
155-52	32206-32208	is	_
155-53	32209-32214	there	_
155-54	32215-32216	a	_
155-55	32217-32221	role	_
155-56	32222-32225	for	_
155-57	32226-32244	dopamine-targeting	_
155-58	32245-32250	drugs	_
155-59	32251-32254	for	_
155-60	32255-32265	depression	_
155-61	32266-32275	Reduction	_
155-62	32276-32278	in	_
155-63	32279-32286	ventral	_
155-64	32287-32295	striatal	_
155-65	32296-32304	activity	_
155-66	32305-32309	when	_
155-67	32310-32322	anticipating	_
155-68	32323-32324	a	_
155-69	32325-32331	reward	_
155-70	32332-32334	in	_
155-71	32335-32345	depression	_
155-72	32346-32349	and	_
155-73	32350-32363	schizophrenia	_
155-74	32363-32364	:	_
155-75	32365-32366	a	_
155-76	32367-32377	replicated	_
155-77	32378-32394	cross-diagnostic	_
155-78	32395-32402	finding	_
155-79	32403-32407	Goal	_
155-80	32408-32423	representations	_
155-81	32424-32427	and	_
155-82	32428-32440	motivational	_
155-83	32441-32446	drive	_
155-84	32447-32449	in	_
155-85	32450-32463	schizophrenia	_
155-86	32463-32464	:	_
155-87	32465-32468	the	_
155-88	32469-32473	role	_
155-89	32474-32476	of	_
155-90	32477-32496	prefrontal-striatal	_
155-91	32497-32509	interactions	_
155-92	32510-32517	Parsing	_
155-93	32518-32524	reward	_
155-94	32525-32533	Gambling	_
155-95	32534-32545	near-misses	_
155-96	32546-32553	enhance	_
155-97	32554-32564	motivation	_
155-98	32565-32567	to	_
155-99	32568-32574	gamble	_
155-100	32575-32578	and	_
155-101	32579-32586	recruit	_
155-102	32587-32598	win-related	_
155-103	32599-32604	brain	_
155-104	32605-32614	circuitry	_
155-105	32615-32618	The	_
155-106	32619-32623	RDoC	_
155-107	32624-32633	framework	_
155-108	32633-32634	:	_
155-109	32635-32647	facilitating	_
155-110	32648-32658	transition	_
155-111	32659-32663	from	_
155-112	32664-32667	ICD	_
155-113	32667-32668	/	_
155-114	32668-32671	DSM	_
155-115	32672-32674	to	_
155-116	32675-32686	dimensional	_
155-117	32687-32697	approaches	_
155-118	32698-32702	that	_
155-119	32703-32712	integrate	_
155-120	32713-32725	neuroscience	_
155-121	32726-32729	and	_
155-122	32730-32745	psychopathology	_
155-123	32746-32751	Peril	_
155-124	32752-32755	and	_
155-125	32756-32764	pleasure	_
155-126	32764-32765	:	_
155-127	32766-32768	an	_
155-128	32769-32782	RDoC-inspired	_
155-129	32783-32794	examination	_
155-130	32795-32797	of	_
155-131	32798-32804	threat	_
155-132	32805-32814	responses	_
155-133	32815-32818	and	_
155-134	32819-32825	reward	_
155-135	32826-32836	processing	_
155-136	32837-32839	in	_
155-137	32840-32847	anxiety	_
155-138	32848-32851	and	_
155-139	32852-32862	depression	_
155-140	32863-32872	Pavlovian	_
155-141	32873-32879	reward	_
155-142	32880-32890	prediction	_
155-143	32891-32894	and	_
155-144	32895-32902	receipt	_
155-145	32903-32905	in	_
155-146	32906-32919	schizophrenia	_
155-147	32919-32920	:	_
155-148	32921-32933	relationship	_
155-149	32934-32936	to	_
155-150	32937-32946	anhedonia	_
155-151	32947-32959	Neuroimaging	_
155-152	32960-32963	and	_
155-153	32964-32981	neuropathological	_
155-154	32982-32989	studies	_
155-155	32990-32992	of	_
155-156	32993-33003	depression	_
155-157	33003-33004	:	_
155-158	33005-33017	implications	_
155-159	33018-33021	for	_
155-160	33022-33025	the	_
155-161	33026-33045	cognitive-emotional	_
155-162	33046-33054	features	_
155-163	33055-33057	of	_
155-164	33058-33062	mood	_
155-165	33063-33072	disorders	_
155-166	33073-33083	Perceiving	_
155-167	33084-33086	is	_
155-168	33087-33096	believing	_
155-169	33096-33097	:	_
155-170	33098-33099	a	_
155-171	33100-33108	Bayesian	_
155-172	33109-33117	approach	_
155-173	33118-33120	to	_
155-174	33121-33131	explaining	_
155-175	33132-33135	the	_
155-176	33136-33144	positive	_
155-177	33145-33153	symptoms	_
155-178	33154-33156	of	_
155-179	33157-33170	schizophrenia	_
155-180	33171-33179	Anatomic	_
155-181	33180-33193	abnormalities	_
155-182	33194-33196	of	_
155-183	33197-33200	the	_
155-184	33201-33209	anterior	_
155-185	33210-33219	cingulate	_
155-186	33220-33226	cortex	_
155-187	33227-33233	before	_
155-188	33234-33243	psychosis	_
155-189	33244-33249	onset	_
155-190	33249-33250	:	_
155-191	33251-33253	an	_
155-192	33254-33257	MRI	_
155-193	33258-33263	study	_
155-194	33264-33266	of	_
155-195	33267-33282	ultra-high-risk	_
155-196	33283-33294	individuals	_
155-197	33295-33298	The	_
155-198	33299-33309	assessment	_
155-199	33310-33312	of	_
155-200	33313-33322	anhedonia	_
155-201	33323-33325	in	_
155-202	33326-33334	clinical	_
155-203	33335-33338	and	_
155-204	33339-33351	non-clinical	_
155-205	33352-33363	populations	_
155-206	33363-33364	:	_
155-207	33365-33372	further	_
155-208	33373-33383	validation	_
155-209	33384-33386	of	_
155-210	33387-33390	the	_
155-211	33391-33406	Snaith-Hamilton	_
155-212	33407-33415	Pleasure	_
155-213	33416-33421	Scale	_
155-214	33422-33423	(	_
155-215	33423-33428	SHAPS	_
155-216	33428-33429	)	_
155-217	33430-33439	Anhedonia	_
155-218	33440-33442	in	_
155-219	33443-33456	schizophrenia	_
155-220	33456-33457	:	_
155-221	33458-33470	distinctions	_
155-222	33471-33478	between	_
155-223	33479-33491	anticipatory	_
155-224	33492-33495	and	_
155-225	33496-33508	consummatory	_
155-226	33509-33517	pleasure	_
155-227	33518-33528	Prediction	_
155-228	33529-33534	error	_
155-229	33535-33537	in	_
155-230	33538-33551	reinforcement	_
155-231	33552-33560	learning	_
155-232	33560-33561	:	_
155-233	33562-33563	a	_
155-234	33564-33577	meta-analysis	_
155-235	33578-33580	of	_
155-236	33581-33593	neuroimaging	_
155-237	33594-33601	studies	_
155-238	33602-33610	Impaired	_
155-239	33611-33621	subjective	_
155-240	33622-33632	well-being	_
155-241	33633-33635	in	_
155-242	33636-33649	schizophrenia	_
155-243	33650-33652	is	_
155-244	33653-33663	associated	_
155-245	33664-33668	with	_
155-246	33669-33676	reduced	_
155-247	33677-33685	anterior	_
155-248	33686-33695	cingulate	_
155-249	33696-33704	activity	_
155-250	33705-33711	during	_
155-251	33712-33718	reward	_
155-252	33719-33729	processing	_
155-253	33730-33736	States	_
155-254	33737-33743	versus	_
155-255	33744-33751	rewards	_
155-256	33751-33752	:	_
155-257	33753-33764	dissociable	_
155-258	33765-33771	neural	_
155-259	33772-33782	prediction	_
155-260	33783-33788	error	_
155-261	33789-33796	signals	_
155-262	33797-33807	underlying	_
155-263	33808-33819	model-based	_
155-264	33820-33823	and	_
155-265	33824-33834	model-free	_
155-266	33835-33848	reinforcement	_
155-267	33849-33857	learning	_
155-268	33858-33866	Negative	_
155-269	33867-33875	symptoms	_
155-270	33876-33879	and	_
155-271	33880-33883	the	_
155-272	33884-33891	failure	_
155-273	33892-33894	to	_
155-274	33895-33904	represent	_
155-275	33905-33908	the	_
155-276	33909-33917	expected	_
155-277	33918-33924	reward	_
155-278	33925-33930	value	_
155-279	33931-33933	of	_
155-280	33934-33941	actions	_
155-281	33941-33942	:	_
155-282	33943-33954	behavioural	_
155-283	33955-33958	and	_
155-284	33959-33972	computational	_
155-285	33973-33981	modeling	_
155-286	33982-33990	evidence	_
155-287	33991-33999	Expected	_
155-288	34000-34005	value	_
155-289	34006-34009	and	_
155-290	34010-34020	prediction	_
155-291	34021-34026	error	_
155-292	34027-34040	abnormalities	_
155-293	34041-34043	in	_
155-294	34044-34054	depression	_
155-295	34055-34058	and	_
155-296	34059-34072	schizophrenia	_
155-297	34073-34079	Erotic	_
155-298	34080-34088	stimulus	_
155-299	34089-34099	processing	_
155-300	34100-34105	under	_
155-301	34106-34117	amisulpride	_
155-302	34118-34121	and	_
155-303	34122-34132	reboxetine	_
155-304	34132-34133	:	_
155-305	34134-34135	a	_
155-306	34136-34154	placebo-controlled	_
155-307	34155-34159	fMRI	_
155-308	34160-34165	study	_
155-309	34166-34168	in	_
155-310	34169-34176	healthy	_
155-311	34177-34185	subjects	_
155-312	34186-34189	The	_
155-313	34190-34196	reward	_
155-314	34197-34204	circuit	_
155-315	34204-34205	:	_
155-316	34206-34213	linking	_
155-317	34214-34221	primate	_
155-318	34222-34229	anatomy	_
155-319	34230-34233	and	_
155-320	34234-34239	human	_
155-321	34240-34247	imaging	_
155-322	34248-34257	Anhedonia	_
155-323	34258-34260	in	_
155-324	34261-34274	schizophrenic	_
155-325	34274-34275	,	_
155-326	34276-34285	depressed	_
155-327	34286-34288	or	_
155-328	34289-34306	alcohol-dependent	_
155-329	34307-34331	patients—neurobiological	_
155-330	34332-34342	correlates	_
155-331	34343-34354	Dimensional	_
155-332	34355-34365	psychiatry	_
155-333	34365-34366	:	_
155-334	34367-34373	reward	_
155-335	34374-34385	dysfunction	_
155-336	34386-34389	and	_
155-337	34390-34400	depressive	_
155-338	34401-34405	mood	_
155-339	34406-34412	across	_
155-340	34413-34424	psychiatric	_
155-341	34425-34434	disorders	_
155-342	34435-34443	Research	_
155-343	34444-34450	domain	_
155-344	34451-34459	criteria	_
155-345	34460-34461	(	_
155-346	34461-34465	RDoC	_
155-347	34465-34466	)	_
155-348	34466-34467	:	_
155-349	34468-34474	toward	_
155-350	34475-34476	a	_
155-351	34477-34480	new	_
155-352	34481-34495	classification	_
155-353	34496-34505	framework	_
155-354	34506-34509	for	_
155-355	34510-34518	research	_
155-356	34519-34521	on	_
155-357	34522-34528	mental	_
155-358	34529-34538	disorders	_
155-359	34540-34557	Dopamine-mediated	_
155-360	34558-34571	reinforcement	_
155-361	34572-34580	learning	_
155-362	34581-34588	signals	_
155-363	34589-34591	in	_
155-364	34592-34595	the	_
155-365	34596-34604	striatum	_
155-366	34605-34608	and	_
155-367	34609-34621	ventromedial	_
155-368	34622-34632	prefrontal	_
155-369	34633-34639	cortex	_
155-370	34640-34648	underlie	_
155-371	34649-34660	value-based	_
155-372	34661-34668	choices	_
155-373	34669-34680	Dysfunction	_
155-374	34681-34683	of	_
155-375	34684-34691	ventral	_
155-376	34692-34700	striatal	_
155-377	34701-34707	reward	_
155-378	34708-34718	prediction	_
155-379	34719-34721	in	_
155-380	34722-34735	schizophrenia	_
155-381	34736-34739	The	_
155-382	34740-34749	influence	_
155-383	34750-34752	of	_
155-384	34753-34766	antipsychotic	_
155-385	34767-34776	treatment	_
155-386	34777-34779	on	_
155-387	34780-34785	brain	_
155-388	34786-34792	reward	_
155-389	34793-34799	system	_
155-390	34800-34810	reactivity	_
155-391	34811-34813	in	_
155-392	34814-34827	schizophrenia	_
155-393	34828-34836	patients	_
155-394	34837-34849	Anticipation	_
155-395	34850-34852	of	_
155-396	34853-34863	increasing	_
155-397	34864-34872	monetary	_
155-398	34873-34879	reward	_
155-399	34880-34891	selectively	_
155-400	34892-34900	recruits	_
155-401	34901-34908	nucleus	_
155-402	34909-34918	accumbens	_
155-403	34919-34920	A	_
155-404	34921-34927	region	_
155-405	34928-34930	of	_
155-406	34931-34937	mesial	_
155-407	34938-34948	prefrontal	_
155-408	34949-34955	cortex	_
155-409	34956-34962	tracks	_
155-410	34963-34973	monetarily	_
155-411	34974-34983	rewarding	_
155-412	34984-34992	outcomes	_
155-413	34992-34993	:	_
155-414	34994-35010	characterization	_
155-415	35011-35015	with	_
155-416	35016-35021	rapid	_
155-417	35022-35035	event-related	_
155-418	35036-35040	fMRI	_
155-419	35041-35048	Emotion	_
155-420	35049-35051	in	_
155-421	35052-35065	schizophrenia	_
155-422	35065-35066	:	_
155-423	35067-35072	where	_
155-424	35073-35080	feeling	_
155-425	35081-35086	meets	_
155-426	35087-35095	thinking	_
155-427	35096-35103	Towards	_
155-428	35104-35105	a	_
155-429	35106-35116	functional	_
155-430	35117-35129	neuroanatomy	_
155-431	35130-35132	of	_
155-432	35133-35141	pleasure	_
155-433	35142-35145	and	_
155-434	35146-35155	happiness	_
155-435	35156-35164	Abnormal	_
155-436	35165-35173	temporal	_
155-437	35174-35184	difference	_
155-438	35185-35200	reward-learning	_
155-439	35201-35208	signals	_
155-440	35209-35211	in	_
155-441	35212-35217	major	_
155-442	35218-35228	depression	_
155-443	35229-35241	Serotonergic	_
155-444	35242-35252	modulation	_
155-445	35253-35255	of	_
155-446	35256-35262	reward	_
155-447	35263-35266	and	_
155-448	35267-35277	punishment	_
155-449	35277-35278	:	_
155-450	35279-35287	evidence	_
155-451	35288-35292	from	_
155-452	35293-35308	pharmacological	_
155-453	35309-35313	fMRI	_
155-454	35314-35321	studies	_
155-455	35322-35330	Dopamine	_
155-456	35331-35340	modulates	_
155-457	35341-35344	the	_
155-458	35345-35351	neural	_
155-459	35352-35366	representation	_
155-460	35367-35369	of	_
155-461	35370-35380	subjective	_
155-462	35381-35386	value	_
155-463	35387-35389	of	_
155-464	35390-35394	food	_
155-465	35395-35397	in	_
155-466	35398-35404	hungry	_
155-467	35405-35413	subjects	_
155-468	35414-35428	Disambiguating	_
155-469	35429-35436	ventral	_
155-470	35437-35445	striatum	_
155-471	35446-35458	fMRI-related	_
155-472	35459-35463	BOLD	_
155-473	35464-35470	signal	_
155-474	35471-35477	during	_
155-475	35478-35484	reward	_
155-476	35485-35495	prediction	_
155-477	35496-35498	in	_
155-478	35499-35512	schizophrenia	_
155-479	35513-35525	Dissociation	_
155-480	35526-35528	of	_
155-481	35529-35537	response	_
155-482	35538-35541	and	_
155-483	35542-35550	feedback	_
155-484	35551-35561	negativity	_
155-485	35562-35564	in	_
155-486	35565-35578	schizophrenia	_
155-487	35578-35579	:	_
155-488	35580-35600	electrophysiological	_
155-489	35601-35604	and	_
155-490	35605-35618	computational	_
155-491	35619-35627	evidence	_
155-492	35628-35631	for	_
155-493	35632-35633	a	_
155-494	35634-35641	deficit	_
155-495	35642-35644	in	_
155-496	35645-35648	the	_
155-497	35649-35663	representation	_
155-498	35664-35666	of	_
155-499	35667-35672	value	_
155-500	35673-35681	Dopamine	_
155-501	35682-35693	dysfunction	_
155-502	35694-35697	and	_
155-503	35698-35707	delusions	_
155-504	35707-35708	,	_
155-505	35709-35723	hallucinations	_
155-506	35724-35727	and	_
155-507	35728-35737	anhedonia	_
155-508	35738-35748	Substantia	_
155-509	35749-35754	nigra	_
155-510	35754-35755	/	_
155-511	35755-35762	ventral	_
155-512	35763-35772	tegmental	_
155-513	35773-35779	reward	_
155-514	35780-35790	prediction	_
155-515	35791-35796	error	_
155-516	35797-35807	disruption	_
155-517	35808-35810	in	_
155-518	35811-35820	psychosis	_
155-519	35821-35832	Improvement	_
155-520	35833-35835	of	_
155-521	35836-35841	brain	_
155-522	35842-35848	reward	_
155-523	35849-35862	abnormalities	_
155-524	35863-35865	by	_
155-525	35866-35879	antipsychotic	_
155-526	35880-35891	monotherapy	_
155-527	35892-35894	in	_
155-528	35895-35908	schizophrenia	_
155-529	35909-35917	Activity	_
155-530	35918-35920	in	_
155-531	35921-35926	human	_
155-532	35927-35943	reward-sensitive	_
155-533	35944-35949	brain	_
155-534	35950-35955	areas	_
155-535	35956-35958	is	_
155-536	35959-35967	strongly	_
155-537	35968-35975	context	_
155-538	35976-35985	dependent	_
155-539	35986-35999	Schizophrenia	_
155-540	36000-36008	subjects	_
155-541	36009-36013	show	_
155-542	36014-36020	intact	_
155-543	36021-36036	success-related	_
155-544	36037-36043	neural	_
155-545	36044-36054	activation	_
155-546	36055-36058	but	_
155-547	36059-36067	impaired	_
155-548	36068-36079	uncertainty	_
155-549	36080-36090	processing	_
155-550	36091-36097	during	_
155-551	36098-36113	decision-making	_
155-552	36114-36132	Dopamine-dependent	_
155-553	36133-36143	prediction	_
155-554	36144-36150	errors	_
155-555	36151-36159	underpin	_
155-556	36160-36174	reward-seeking	_
155-557	36175-36184	behaviour	_
155-558	36185-36187	in	_
155-559	36188-36194	humans	_
155-560	36195-36202	Ventral	_
155-561	36203-36211	striatum	_
155-562	36212-36220	response	_
155-563	36221-36227	during	_
155-564	36228-36234	reward	_
155-565	36235-36238	and	_
155-566	36239-36249	punishment	_
155-567	36250-36258	reversal	_
155-568	36259-36267	learning	_
155-569	36268-36270	in	_
155-570	36271-36282	unmedicated	_
155-571	36283-36288	major	_
155-572	36289-36299	depressive	_
155-573	36300-36308	disorder	_
155-574	36309-36310	A	_
155-575	36311-36315	role	_
155-576	36316-36319	for	_
155-577	36320-36323	the	_
155-578	36324-36331	macaque	_
155-579	36332-36340	anterior	_
155-580	36341-36350	cingulate	_
155-581	36351-36356	gyrus	_
155-582	36357-36359	in	_
155-583	36360-36366	social	_
155-584	36367-36376	valuation	_
155-585	36377-36385	Striatal	_
155-586	36386-36397	dysfunction	_
155-587	36398-36404	during	_
155-588	36405-36413	reversal	_
155-589	36414-36422	learning	_
155-590	36423-36425	in	_
155-591	36426-36437	unmedicated	_
155-592	36438-36451	schizophrenia	_
155-593	36452-36460	patients	_
155-594	36461-36467	Reward	_
155-595	36468-36476	feedback	_
155-596	36477-36488	alterations	_
155-597	36489-36491	in	_
155-598	36492-36503	unmedicated	_
155-599	36504-36517	schizophrenia	_
155-600	36518-36526	patients	_
155-601	36526-36527	:	_
155-602	36528-36537	relevance	_
155-603	36538-36541	for	_
155-604	36542-36551	delusions	_
155-605	36552-36553	A	_
155-606	36554-36560	neural	_
155-607	36561-36570	substrate	_
155-608	36571-36573	of	_
155-609	36574-36584	prediction	_
155-610	36585-36588	and	_
155-611	36589-36595	reward	_
155-612	36596-36604	Neuronal	_
155-613	36605-36611	coding	_
155-614	36612-36614	of	_
155-615	36615-36625	prediction	_
155-616	36626-36632	errors	_
155-617	36633-36639	Neural	_
155-618	36640-36650	correlates	_
155-619	36651-36653	of	_
155-620	36654-36660	reward	_
155-621	36661-36671	processing	_
155-622	36672-36674	in	_
155-623	36675-36701	schizophrenia–relationship	_
155-624	36702-36704	to	_
155-625	36705-36711	apathy	_
155-626	36712-36715	and	_
155-627	36716-36726	depression	_
155-628	36727-36731	fMRI	_
155-629	36732-36734	of	_
155-630	36735-36746	alterations	_
155-631	36747-36749	in	_
155-632	36750-36756	reward	_
155-633	36757-36766	selection	_
155-634	36766-36767	,	_
155-635	36768-36780	anticipation	_
155-636	36780-36781	,	_
155-637	36782-36785	and	_
155-638	36786-36794	feedback	_
155-639	36795-36797	in	_
155-640	36798-36803	major	_
155-641	36804-36814	depressive	_
155-642	36815-36823	disorder	_
155-643	36824-36829	Major	_
155-644	36830-36840	depressive	_
155-645	36841-36849	disorder	_
155-646	36850-36852	is	_
155-647	36853-36866	characterized	_
155-648	36867-36869	by	_
155-649	36870-36877	greater	_
155-650	36878-36884	reward	_
155-651	36885-36892	network	_
155-652	36893-36903	activation	_
155-653	36904-36906	to	_
155-654	36907-36915	monetary	_
155-655	36916-36920	than	_
155-656	36921-36929	pleasant	_
155-657	36930-36935	image	_
155-658	36936-36943	rewards	_
155-659	36944-36945	A	_
155-660	36946-36951	scale	_
155-661	36952-36955	for	_
155-662	36956-36959	the	_
155-663	36960-36970	assessment	_
155-664	36971-36973	of	_
155-665	36974-36981	hedonic	_
155-666	36982-36986	tone	_
155-667	36987-36990	the	_
155-668	36991-37006	Snaith-Hamilton	_
155-669	37007-37015	Pleasure	_
155-670	37016-37021	Scale	_
155-671	37022-37036	Hyporeactivity	_
155-672	37037-37039	of	_
155-673	37040-37047	ventral	_
155-674	37048-37056	striatum	_
155-675	37057-37064	towards	_
155-676	37065-37074	incentive	_
155-677	37075-37082	stimuli	_
155-678	37083-37085	in	_
155-679	37086-37097	unmedicated	_
155-680	37098-37107	depressed	_
155-681	37108-37116	patients	_
155-682	37117-37127	normalizes	_
155-683	37128-37133	after	_
155-684	37134-37143	treatment	_
155-685	37144-37148	with	_
155-686	37149-37161	escitalopram	_
155-687	37162-37163	A	_
155-688	37164-37170	review	_
155-689	37171-37173	of	_
155-690	37174-37180	reward	_
155-691	37181-37191	processing	_
155-692	37192-37195	and	_
155-693	37196-37208	motivational	_
155-694	37209-37219	impairment	_
155-695	37220-37222	in	_
155-696	37223-37236	schizophrenia	_
155-697	37237-37245	Variants	_
155-698	37246-37248	of	_
155-699	37249-37260	uncertainty	_
155-700	37261-37263	in	_
155-701	37264-37279	decision-making	_
155-702	37280-37283	and	_
155-703	37284-37289	their	_
155-704	37290-37296	neural	_
155-705	37297-37307	correlates	_
155-706	37308-37318	Functional	_
155-707	37319-37333	specialization	_
155-708	37334-37340	within	_
155-709	37341-37347	medial	_
155-710	37348-37355	frontal	_
155-711	37356-37362	cortex	_
155-712	37363-37365	of	_
155-713	37366-37369	the	_
155-714	37370-37378	anterior	_
155-715	37379-37388	cingulate	_
155-716	37389-37392	for	_
155-717	37393-37403	evaluating	_
155-718	37404-37418	effort-related	_
155-719	37419-37428	decisions	_
155-720	37429-37432	The	_
155-721	37433-37437	role	_
155-722	37438-37440	of	_
155-723	37441-37444	rat	_
155-724	37445-37451	medial	_
155-725	37452-37459	frontal	_
155-726	37460-37466	cortex	_
155-727	37467-37469	in	_
155-728	37470-37482	effort-based	_
155-729	37483-37491	decision	_
155-730	37492-37498	making	_
155-731	37499-37507	Patients	_
155-732	37508-37512	with	_
155-733	37513-37526	schizophrenia	_
155-734	37527-37531	have	_
155-735	37532-37533	a	_
155-736	37534-37541	reduced	_
155-737	37542-37548	neural	_
155-738	37549-37557	response	_
155-739	37558-37560	to	_
155-740	37561-37565	both	_
155-741	37566-37579	unpredictable	_
155-742	37580-37583	and	_
155-743	37584-37595	predictable	_
155-744	37596-37603	primary	_
155-745	37604-37615	reinforcers	_
155-746	37616-37624	Abnormal	_
155-747	37625-37634	responses	_
155-748	37635-37637	to	_
155-749	37638-37646	monetary	_
155-750	37647-37655	outcomes	_
155-751	37656-37658	in	_
155-752	37659-37665	cortex	_
155-753	37665-37666	,	_
155-754	37667-37670	but	_
155-755	37671-37674	not	_
155-756	37675-37677	in	_
155-757	37678-37681	the	_
155-758	37682-37687	basal	_
155-759	37688-37695	ganglia	_
155-760	37695-37696	,	_
155-761	37697-37699	in	_
155-762	37700-37713	schizophrenia	_
155-763	37714-37717	The	_
155-764	37718-37727	relevance	_
155-765	37728-37730	of	_
155-766	37731-37737	reward	_
155-767	37738-37746	pathways	_
155-768	37747-37750	for	_
155-769	37751-37765	schizrophrenia	_
155-770	37766-37779	Supplementary	_
155-771	37780-37788	Material	_
155-772	37789-37796	Example	_
155-773	37797-37799	of	_
155-774	37800-37801	a	_
155-775	37802-37803	‘	_
155-776	37803-37806	win	_
155-777	37807-37812	trial	_
155-778	37812-37813	'	_
155-779	37814-37816	in	_
155-780	37817-37820	the	_
155-781	37821-37825	fMRI	_
155-782	37826-37835	simulated	_
155-783	37836-37848	slot-machine	_
155-784	37849-37853	game	_
155-785	37853-37854	.	_
155-786	37855-37859	fMRI	_
155-787	37860-37867	results	_
155-788	37867-37868	:	_
155-789	37869-37876	receipt	_
155-790	37877-37879	of	_
155-791	37880-37890	unexpected	_
155-792	37891-37897	reward	_
155-793	37897-37898	.	_

#Text=Left hemisphere is shown in the right side of the image.
156-1	37899-37903	Left	_
156-2	37904-37914	hemisphere	_
156-3	37915-37917	is	_
156-4	37918-37923	shown	_
156-5	37924-37926	in	_
156-6	37927-37930	the	_
156-7	37931-37936	right	_
156-8	37937-37941	side	_
156-9	37942-37944	of	_
156-10	37945-37948	the	_
156-11	37949-37954	image	_
156-12	37954-37955	.	_

#Text=Coordinates are expressed in mm, and in standard space.
157-1	37956-37967	Coordinates	_
157-2	37968-37971	are	_
157-3	37972-37981	expressed	_
157-4	37982-37984	in	_
157-5	37985-37987	mm	_
157-6	37987-37988	,	_
157-7	37989-37992	and	_
157-8	37993-37995	in	_
157-9	37996-38004	standard	_
157-10	38005-38010	space	_
157-11	38010-38011	.	_

#Text=Panel a: entire sample pooled analysis.
158-1	38012-38017	Panel	_
158-2	38018-38019	a	_
158-3	38019-38020	:	_
158-4	38021-38027	entire	_
158-5	38028-38034	sample	_
158-6	38035-38041	pooled	_
158-7	38042-38050	analysis	_
158-8	38050-38051	.	_

#Text=The yellow color indicates significant voxels thresholded at p<0.05 family-wise error (FWE) voxelwise corrected for illustrative purposes.
159-1	38052-38055	The	_
159-2	38056-38062	yellow	_
159-3	38063-38068	color	_
159-4	38069-38078	indicates	_
159-5	38079-38090	significant	_
159-6	38091-38097	voxels	_
159-7	38098-38109	thresholded	_
159-8	38110-38112	at	_
159-9	38113-38114	p	_
159-10	38114-38115	<	_
159-11	38115-38119	0.05	_
159-12	38120-38131	family-wise	_
159-13	38132-38137	error	_
159-14	38138-38139	(	_
159-15	38139-38142	FWE	_
159-16	38142-38143	)	_
159-17	38144-38153	voxelwise	_
159-18	38154-38163	corrected	_
159-19	38164-38167	for	_
159-20	38168-38180	illustrative	_
159-21	38181-38189	purposes	_
159-22	38189-38190	.	_

#Text=Panel b: between groups analysis using ANOVA.
160-1	38191-38196	Panel	_
160-2	38197-38198	b	_
160-3	38198-38199	:	_
160-4	38200-38207	between	_
160-5	38208-38214	groups	_
160-6	38215-38223	analysis	_
160-7	38224-38229	using	_
160-8	38230-38235	ANOVA	_
160-9	38235-38236	.	_

#Text=Colored clusters indicate those clusters indicating significant group differences (cluster threshold Z>2.0 p<0.05 FWE whole-brain cluster corrected) and the particular color indicates the results of post hoc tests.
161-1	38237-38244	Colored	_
161-2	38245-38253	clusters	_
161-3	38254-38262	indicate	_
161-4	38263-38268	those	_
161-5	38269-38277	clusters	_
161-6	38278-38288	indicating	_
161-7	38289-38300	significant	_
161-8	38301-38306	group	_
161-9	38307-38318	differences	_
161-10	38319-38320	(	_
161-11	38320-38327	cluster	_
161-12	38328-38337	threshold	_
161-13	38338-38339	Z	_
161-14	38339-38340	>	_
161-15	38340-38343	2.0	_
161-16	38344-38345	p	_
161-17	38345-38346	<	_
161-18	38346-38350	0.05	_
161-19	38351-38354	FWE	_
161-20	38355-38366	whole-brain	_
161-21	38367-38374	cluster	_
161-22	38375-38384	corrected	_
161-23	38384-38385	)	_
161-24	38386-38389	and	_
161-25	38390-38393	the	_
161-26	38394-38404	particular	_
161-27	38405-38410	color	_
161-28	38411-38420	indicates	_
161-29	38421-38424	the	_
161-30	38425-38432	results	_
161-31	38433-38435	of	_
161-32	38436-38440	post	_
161-33	38441-38444	hoc	_
161-34	38445-38450	tests	_
161-35	38450-38451	.	_

#Text=Green areas are clusters where the control group has greater activation compared with the depression group and compared with the schizophrenia group; blue areas are clusters where controls have greater activation compared with the depression group and compared with the schizophrenia group, and the depression group has greater activation than the schizophrenia group; red areas are clusters where controls have more activation than the schizophrenia group and the depression group has more activation than the schizophrenia group; lilac areas are clusters those where the control group has more activation than the schizophrenia group.
162-1	38452-38457	Green	_
162-2	38458-38463	areas	_
162-3	38464-38467	are	_
162-4	38468-38476	clusters	_
162-5	38477-38482	where	_
162-6	38483-38486	the	_
162-7	38487-38494	control	_
162-8	38495-38500	group	_
162-9	38501-38504	has	_
162-10	38505-38512	greater	_
162-11	38513-38523	activation	_
162-12	38524-38532	compared	_
162-13	38533-38537	with	_
162-14	38538-38541	the	_
162-15	38542-38552	depression	_
162-16	38553-38558	group	_
162-17	38559-38562	and	_
162-18	38563-38571	compared	_
162-19	38572-38576	with	_
162-20	38577-38580	the	_
162-21	38581-38594	schizophrenia	_
162-22	38595-38600	group	_
162-23	38600-38601	;	_
162-24	38602-38606	blue	_
162-25	38607-38612	areas	_
162-26	38613-38616	are	_
162-27	38617-38625	clusters	_
162-28	38626-38631	where	_
162-29	38632-38640	controls	_
162-30	38641-38645	have	_
162-31	38646-38653	greater	_
162-32	38654-38664	activation	_
162-33	38665-38673	compared	_
162-34	38674-38678	with	_
162-35	38679-38682	the	_
162-36	38683-38693	depression	_
162-37	38694-38699	group	_
162-38	38700-38703	and	_
162-39	38704-38712	compared	_
162-40	38713-38717	with	_
162-41	38718-38721	the	_
162-42	38722-38735	schizophrenia	_
162-43	38736-38741	group	_
162-44	38741-38742	,	_
162-45	38743-38746	and	_
162-46	38747-38750	the	_
162-47	38751-38761	depression	_
162-48	38762-38767	group	_
162-49	38768-38771	has	_
162-50	38772-38779	greater	_
162-51	38780-38790	activation	_
162-52	38791-38795	than	_
162-53	38796-38799	the	_
162-54	38800-38813	schizophrenia	_
162-55	38814-38819	group	_
162-56	38819-38820	;	_
162-57	38821-38824	red	_
162-58	38825-38830	areas	_
162-59	38831-38834	are	_
162-60	38835-38843	clusters	_
162-61	38844-38849	where	_
162-62	38850-38858	controls	_
162-63	38859-38863	have	_
162-64	38864-38868	more	_
162-65	38869-38879	activation	_
162-66	38880-38884	than	_
162-67	38885-38888	the	_
162-68	38889-38902	schizophrenia	_
162-69	38903-38908	group	_
162-70	38909-38912	and	_
162-71	38913-38916	the	_
162-72	38917-38927	depression	_
162-73	38928-38933	group	_
162-74	38934-38937	has	_
162-75	38938-38942	more	_
162-76	38943-38953	activation	_
162-77	38954-38958	than	_
162-78	38959-38962	the	_
162-79	38963-38976	schizophrenia	_
162-80	38977-38982	group	_
162-81	38982-38983	;	_
162-82	38984-38989	lilac	_
162-83	38990-38995	areas	_
162-84	38996-38999	are	_
162-85	39000-39008	clusters	_
162-86	39009-39014	those	_
162-87	39015-39020	where	_
162-88	39021-39024	the	_
162-89	39025-39032	control	_
162-90	39033-39038	group	_
162-91	39039-39042	has	_
162-92	39043-39047	more	_
162-93	39048-39058	activation	_
162-94	39059-39063	than	_
162-95	39064-39067	the	_
162-96	39068-39081	schizophrenia	_
162-97	39082-39087	group	_
162-98	39087-39088	.	_

#Text=Left panel: yellow color indicates a significant cluster resulting from the linear regression of brain activation during an unexpected win against subjective ratings of task-related motivation (all participants pooled, adjusted by group).
163-1	39089-39093	Left	_
163-2	39094-39099	panel	_
163-3	39099-39100	:	_
163-4	39101-39107	yellow	_
163-5	39108-39113	color	_
163-6	39114-39123	indicates	_
163-7	39124-39125	a	_
163-8	39126-39137	significant	_
163-9	39138-39145	cluster	_
163-10	39146-39155	resulting	_
163-11	39156-39160	from	_
163-12	39161-39164	the	_
163-13	39165-39171	linear	_
163-14	39172-39182	regression	_
163-15	39183-39185	of	_
163-16	39186-39191	brain	_
163-17	39192-39202	activation	_
163-18	39203-39209	during	_
163-19	39210-39212	an	_
163-20	39213-39223	unexpected	_
163-21	39224-39227	win	_
163-22	39228-39235	against	_
163-23	39236-39246	subjective	_
163-24	39247-39254	ratings	_
163-25	39255-39257	of	_
163-26	39258-39270	task-related	_
163-27	39271-39281	motivation	_
163-28	39282-39283	(	_
163-29	39283-39286	all	_
163-30	39287-39299	participants	_
163-31	39300-39306	pooled	_
163-32	39306-39307	,	_
163-33	39308-39316	adjusted	_
163-34	39317-39319	by	_
163-35	39320-39325	group	_
163-36	39325-39326	)	_
163-37	39326-39327	.	_

#Text=Left hemisphere is shown in the right side of the image.
164-1	39328-39332	Left	_
164-2	39333-39343	hemisphere	_
164-3	39344-39346	is	_
164-4	39347-39352	shown	_
164-5	39353-39355	in	_
164-6	39356-39359	the	_
164-7	39360-39365	right	_
164-8	39366-39370	side	_
164-9	39371-39373	of	_
164-10	39374-39377	the	_
164-11	39378-39383	image	_
164-12	39383-39384	.	_

#Text=Coordinates are expressed in mm, and in standard space.
165-1	39385-39396	Coordinates	_
165-2	39397-39400	are	_
165-3	39401-39410	expressed	_
165-4	39411-39413	in	_
165-5	39414-39416	mm	_
165-6	39416-39417	,	_
165-7	39418-39421	and	_
165-8	39422-39424	in	_
165-9	39425-39433	standard	_
165-10	39434-39439	space	_
165-11	39439-39440	.	_

#Text=FWE whole-brain corrected, cluster threshold Z>2.0 p<0.05.
166-1	39441-39444	FWE	_
166-2	39445-39456	whole-brain	_
166-3	39457-39466	corrected	_
166-4	39466-39467	,	_
166-5	39468-39475	cluster	_
166-6	39476-39485	threshold	_
166-7	39486-39487	Z	_
166-8	39487-39488	>	_
166-9	39488-39491	2.0	_
166-10	39492-39493	p	_
166-11	39493-39494	<	_
166-12	39494-39498	0.05	_
166-13	39498-39499	.	_

#Text=Centre panel: scatterplot of the extracted contrast parameter estimates during an unexpected win from the cluster depicted in left panel vs subjective task-related motivation (blue square, controls; green triangle, depression; red circle, schizophrenia).
167-1	39500-39506	Centre	_
167-2	39507-39512	panel	_
167-3	39512-39513	:	_
167-4	39514-39525	scatterplot	_
167-5	39526-39528	of	_
167-6	39529-39532	the	_
167-7	39533-39542	extracted	_
167-8	39543-39551	contrast	_
167-9	39552-39561	parameter	_
167-10	39562-39571	estimates	_
167-11	39572-39578	during	_
167-12	39579-39581	an	_
167-13	39582-39592	unexpected	_
167-14	39593-39596	win	_
167-15	39597-39601	from	_
167-16	39602-39605	the	_
167-17	39606-39613	cluster	_
167-18	39614-39622	depicted	_
167-19	39623-39625	in	_
167-20	39626-39630	left	_
167-21	39631-39636	panel	_
167-22	39637-39639	vs	_
167-23	39640-39650	subjective	_
167-24	39651-39663	task-related	_
167-25	39664-39674	motivation	_
167-26	39675-39676	(	_
167-27	39676-39680	blue	_
167-28	39681-39687	square	_
167-29	39687-39688	,	_
167-30	39689-39697	controls	_
167-31	39697-39698	;	_
167-32	39699-39704	green	_
167-33	39705-39713	triangle	_
167-34	39713-39714	,	_
167-35	39715-39725	depression	_
167-36	39725-39726	;	_
167-37	39727-39730	red	_
167-38	39731-39737	circle	_
167-39	39737-39738	,	_
167-40	39739-39752	schizophrenia	_
167-41	39752-39753	)	_
167-42	39753-39754	.	_

#Text=Right panel: scatterplot of SHAPS (Snaith Hamilton pleasure scale) score vs the subjective rating of motivation in the schizophrenia group.
168-1	39755-39760	Right	_
168-2	39761-39766	panel	_
168-3	39766-39767	:	_
168-4	39768-39779	scatterplot	_
168-5	39780-39782	of	_
168-6	39783-39788	SHAPS	_
168-7	39789-39790	(	_
168-8	39790-39796	Snaith	_
168-9	39797-39805	Hamilton	_
168-10	39806-39814	pleasure	_
168-11	39815-39820	scale	_
168-12	39820-39821	)	_
168-13	39822-39827	score	_
168-14	39828-39830	vs	_
168-15	39831-39834	the	_
168-16	39835-39845	subjective	_
168-17	39846-39852	rating	_
168-18	39853-39855	of	_
168-19	39856-39866	motivation	_
168-20	39867-39869	in	_
168-21	39870-39873	the	_
168-22	39874-39887	schizophrenia	_
168-23	39888-39893	group	_
168-24	39893-39894	.	_

#Text=The upper panel shows the mean percent signal change for unexpected reward receipt for the left ventral striatal/orbitofrontal cluster where both patient groups had suppressed activation relative to controls.
169-1	39895-39898	The	_
169-2	39899-39904	upper	_
169-3	39905-39910	panel	_
169-4	39911-39916	shows	_
169-5	39917-39920	the	_
169-6	39921-39925	mean	_
169-7	39926-39933	percent	_
169-8	39934-39940	signal	_
169-9	39941-39947	change	_
169-10	39948-39951	for	_
169-11	39952-39962	unexpected	_
169-12	39963-39969	reward	_
169-13	39970-39977	receipt	_
169-14	39978-39981	for	_
169-15	39982-39985	the	_
169-16	39986-39990	left	_
169-17	39991-39998	ventral	_
169-18	39999-40007	striatal	_
169-19	40007-40008	/	_
169-20	40008-40021	orbitofrontal	_
169-21	40022-40029	cluster	_
169-22	40030-40035	where	_
169-23	40036-40040	both	_
169-24	40041-40048	patient	_
169-25	40049-40055	groups	_
169-26	40056-40059	had	_
169-27	40060-40070	suppressed	_
169-28	40071-40081	activation	_
169-29	40082-40090	relative	_
169-30	40091-40093	to	_
169-31	40094-40102	controls	_
169-32	40102-40103	.	_

#Text=In contrast, the lower panel shows the mean percent signal change for unexpected reward receipt in the left lateral parietal lobe (angular gyrus and supramarginal gyrus) where activation was suppressed in schizophrenia compared with controls but relatively intact in depression.
170-1	40104-40106	In	_
170-2	40107-40115	contrast	_
170-3	40115-40116	,	_
170-4	40117-40120	the	_
170-5	40121-40126	lower	_
170-6	40127-40132	panel	_
170-7	40133-40138	shows	_
170-8	40139-40142	the	_
170-9	40143-40147	mean	_
170-10	40148-40155	percent	_
170-11	40156-40162	signal	_
170-12	40163-40169	change	_
170-13	40170-40173	for	_
170-14	40174-40184	unexpected	_
170-15	40185-40191	reward	_
170-16	40192-40199	receipt	_
170-17	40200-40202	in	_
170-18	40203-40206	the	_
170-19	40207-40211	left	_
170-20	40212-40219	lateral	_
170-21	40220-40228	parietal	_
170-22	40229-40233	lobe	_
170-23	40234-40235	(	_
170-24	40235-40242	angular	_
170-25	40243-40248	gyrus	_
170-26	40249-40252	and	_
170-27	40253-40266	supramarginal	_
170-28	40267-40272	gyrus	_
170-29	40272-40273	)	_
170-30	40274-40279	where	_
170-31	40280-40290	activation	_
170-32	40291-40294	was	_
170-33	40295-40305	suppressed	_
170-34	40306-40308	in	_
170-35	40309-40322	schizophrenia	_
170-36	40323-40331	compared	_
170-37	40332-40336	with	_
170-38	40337-40345	controls	_
170-39	40346-40349	but	_
170-40	40350-40360	relatively	_
170-41	40361-40367	intact	_
170-42	40368-40370	in	_
170-43	40371-40381	depression	_
170-44	40381-40382	.	_

#Text=Error bars are 95% confidence intervals.
171-1	40383-40388	Error	_
171-2	40389-40393	bars	_
171-3	40394-40397	are	_
171-4	40398-40401	95%	_
171-5	40402-40412	confidence	_
171-6	40413-40422	intervals	_
171-7	40422-40423	.	_

#Text=For graphs of results of other clusters please see Supplementary Material.
172-1	40424-40427	For	_
172-2	40428-40434	graphs	_
172-3	40435-40437	of	_
172-4	40438-40445	results	_
172-5	40446-40448	of	_
172-6	40449-40454	other	_
172-7	40455-40463	clusters	_
172-8	40464-40470	please	_
172-9	40471-40474	see	_
172-10	40475-40488	Supplementary	_
172-11	40489-40497	Material	_
172-12	40497-40498	.	_

#Text=Subjects' Demographics and Clinical Characteristics
#Text= \tControls (n=21)mean/SD\tDepression (n=24)mean/SD\tSchizophrenia (n=21)mean/SD\tF/X2\tP-value\tPost hoc tests\t \tAge\t34.33/±10.11\t33.08±9.15\t32.24±7.44\t0.29\t0.749\t \t \tGender (male/female)\t17/4\t17/7\t18/3\t1.712\t0.425\t \t \tHandedness (right/left)\t18/3\t22/2\t16/5\t2.004\t0.367\t \t \tWhite-British\t17\t20\t17\t0.044\t0.978\t \t \tCulture fair (IQ)\t114.24±19.97\t107.08±16.6\t100.20±19.28\t2.93\t0.061\t \t \tEducation (years)\t14.85±1.93\t13.43±2.21\t13.50±2.09\t3.01\t0.057\t \t \tBPRS\t \t \t43.14±11.89\t \t \t \t \tBDI total\t4.29±4.89\t32.62±7.06\t21.05±8.95\t88.19\t<0.001\tC<D C<S S<D\t \tSHAPS\t23.38±3.58\t33.42±6.81\t29.19±6.2\t17.00\t<0.001\tC<D C<S S<D\t \tAntipsychotics (chlorpromazine equivalents)\t \ta\t377±424\t \t \t \t \tAntidepressants prescribed\t \t13 (54%)\t8 (38%)\t \t \t \t \t
#Text=Four depression participants were prescribed low-dose antipsychotic medication; see Supplementary Text for further medication details.
173-1	40499-40507	Subjects	_
173-2	40507-40508	'	_
173-3	40509-40521	Demographics	_
173-4	40522-40525	and	_
173-5	40526-40534	Clinical	_
173-6	40535-40550	Characteristics	_
173-7	40551-40552	 	_
173-8	40553-40561	Controls	_
173-9	40562-40563	(	_
173-10	40563-40564	n	_
173-11	40564-40565	=	_
173-12	40565-40567	21	_
173-13	40567-40568	)	_
173-14	40568-40572	mean	_
173-15	40572-40573	/	_
173-16	40573-40575	SD	_
173-17	40576-40586	Depression	_
173-18	40587-40588	(	_
173-19	40588-40589	n	_
173-20	40589-40590	=	_
173-21	40590-40592	24	_
173-22	40592-40593	)	_
173-23	40593-40597	mean	_
173-24	40597-40598	/	_
173-25	40598-40600	SD	_
173-26	40601-40614	Schizophrenia	_
173-27	40615-40616	(	_
173-28	40616-40617	n	_
173-29	40617-40618	=	_
173-30	40618-40620	21	_
173-31	40620-40621	)	_
173-32	40621-40625	mean	_
173-33	40625-40626	/	_
173-34	40626-40628	SD	_
173-35	40629-40630	F	_
173-36	40630-40631	/	_
173-37	40631-40633	X2	_
173-38	40634-40641	P-value	_
173-39	40642-40646	Post	_
173-40	40647-40650	hoc	_
173-41	40651-40656	tests	_
173-42	40659-40662	Age	_
173-43	40663-40668	34.33	_
173-44	40668-40669	/	_
173-45	40669-40670	±	_
173-46	40670-40675	10.11	_
173-47	40676-40681	33.08	_
173-48	40681-40682	±	_
173-49	40682-40686	9.15	_
173-50	40687-40692	32.24	_
173-51	40692-40693	±	_
173-52	40693-40697	7.44	_
173-53	40698-40702	0.29	_
173-54	40703-40708	0.749	_
173-55	40709-40710	 	_
173-56	40713-40719	Gender	_
173-57	40720-40721	(	_
173-58	40721-40725	male	_
173-59	40725-40726	/	_
173-60	40726-40732	female	_
173-61	40732-40733	)	_
173-62	40734-40736	17	_
173-63	40736-40737	/	_
173-64	40737-40738	4	_
173-65	40739-40741	17	_
173-66	40741-40742	/	_
173-67	40742-40743	7	_
173-68	40744-40746	18	_
173-69	40746-40747	/	_
173-70	40747-40748	3	_
173-71	40749-40754	1.712	_
173-72	40755-40760	0.425	_
173-73	40761-40762	 	_
173-74	40765-40775	Handedness	_
173-75	40776-40777	(	_
173-76	40777-40782	right	_
173-77	40782-40783	/	_
173-78	40783-40787	left	_
173-79	40787-40788	)	_
173-80	40789-40791	18	_
173-81	40791-40792	/	_
173-82	40792-40793	3	_
173-83	40794-40796	22	_
173-84	40796-40797	/	_
173-85	40797-40798	2	_
173-86	40799-40801	16	_
173-87	40801-40802	/	_
173-88	40802-40803	5	_
173-89	40804-40809	2.004	_
173-90	40810-40815	0.367	_
173-91	40816-40817	 	_
173-92	40820-40833	White-British	_
173-93	40834-40836	17	_
173-94	40837-40839	20	_
173-95	40840-40842	17	_
173-96	40843-40848	0.044	_
173-97	40849-40854	0.978	_
173-98	40855-40856	 	_
173-99	40859-40866	Culture	_
173-100	40867-40871	fair	_
173-101	40872-40873	(	_
173-102	40873-40875	IQ	_
173-103	40875-40876	)	_
173-104	40877-40883	114.24	_
173-105	40883-40884	±	_
173-106	40884-40889	19.97	_
173-107	40890-40896	107.08	_
173-108	40896-40897	±	_
173-109	40897-40901	16.6	_
173-110	40902-40908	100.20	_
173-111	40908-40909	±	_
173-112	40909-40914	19.28	_
173-113	40915-40919	2.93	_
173-114	40920-40925	0.061	_
173-115	40926-40927	 	_
173-116	40930-40939	Education	_
173-117	40940-40941	(	_
173-118	40941-40946	years	_
173-119	40946-40947	)	_
173-120	40948-40953	14.85	_
173-121	40953-40954	±	_
173-122	40954-40958	1.93	_
173-123	40959-40964	13.43	_
173-124	40964-40965	±	_
173-125	40965-40969	2.21	_
173-126	40970-40975	13.50	_
173-127	40975-40976	±	_
173-128	40976-40980	2.09	_
173-129	40981-40985	3.01	_
173-130	40986-40991	0.057	_
173-131	40992-40993	 	_
173-132	40996-41000	BPRS	_
173-133	41001-41004	 	 	_
173-134	41005-41010	43.14	_
173-135	41010-41011	±	_
173-136	41011-41016	11.89	_
173-137	41017-41022	 	 	 	_
173-138	41025-41028	BDI	_
173-139	41029-41034	total	_
173-140	41035-41039	4.29	_
173-141	41039-41040	±	_
173-142	41040-41044	4.89	_
173-143	41045-41050	32.62	_
173-144	41050-41051	±	_
173-145	41051-41055	7.06	_
173-146	41056-41061	21.05	_
173-147	41061-41062	±	_
173-148	41062-41066	8.95	_
173-149	41067-41072	88.19	_
173-150	41073-41074	<	_
173-151	41074-41079	0.001	_
173-152	41080-41081	C	_
173-153	41081-41082	<	_
173-154	41082-41083	D	_
173-155	41084-41085	C	_
173-156	41085-41086	<	_
173-157	41086-41087	S	_
173-158	41088-41089	S	_
173-159	41089-41090	<	_
173-160	41090-41091	D	_
173-161	41094-41099	SHAPS	_
173-162	41100-41105	23.38	_
173-163	41105-41106	±	_
173-164	41106-41110	3.58	_
173-165	41111-41116	33.42	_
173-166	41116-41117	±	_
173-167	41117-41121	6.81	_
173-168	41122-41127	29.19	_
173-169	41127-41128	±	_
173-170	41128-41131	6.2	_
173-171	41132-41137	17.00	_
173-172	41138-41139	<	_
173-173	41139-41144	0.001	_
173-174	41145-41146	C	_
173-175	41146-41147	<	_
173-176	41147-41148	D	_
173-177	41149-41150	C	_
173-178	41150-41151	<	_
173-179	41151-41152	S	_
173-180	41153-41154	S	_
173-181	41154-41155	<	_
173-182	41155-41156	D	_
173-183	41159-41173	Antipsychotics	_
173-184	41174-41175	(	_
173-185	41175-41189	chlorpromazine	_
173-186	41190-41201	equivalents	_
173-187	41201-41202	)	_
173-188	41203-41204	 	_
173-189	41205-41206	a	_
173-190	41207-41210	377	_
173-191	41210-41211	±	_
173-192	41211-41214	424	_
173-193	41215-41220	 	 	 	_
173-194	41223-41238	Antidepressants	_
173-195	41239-41249	prescribed	_
173-196	41250-41251	 	_
173-197	41252-41254	13	_
173-198	41255-41256	(	_
173-199	41256-41259	54%	_
173-200	41259-41260	)	_
173-201	41261-41262	8	_
173-202	41263-41264	(	_
173-203	41264-41267	38%	_
173-204	41267-41268	)	_
173-205	41269-41274	 	 	 	_
173-206	41278-41282	Four	_
173-207	41283-41293	depression	_
173-208	41294-41306	participants	_
173-209	41307-41311	were	_
173-210	41312-41322	prescribed	_
173-211	41323-41331	low-dose	_
173-212	41332-41345	antipsychotic	_
173-213	41346-41356	medication	_
173-214	41356-41357	;	_
173-215	41358-41361	see	_
173-216	41362-41375	Supplementary	_
173-217	41376-41380	Text	_
173-218	41381-41384	for	_
173-219	41385-41392	further	_
173-220	41393-41403	medication	_
173-221	41404-41411	details	_
173-222	41411-41412	.	_

#Text=Any significant post hoc test results for two-group comparisons (p<0.05) are also indicated by the use of ‘greater than' symbols.
174-1	41413-41416	Any	_
174-2	41417-41428	significant	_
174-3	41429-41433	post	_
174-4	41434-41437	hoc	_
174-5	41438-41442	test	_
174-6	41443-41450	results	_
174-7	41451-41454	for	_
174-8	41455-41464	two-group	_
174-9	41465-41476	comparisons	_
174-10	41477-41478	(	_
174-11	41478-41479	p	_
174-12	41479-41480	<	_
174-13	41480-41484	0.05	_
174-14	41484-41485	)	_
174-15	41486-41489	are	_
174-16	41490-41494	also	_
174-17	41495-41504	indicated	_
174-18	41505-41507	by	_
174-19	41508-41511	the	_
174-20	41512-41515	use	_
174-21	41516-41518	of	_
174-22	41519-41520	‘	_
174-23	41520-41527	greater	_
174-24	41528-41532	than	_
174-25	41532-41533	'	_
174-26	41534-41541	symbols	_
174-27	41541-41542	.	_

#Text=Unexpected Reward Receipt Group Differences (One-Way ANOVA Implemented in FSL, FWE Corrected, Cluster Threshold Z>2.0, p<0.05.)
175-1	41543-41553	Unexpected	_
175-2	41554-41560	Reward	_
175-3	41561-41568	Receipt	_
175-4	41569-41574	Group	_
175-5	41575-41586	Differences	_
175-6	41587-41588	(	_
175-7	41588-41595	One-Way	_
175-8	41596-41601	ANOVA	_
175-9	41602-41613	Implemented	_
175-10	41614-41616	in	_
175-11	41617-41620	FSL	_
175-12	41620-41621	,	_
175-13	41622-41625	FWE	_
175-14	41626-41635	Corrected	_
175-15	41635-41636	,	_
175-16	41637-41644	Cluster	_
175-17	41645-41654	Threshold	_
175-18	41655-41656	Z	_
175-19	41656-41657	>	_
175-20	41657-41660	2.0	_
175-21	41660-41661	,	_
175-22	41662-41663	p	_
175-23	41663-41664	<	_
175-24	41664-41668	0.05	_
175-25	41668-41669	.	_
175-26	41669-41670	)	_

#Text=Anatomical location\tCluster size\tZ-score\tMNI coordinates\tPost hoctest\t \t \t \t \tx\ty\tz\t \t \tMedial frontal cortex (right superior frontal gyrus and paracingulate)\t754\t3.52\t14\t30\t56\tC>S; C>D; D>S\t \tRight ventral striatum orbitofrontal cortex, thalamus, and midbrain\t1977\t4.25\t8\t6\t−2\tC>D; C>S\t \tLeft lingual gyrus, occipital lobe\t1577\t3.72\t−6\t−80\t2\tC>D; C>S\t \tLeft orbitofrontal cortex\t1120\t3.4\t−48\t40\t−22\tC>D; C>S\t \tRight inferior and middle temporal gyri\t742\t3.52\t62\t−26\t−22\tC>D; C>S\t \tRight occipital pole and right cerebellum\t2631\t4.85\t−20\t−100\t6\tC>S\t \tPosterior cingulate gyrus\t830\t4.33\t0\t−24\t30\tC>S\t \tLeft cerebellum\t705\t4.23\t−14\t−76\t−34\tC>S\t \tRight angular and supramarginal gyri, parietal lobe\t1815\t4.75\t54\t−54\t40\tC>S; D>S\t \tLeft angular and supramarginal gyri, parietal lobe\t1016\t4.02\t−40\t−62\t40\tC>S; D>S\t \t
#Text=Abbreviations: C, controls; D, depression; MNI, Montreal Institute of Neurology; S, schizophrenia.
176-1	41671-41681	Anatomical	_
176-2	41682-41690	location	_
176-3	41691-41698	Cluster	_
176-4	41699-41703	size	_
176-5	41704-41711	Z-score	_
176-6	41712-41715	MNI	_
176-7	41716-41727	coordinates	_
176-8	41728-41732	Post	_
176-9	41733-41740	hoctest	_
176-10	41743-41748	 	 	 	_
176-11	41749-41750	x	_
176-12	41751-41752	y	_
176-13	41753-41754	z	_
176-14	41755-41756	 	_
176-15	41759-41765	Medial	_
176-16	41766-41773	frontal	_
176-17	41774-41780	cortex	_
176-18	41781-41782	(	_
176-19	41782-41787	right	_
176-20	41788-41796	superior	_
176-21	41797-41804	frontal	_
176-22	41805-41810	gyrus	_
176-23	41811-41814	and	_
176-24	41815-41828	paracingulate	_
176-25	41828-41829	)	_
176-26	41830-41833	754	_
176-27	41834-41838	3.52	_
176-28	41839-41841	14	_
176-29	41842-41844	30	_
176-30	41845-41847	56	_
176-31	41848-41849	C	_
176-32	41849-41850	>	_
176-33	41850-41851	S	_
176-34	41851-41852	;	_
176-35	41853-41854	C	_
176-36	41854-41855	>	_
176-37	41855-41856	D	_
176-38	41856-41857	;	_
176-39	41858-41859	D	_
176-40	41859-41860	>	_
176-41	41860-41861	S	_
176-42	41864-41869	Right	_
176-43	41870-41877	ventral	_
176-44	41878-41886	striatum	_
176-45	41887-41900	orbitofrontal	_
176-46	41901-41907	cortex	_
176-47	41907-41908	,	_
176-48	41909-41917	thalamus	_
176-49	41917-41918	,	_
176-50	41919-41922	and	_
176-51	41923-41931	midbrain	_
176-52	41932-41936	1977	_
176-53	41937-41941	4.25	_
176-54	41942-41943	8	_
176-55	41944-41945	6	_
176-56	41946-41947	−	_
176-57	41947-41948	2	_
176-58	41949-41950	C	_
176-59	41950-41951	>	_
176-60	41951-41952	D	_
176-61	41952-41953	;	_
176-62	41954-41955	C	_
176-63	41955-41956	>	_
176-64	41956-41957	S	_
176-65	41960-41964	Left	_
176-66	41965-41972	lingual	_
176-67	41973-41978	gyrus	_
176-68	41978-41979	,	_
176-69	41980-41989	occipital	_
176-70	41990-41994	lobe	_
176-71	41995-41999	1577	_
176-72	42000-42004	3.72	_
176-73	42005-42006	−	_
176-74	42006-42007	6	_
176-75	42008-42009	−	_
176-76	42009-42011	80	_
176-77	42012-42013	2	_
176-78	42014-42015	C	_
176-79	42015-42016	>	_
176-80	42016-42017	D	_
176-81	42017-42018	;	_
176-82	42019-42020	C	_
176-83	42020-42021	>	_
176-84	42021-42022	S	_
176-85	42025-42029	Left	_
176-86	42030-42043	orbitofrontal	_
176-87	42044-42050	cortex	_
176-88	42051-42055	1120	_
176-89	42056-42059	3.4	_
176-90	42060-42061	−	_
176-91	42061-42063	48	_
176-92	42064-42066	40	_
176-93	42067-42068	−	_
176-94	42068-42070	22	_
176-95	42071-42072	C	_
176-96	42072-42073	>	_
176-97	42073-42074	D	_
176-98	42074-42075	;	_
176-99	42076-42077	C	_
176-100	42077-42078	>	_
176-101	42078-42079	S	_
176-102	42082-42087	Right	_
176-103	42088-42096	inferior	_
176-104	42097-42100	and	_
176-105	42101-42107	middle	_
176-106	42108-42116	temporal	_
176-107	42117-42121	gyri	_
176-108	42122-42125	742	_
176-109	42126-42130	3.52	_
176-110	42131-42133	62	_
176-111	42134-42135	−	_
176-112	42135-42137	26	_
176-113	42138-42139	−	_
176-114	42139-42141	22	_
176-115	42142-42143	C	_
176-116	42143-42144	>	_
176-117	42144-42145	D	_
176-118	42145-42146	;	_
176-119	42147-42148	C	_
176-120	42148-42149	>	_
176-121	42149-42150	S	_
176-122	42153-42158	Right	_
176-123	42159-42168	occipital	_
176-124	42169-42173	pole	_
176-125	42174-42177	and	_
176-126	42178-42183	right	_
176-127	42184-42194	cerebellum	_
176-128	42195-42199	2631	_
176-129	42200-42204	4.85	_
176-130	42205-42206	−	_
176-131	42206-42208	20	_
176-132	42209-42210	−	_
176-133	42210-42213	100	_
176-134	42214-42215	6	_
176-135	42216-42217	C	_
176-136	42217-42218	>	_
176-137	42218-42219	S	_
176-138	42222-42231	Posterior	_
176-139	42232-42241	cingulate	_
176-140	42242-42247	gyrus	_
176-141	42248-42251	830	_
176-142	42252-42256	4.33	_
176-143	42257-42258	0	_
176-144	42259-42260	−	_
176-145	42260-42262	24	_
176-146	42263-42265	30	_
176-147	42266-42267	C	_
176-148	42267-42268	>	_
176-149	42268-42269	S	_
176-150	42272-42276	Left	_
176-151	42277-42287	cerebellum	_
176-152	42288-42291	705	_
176-153	42292-42296	4.23	_
176-154	42297-42298	−	_
176-155	42298-42300	14	_
176-156	42301-42302	−	_
176-157	42302-42304	76	_
176-158	42305-42306	−	_
176-159	42306-42308	34	_
176-160	42309-42310	C	_
176-161	42310-42311	>	_
176-162	42311-42312	S	_
176-163	42315-42320	Right	_
176-164	42321-42328	angular	_
176-165	42329-42332	and	_
176-166	42333-42346	supramarginal	_
176-167	42347-42351	gyri	_
176-168	42351-42352	,	_
176-169	42353-42361	parietal	_
176-170	42362-42366	lobe	_
176-171	42367-42371	1815	_
176-172	42372-42376	4.75	_
176-173	42377-42379	54	_
176-174	42380-42381	−	_
176-175	42381-42383	54	_
176-176	42384-42386	40	_
176-177	42387-42388	C	_
176-178	42388-42389	>	_
176-179	42389-42390	S	_
176-180	42390-42391	;	_
176-181	42392-42393	D	_
176-182	42393-42394	>	_
176-183	42394-42395	S	_
176-184	42398-42402	Left	_
176-185	42403-42410	angular	_
176-186	42411-42414	and	_
176-187	42415-42428	supramarginal	_
176-188	42429-42433	gyri	_
176-189	42433-42434	,	_
176-190	42435-42443	parietal	_
176-191	42444-42448	lobe	_
176-192	42449-42453	1016	_
176-193	42454-42458	4.02	_
176-194	42459-42460	−	_
176-195	42460-42462	40	_
176-196	42463-42464	−	_
176-197	42464-42466	62	_
176-198	42467-42469	40	_
176-199	42470-42471	C	_
176-200	42471-42472	>	_
176-201	42472-42473	S	_
176-202	42473-42474	;	_
176-203	42475-42476	D	_
176-204	42476-42477	>	_
176-205	42477-42478	S	_
176-206	42482-42495	Abbreviations	_
176-207	42495-42496	:	_
176-208	42497-42498	C	_
176-209	42498-42499	,	_
176-210	42500-42508	controls	_
176-211	42508-42509	;	_
176-212	42510-42511	D	_
176-213	42511-42512	,	_
176-214	42513-42523	depression	_
176-215	42523-42524	;	_
176-216	42525-42528	MNI	_
176-217	42528-42529	,	_
176-218	42530-42538	Montreal	_
176-219	42539-42548	Institute	_
176-220	42549-42551	of	_
176-221	42552-42561	Neurology	_
176-222	42561-42562	;	_
176-223	42563-42564	S	_
176-224	42564-42565	,	_
176-225	42566-42579	schizophrenia	_
176-226	42579-42580	.	_

#Text=The Z-score for the maximum peak value of each cluster is provided.
177-1	42581-42584	The	_
177-2	42585-42592	Z-score	_
177-3	42593-42596	for	_
177-4	42597-42600	the	_
177-5	42601-42608	maximum	_
177-6	42609-42613	peak	_
177-7	42614-42619	value	_
177-8	42620-42622	of	_
177-9	42623-42627	each	_
177-10	42628-42635	cluster	_
177-11	42636-42638	is	_
177-12	42639-42647	provided	_
177-13	42647-42648	.	_

#Text=Any significant post hoc test results for two-group comparisons (p<0.05) on extracted contrast parameter estimates are also indicated for each cluster by the use of ‘greater than' symbols.
178-1	42649-42652	Any	_
178-2	42653-42664	significant	_
178-3	42665-42669	post	_
178-4	42670-42673	hoc	_
178-5	42674-42678	test	_
178-6	42679-42686	results	_
178-7	42687-42690	for	_
178-8	42691-42700	two-group	_
178-9	42701-42712	comparisons	_
178-10	42713-42714	(	_
178-11	42714-42715	p	_
178-12	42715-42716	<	_
178-13	42716-42720	0.05	_
178-14	42720-42721	)	_
178-15	42722-42724	on	_
178-16	42725-42734	extracted	_
178-17	42735-42743	contrast	_
178-18	42744-42753	parameter	_
178-19	42754-42763	estimates	_
178-20	42764-42767	are	_
178-21	42768-42772	also	_
178-22	42773-42782	indicated	_
178-23	42783-42786	for	_
178-24	42787-42791	each	_
178-25	42792-42799	cluster	_
178-26	42800-42802	by	_
178-27	42803-42806	the	_
178-28	42807-42810	use	_
178-29	42811-42813	of	_
178-30	42814-42815	‘	_
178-31	42815-42822	greater	_
178-32	42823-42827	than	_
178-33	42827-42828	'	_
178-34	42829-42836	symbols	_
178-35	42836-42837	.	_
